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Foreword 
This thesis work summarizes the main findings I obtained during the last 3 and 
half years (October 2008 to now), working in the laboratory of Genome Biology 
of the Discovery and Investigative Safety in the Pre-Clinical Safety department of 
NIBR. Our section is particularly interested in all aspects of molecular toxicology, 
in order to better define the safety profiles of drugs before clinical testing. Our 
department aims at elucidating the mechanisms of drug toxicity, predicting the 
impact on human subjects, and suggesting translatable safety indicators to 
monitor the toxic effects in the clinic. 
We chose to start working on microRNAs since no previous work specifically 
covered their role in drug-induced cardiac toxicity, and because of the proven 
impact of disturbances in microRNAs homeostasis on cardiac physiology. 
The main findings were arranged in 2 manuscripts, each covered in the central 
chapters of this thesis. Chapter 2 illustrates an example of drug-induced cardiac 
injury, and its impact on expression of microRNAs in rats’ hearts. This 
manuscript has been submitted to PLoS ONE, and we are currently responding to 
the reviewers’ questions. At the moment, we are running a few more functional 
experiments in cardiac myoblasts, and we could not fully incorporate these results 
in this thesis. Chapter 3 will describe an approach to determine the distribution of 
mRNAs and microRNAs in different cardiac structures in rat, dog and 
Cynomolgus monkey, since these are the most used model species in 
pharmaceutical research, and are still poorly annotated for mRNAs and 
microRNAs distribution. This manuscript will be submitted in the course of the 
next days to PLoS Genetics. 
Importantly, only the material that was considered sensible for complete 
publication in peer reviewed journals will be reported in this thesis. With a few 
exceptions in Chapter 2, techniques validation, incomplete or inconclusive data 
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will not be shown. This is in line with the guidelines of the University of Basel 
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manuscripts. 
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gratitude also goes to Prof. Alex Odermatt for the great exchange of scientific 
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requirements at the University of Basel. 
The most special thanks go to Estelle Marrer, who devoted her personal 
commitment to this thesis and greatly contributed to the accomplishments 
obtained in the course of my PhD.  
A great “thank you” goes of course to my colleagues from the lab: Magali, 
Gregory, Sarah, Tulipan and especially Manuela from whom I learnt a lot of 
tricks that have made my life much easier.  
Particular thanks go to Yasmina Bauer, Chiara Buono-Dalton, André Cordier, 
Valerie Dubost, Bérengère Dumotier, Florian Hahne, Pierre Moulin and Philippe 
Scheubel, who contributed with their life-long experience on special topics. All 
the present and past members of the Molecular Toxicology and Molecular 
Pathology section deserve my special gratitude, as everyone contributed with 
precious advices and made the time to sit with me throughout the years.  
My best acknowledgments go to all co-authors of my two manuscripts: in 
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Summary 
A long time and many steps are needed to bring valuable drugs to patients. 
Drugs not only have to be effective against the disease which they are intended 
for, but also safe. All drugs cause toxic effects in proportion to the dose 
(Paracelsus, ca. XVI cent.). Therefore, assessing carefully the optimal dose at the 
desired benefit/risk ratio (Stevens and Baker, 2009) and characterizing 
mechanisms of toxicity are essential for maintaining high safety standards. The 
experimental strategies used to predict drugs’ adverse events are many, and 
include the use of non-invasive biomarkers that can ideally be translated from test 
species to humans. In particular, cardiac safety requires special attentions, as it 
causes the cessation of drug development in over the 30% of cases due to toxic 
liabilities in Phase III, and over 40% post-approval (Redfern et al., 2011). 
In 1993 Victor Ambros, Rosalind Lee and Rhonda Feinbaum (Lee et al., 1993) 
described for the first time in C. elegans the role of short non-coding RNAs, 
called microRNAs. MicroRNAs pair with target mRNAs via sequence 
complementarity, and lead to mRNA degradation or translation inhibition 
(Filipowicz et al., 2008; Guo et al., 2010). MicroRNAs are implicated in many 
biological processes and in the evolution of the complexity of superior organisms, 
for review see (Bartel, 2004; Berezikov, 2011). Their role in cardiovascular 
development and diseases has been supported by an increasing number of 
publications, for review see (Kinet et al., 2012; Small and Olson, 2011). Recently, 
tissue-specific microRNAs were found in a variety of body fluids following drug-
induced tissue injury (Wang et al., 2009). In particular, myocardial necrosis of 
different etiologies (such as acute coronary syndrome and myocardial infarction) 
caused an increase of heart enriched microRNAs in plasma/serum of patients, as 
reviewed by (McManus and Ambros, 2011).  
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This work is aimed at increasing our knowledge about cardiac microRNAs 
function in different toxicological contexts and across species. 
Chapter 1 will give an overview of drug safety assessment focusing on the 
cardiovascular system, microRNAs biology and their potential as toxicity 
biomarkers. 
In Chapter 2 I will illustrate an example of drug-induced cardiac injury, and its 
impact on expression of microRNAs in rats’ hearts. Chronic treatment of rats with 
low amounts of doxorubicin (an anti-tumoral compound) caused myocardial 
vacuolation in ventricular tissue and a significant increase of specific microRNAs 
and genomic indicators of cardiomyopathy.  We found that Sipa1 could be 
directly inhibited by miR-34c by using a luciferase assay. Notably, the phenotypic 
anchoring of microRNAs with histopathological read-outs in the tissue showed 
that over-expression of miR-216b in the heart preceded the rise of overt lesions. 
Chapter 3 will describe an approach to determine the distribution of mRNAs 
and microRNAs in different cardiac structures in rat, dog and Cynomolgus 
monkey. We showed that microRNAs could discriminate the different heart 
structures as good as mRNAs. We also assessed the expected anti-correlation 
between microRNAs levels and their predicted target mRNAs, and showed that 
mRNAs of 4 genes implicated in cardiac diseases and muscular development 
could be inhibited at the post-transcriptional level by 4 distinct microRNAs. We 
propose that our mRNAs and microRNAs data sets could be used to assess the 
human relevance of preclinical findings in these 3 species, and to derive potential 
tissue and circulating biomarkers for drug-induced cardiac injury. 
In conclusion, profiling microRNAs have the potential to help biomedical 
research in bringing drugs to patients, since they can shed light on toxicity 
mechanisms in the tissues (Taylor and Gant, 2008) and are a source of translatable 
non-invasive toxicity biomarkers in body fluids.  
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Chapter 1:  Literature review on cardiac toxicity and 
microRNAs 
1.1 Drug development and safety assessment 
1.1.1 Impact of safety liabilities in drug development  
The rise of safety concerns for patients in the past 10 years increased the 
attrition rate due to organ toxicity in drug development (Figure 1-1), and today 
between 25 and 30% of the causes of attrition can be attributed to pre-clinical and 
clinical toxicity (adverse drug reactions) (Guengerich, 2011).  
 
Figure 1-1: Reasons for drug attrition in 1991 and 2000. Rising safety concerns increased 
the number of drugs withdrawn from market or discontinued (Laverty et al., 2011). 
Modified from (Kola and Landis, 2004). 
 
Safety aspects contribute to decisions during the whole pharmaceutical R&D: 
from target characterization, to candidate and back-up compounds selection, lead 
optimization, pre-clinical and clinical phases. Pre-clinical and clinical tests are 
aimed at balancing predicted risk against expected benefit, and are tightly 
interconnected.  
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During all drug development pre-clinical findings influence clinical 
development and vice versa: animal studies are run after first-in-human stage, to 
better understand the toxic mechanisms observed, and to mitigate risks. 
Mandatory pre-clinical  safety tests include genotoxicity (mainly in vitro), core 
safety pharmacology (SP) studies (in vivo cardiovascular SP, in vitro cardiac SP, 
respiratory SP and central nervous system SP) (Gad, 2008), and repeated dose in 
vivo toxicity studies. Animal studies that run in parallel with clinical phases 
include: repeated dose (13-26 weeks), in vivo genotoxicity, reproductive toxicity 
(segments I, II and III), immunotoxicity and carcinogenicity (2 years).  
Factors influencing the definition of safety margins include the indication of 
the drug, foreseen co-medications and co-morbidities and relevance of the pre-
clinical species used, among others.  Integrated risk assessment and evaluation of 
pre-clinical safety profile are strategic elements for taking successful go/no-go 
decisions.  
1.1.2 Terminology and definitions in safety assessment 
1.1.2.1 Safety Biomarker 
The term “biomarker” has several definitions, depending on the field of use. A 
drug safety biomarker is an objectively measured parameter that indicates whether 
a biological process is normal or pathological in response to a therapeutic 
intervention (Biomarkers Definitions Working Group, 2001). 
Regulatory authorities require biomarkers to be: 
 Validated, which includes establishing characteristics of the analytical 
assay, such as accuracy, precision, limit of quantification (LOQ), stability of 
analyte (Lee et al., 2006). 
 Qualified, which includes establishing the physiological, toxicological, 
pharmacological or clinical significance (Goodsaid and Frueh, 2007). 
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Ideally, biomarkers developed at the pre-clinical stage should be translatable 
for human use. 
1.1.2.2 Adverse effect 
An adverse effect is a harmful and undesired effect resulting from a 
medication. 
1.1.2.3 Toxicity endpoints 
A toxic endpoint is a parameter monitored during an in vivo study in animal or 
human, that reflects the toxicity of a compound. Data on endpoints are used to 
determine the No Observed Adverse Effect Level (NOAEL) and the Lowest 
Observed Adverse Effect Level (LOAEL). Toxic endpoints include, (but are not 
limited to): 
 In life changes: food/water consumption, weight gain, behavior, 
reproductive rate, etc. 
 Primary immunotoxicity: leukocytes count, hematology, coagulation, 
globulin and albumin levels, gross evaluation of thymus and spleen, etc. 
 Histopathology: macroscopic and microscopic alteration of tissues and cells 
 Gene expression changes: transcriptomics and proteomics in affected 
organs 
 Metabolic changes: metabolomics and clinical chemistry 
 Organ and tissue function: imaging techniques, hemodynamic, metabolic 
circulating markers 
 Clinical chemistry biomarkers: circulating tissue injury indicators 
Endpoints can be validated and qualified to become biomarkers. 
1.1.2.4 Adverse vs. non adverse effect 
When differences in selected endpoints are observed in a treatment group it is 
necessary to determine whether these a) are treatment related, and b) they are 
adverse. 
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Discriminating factors a): 
 There is no obvious dose response 
 Findings encountered in “outlier” animals 
 Measurement of selected endpoint are inherently imprecise 
 Values measured are within normal biological variation (historical control 
data) 
 Lack of biological plausibility 
Discriminating factors b) 
 There is no alteration in the general function of the test organism or of the 
organ/tissue tested 
 Secondary to other adverse effects 
 Adaptive response 
 Transient 
 Limited severity (magnitude of change) 
 Effect is isolated or independent and/or is not a precursor of changes 
known to progress and establish adverse effects 
 A consequence of the experimental model 
1.1.2.5 NOAEL: No Observed Adverse Effect Level 
The highest exposure level at which there is no statistically significant 
increases in the frequency or severity of adverse effect between the exposed 
population and its appropriate control. Some effects may be produced at this level, 
but they are not considered to be adverse or precursors to adverse effects (Figure 
1-2). 
1.1.2.6 LOAEL: Lowest Observed Adverse Effect Level 
The lowest exposure level at which there is a statistically or biologically 
significant increase in the frequency or severity of adverse effects between the 
exposed population and its appropriate control (Figure 1-2). 
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1.1.2.7 MTD: Maximum Tolerated Dose 
The highest dose of a pharmacological treatment that will produce the desired 
effect without unacceptable toxicity (lethality is never an intended endpoint). 
 
Figure 1-2: Dose escalation according to NOEL, NOAEL, and LOAEL. Doses used in a 
toxicity study should be chosen accordingly to observe no effects, no adverse effects, and 
some adverse effects. NOEL: no effect level; NOAEL: No Adverse Effect Level; LOAEL: 
lowest observed adverse effect level.  
 
1.1.3 Impact of current strategies for organ toxicity assessment 
Hepatic, neurological and cardiovascular adverse drug reactions rank in the top 
positions of reasons for development interruption or withdrawal due to toxicity, 
especially during the clinical phase as shown in Table 1-1 (Hamadeh et al., 2002; 
Redfern et al., 2011; Stummann et al., 2009). It has been proposed that 
implementation of more predictive tests of liabilities in these organs already in the 
earliest research phases would significantly lessen the overall compound attrition 
due to toxicity concerns (Stevens and Baker, 2009).  
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Table 1-1: Drug safety impact by target organ.  
 
Reproduced with permission of W. Redfern  (Redfern et al., 2011). Information collated 
from published articles and from database BioPrint

 (Budnitz et al., 2006; Car, 2006; 
Krejsa et al., 2003; Olson et al., 2000; Sibille et al., 1998; Stevens and Baker, 2009). 
 
The choice of the species to use for in vivo pre-clinical studies is critical, and is 
conditioned by the relevance to human. It is noted that cardiovascular and 
oncology disease areas have the highest attrition rate due to poor predictivity of 
the animal models (Kola and Landis, 2004), and this can be applied to safety 
testing too. Crucial is to characterize the mechanisms of drug-induced toxicity, 
the target organ, whether it is an on-target, off-target, idiosyncratic or 
immunological mediated effect and evaluate the translatability of the findings to 
the patients. Accumulating data on biological processes and gene/protein 
expression in model organisms serve as basis for understanding the translatability 
of toxic findings to human. Of utmost importance is to be aware of similarities 
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and differences at the molecular level (single genes and pathways) between test 
species and human. For this purpose genomic techniques are being widely 
employed to describe molecular mechanisms of pathologies and diseases, and 
propose novel toxicity/efficacy biomarkers.  
1.1.4 Additional Considerations 
An earlier and more cost-effective evaluation of the safety profile is essential, 
in order to make drug development process less cost-intensive, and reduce the 
attrition of promising compounds at expenses of those at risk of liabilities once in 
the clinic. The combination of mechanism-based toxicity evaluations and 
availability of predictive translational biomarkers provides a safer ground for 
decisions regarding advancing compounds in development. 
Knowledge generated by the progress in biological research is constantly taken 
in consideration throughout drug development, and safety assessment is not an 
exception. Novel molecular entities, and technologies, should be implemented in 
safety assessment, to provide new predictive endpoints, elucidation of drug-
related molecular events and potential safety/efficacy biomarkers. 
1.2 Drug-induced cardiac liabilities  
1.2.1 Common drug-induced cardiovascular safety concerns 
Drug-induced cardiac liabilities leading to withdrawal and research program 
discontinuation can be broadly divided into the following classes, according to 
their pathological outcome (Stummann et al., 2009): 
 Arrhythmias: a large spectrum of conditions induced by conduction 
abnormalities 
 Contractility: interference with the ability of muscle fibers to contract 
(inotropic effects) 
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 Ischemia: restriction of blood supply to the heart, due to blood vessels 
(coronary) restrictions 
 Secondary toxicity: caused by vascular effects 
 Valve toxicity: impairment of valve function to keep unidirectional blood 
flow between chambers and vessels. 
1.2.2 Routine cardiac safety studies and regulatory guidelines 
A plethora of morphological, functional and biochemical parameters are used 
to diagnose classify and characterize these cardiopathies at the pre-clinical and 
clinical level.  
EMEA/CHMP/SWP/488313/2007, ICH S4, ICH S7A and ICH S7B guidelines, 
issued by the International Conference on Harmonization (ICH), recommend the 
strategy for the design of cardiac safety pharmacology studies (International 
Conference for Harmonization, 2011). The requirement for an integrated safety 
assessment approach include a two-weeks repeated dose toxicity study in a rodent 
(rat) and a non-rodent species (dog or monkey) followed by histopathology, 
clinical chemistry parameters and functional endpoints.  In vitro assays include IKr 
(hERG) patch-clamp inhibition assay, ADP studies in cardiac cellular animal 
preparation to evaluate the effect of the compound on voltage-gated ion channels. 
Inhibition of Ikr, L-type Ca2
+
 and Na
+
 currents lead to slower repolarisation and 
consequent elongation of QT phase in the electrophysiological track. A long QT 
syndrome (LQTS) is associated to Torsade de Pointes (TdP) and pro-arrhythmic 
potential of compounds. However, evidences suggest that a long QT measured in 
vitro within IKr (hERG) assays is not necessarily associated to cardiac liabilities in 
human (Redfern et al., 2003). Conversely voltage-gated channel alterations are 
not causally implicated in other compound-induced cardiovascular pathologies, 
such dilating cardiomyopathy and valvular heart disease. The toolbox of 
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experimental techniques to tackle each type of cardiovascular toxicity is reviewed 
in Stumman C. et al. (Stummann et al., 2009).  
1.2.3 Impact and shortcomings of current pre-clinical cardiovascular safety 
strategy 
Laverty et al. review the impact of pre-clinical strategies in place to prevent the 
risk of liabilities in patients (Laverty et al., 2011). Arrhythmic potential (TdP) is 
tackled thanks to the systematic focus on QT interval in ECG investigations. 
Ischemic diseases however are often not detected, in part due to the use of young 
animals in pre-clinical studies and young healthy volunteers in Phase I, which do 
not represent populations at risk, especially elders with elevated blood pressure 
and atherosclerosis. It has been proposed that monitoring of T-waves may predict 
the risk of infarction in population at risk. Myocardial necrosis can be monitored 
via clinical chemistry endpoints like circulating cardiac troponin I (cTnI), 
creatinine kinase (CK-MB) and N terminal pro-natriuretic peptide (NT-pro BNP) 
(Marrer and Dieterle, 2010; Muller and Dieterle, 2009; Wallace et al., 2004). 
However, these markers are elevated when the damage has already occurred and 
what are lacking are robust biomarkers to detect and monitor rather the onset of 
cardiac structural damage or changes in cardiomyocytes homeostasis (Buck et al., 
2008). Risk of heart failure can be determined by hemodynamic measurements, 
such as left ventricle ejection fraction (LVEF) and cardiac contractility. However 
these techniques are not routinely applied in all companies at the pre-clinical 
stage. Cardiac valves disorders are rather difficult to observe in animals: the 
incidence is quite low, no circulating biomarkers exist and only direct histological 
evaluation can confirm it. However fixed cardiac samples from animal studies for 
histopathology rarely contain the valves, and only a few slides per organ are 
evaluated.  
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Further needs identified by Laverty and colleagues include better understanding 
of the mechanisms of the drug-induced cardiac injury (DICI) at the cellular and 
structural level (Laverty et al., 2011). 
1.2.4 Reference compounds of cardiac toxicity 
The use of compounds with known adverse cardiovascular effects  may help to 
extensively characterize and classify new chemical entities, and establish 
alternative assays in vitro to be applied very early on during target discovery 
(Stevens and Baker, 2009).  
Drugs belonging to the same pharmacological class, i.e. sharing the same 
target, tend to have similar liabilities pattern. Increase of focus on kinases as 
targets for oncology indications in the last 10 years also drag the attention on the 
safety liabilities of kinase inhibitors. While inhibiting mutated or over expressed 
kinases in tumors is a very promising strategy, kinases are pivotal genes in 
sustaining physiological activity in all organs. However, designing compounds 
that mimic ATP (Type I inhibitors, small molecules) or that target sites adjacent 
to the catalytical pockets leads to high probability of off-target toxicity. 
Nevertheless, Type III inhibitors with increased single kinase specificity achieved 
by target regions of the proteins far from the ATP binding pocket, do not fully 
prevent kinase mediated cardiotoxicity, as cardiac performances depend on 
multiple kinase-regulated pathways such as the ATP and Ca
2+
 dependent 
processes, as illustrated in Figure 1-3 (Force and Kolaja, 2011).  
Drugs withdrawn from the market due to valvular dysfunction in the past were 
all 5-HT2B receptor agonists (serotonin receptors), which is highly expressed in 
valve leaflets (Bhattacharyya et al., 2009; Elangbam, 2010). These include 
appetite suppressants (fenfluramine and dexfenfluramine), dopamine agonists 
indicated for Parkinson’s disease (pergolide and cabergoline) and ergot alkaloids 
against migraine (methysergide and ergotamine). Highly selective agonists of 
other serotonin receptor isoforms are devoid of valve liabilities. The mechanism 
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of 5-HT receptors-induced proliferation implicates downstream activation of G 
protein coupled/ERK and phospholipase C-β/PKC. TGF-βR and Smad2/4 
pathway is also activated. 5-HT2BR expression levels are similar between rat, 
monkey and human (Elangbam, 2010), suggesting these species are of practical 
use to establish animal models to predict drug-induced valvular liabilities. 
1.2.5 Additional Considerations 
It is widely understood that routine cardiac safety assessment is not fully 
predictive of findings in the clinics, and that mechanistic understanding is 
essential to distinguish physiological vs. pathological processes. Furthermore, 
physiological differences across test species and human patients should be 
clarified and taken in account. Both these aspects have to be taken in 
consideration for an integrated cardiovascular safety assessment. 
 
Figure 1-3: Crucial signaling pathways in the heart and consequences of their activation 
or inhibition (Force and Kolaja, 2011). Kinases are circled in light yellow ovals. 
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1.3 Impact of transcriptomics in drug safety assessment and biomarker 
discovery 
1.3.1 Impact of toxicogenomics in drug safety assessment 
Technical advancements of the post-genomic era are supported by high-
throughput nucleic acid profiling platforms, such as RNA or DNA based 
microarray (Figure 1-4) that can quantify transcription changes at the global level, 
reveal association between diseases and genetic mutations, or characterize the 
epigenetic changes at the chromatin level. Although next-generation sequencing is 
becoming more affordable, microarray based profiling are routinely used in drug 
discovery during the preclinical safety assessment. 
 
 
Figure 1-4: Experimental process of microarray hybridization experiments for gene 
expression determination (Butte, 2002). 
 
Specific signatures of altered genes can be causally implicated into drugs 
toxicity in the tissue of interest (Buck et al., 2008; Chen et al., 2008a; Mori et al., 
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2010). Goals of toxicogenomics in drug safety assessment screenings are multiple 
(Van and Sasaki, 2010): 1) formulate hypothesis on the molecular mechanism of 
undesired phenotypic changes, uncoupling them from the pharmacological 
effects, 4) give information on the organ structures mostly affected by the drug , 
3) support the identification of biomarkers of the pathological process that can be 
used as screening endpoints for same class and backup compounds and 4) classify 
compounds in classes based on the toxicity outcome (Ruepp et al., 2005; Steiner 
et al., 2004).  
1.3.2 Experimental approach of genomics studies for organ toxicity 
assessment 
Upon stress stimuli, including xenobiotics exposure, a series of changes take 
place in the cells, ultimately leading to adaptation or functional impairment of the 
organ. Molecular alterations precede morphological changes and can be identified 
early on upon treatment, after only one or two doses of the drug, and in absence of 
overt toxicity (Hamadeh et al., 2002). Data collection at multiple time points 
reveals cause-effect relationship between early and later gene expression (Buck et 
al., 2008). 
In a complex toxicity in vivo study including several doses and time points, 
data analysis still remains the bottle-neck, as the analyst has to take in 
consideration a plethora of accompanying data (histopathology, clinical 
pathology, and imaging) to carefully choose the most significant samples set to 
answer biological questions and enable critical compound prioritization and limit 
attrition as early as possible.  
1.3.3 Data analysis strategy depends on the goal of toxicogenomics studies  
A variety of approaches for analysis of large data sets are available, between 
supervised and unsupervised methods (Butte, 2002). Unsupervised approaches 
include principal component analysis, clustering and Bayesian networks. 
Supervised approaches range from the nearest-neighbor analysis and support 
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vector machine (machine-learning algorithms able to recognize patterns in 
analyzed data). It is important to decide a priori whether the outcome of the 
analysis is aimed at predicting toxicity only, or at obtaining a mechanistic 
interpretation of the molecular modifications involved. Gene signatures extracted 
from the analysis can be long (thousands of genes) in the former case, but must be 
much shorter (few tens of genes) in the latter case (Natsoulis et al., 2005). In any 
case, transcriptomics results must be anchored to ancillary data, such as 
histopathology, in order to establish a temporal evolution of the findings, and 
propose relevant predictive toxicity indicators that would be noted earlier than 
overt lesions.  
1.3.4 Toxicogenomics in biomarker discovery 
Transcriptomics analysis can support discovery and validation of molecular 
indicators (biomarkers) of toxicity 1) in the tissue (pre-clinical only) and 2) in 
body fluids (pre-clinical and clinical), i.e. if a certain gene is translated to a 
released protein product. Elevated levels of these molecules can be measured in 
the peripheral circulation of patients, and specifically reflect leakage of cell 
content due to tissue injury. Ideally, biomarkers should be translatable across 
species, including preclinical species, and restricted in expression to the tissue of 
interest (Decristofaro and Daniels, 2008). 
Since the mRNA expression levels may not match in all cases with the level of 
functional protein translated, proteomics investigations may be needed to confirm 
the functional outcome of altered gene expression. 
1.3.5 Examples of transcriptomics studies for drug-induced cardiac toxicity 
(DICI) 
In the case of drug-induced cardiac injury (DICI) histopathological readouts are 
limited to few qualitative observations (cardiomyocytes degeneration, vacuolation 
or necrosis) and do not provide explanations of the molecular events causing the 
injury (Buck et al., 2008), since similar adverse phenotypes can be caused by 
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different mechanisms. Hemodynamic measurements supported by electro- and 
echocardiography are operationally intensive and detect the damage when the 
affected structure is functionally compromised. Therefore transcriptomics 
investigations bear the great potential of unveiling the mechanistic progression of 
toxicity. To date the vast majority of literature on toxicogenomics studies 
available in the public domain regard drug-induced liver toxicity (DILI) (Van and 
Sasaki, 2010), while cardiovascular toxicants have not received such systematic 
attention. Two examples of gene expression studies applied to cardiac safety are 
illustrated below.  
Mori and colleagues illustrated the effects on gene expression of 3 known 
cardiotoxicants: a pesticide (carbofuran), a beta-adrenergic agonist (isoproterenol) 
and a DNA intercalator (doxorubicin, DOX) (Mori et al., 2010). Several genes 
were consistently up-regulated after 1 dose only of the three compounds even 
earlier than histopathological findings, suggesting similar molecular mechanism 
may be involved in the toxic outcome for all the 3 compounds. These include 
Spp1, Fhl1, Timp1, Ccl7 and Reg3b genes. However, dosage and administration 
scheme did not reflect a real accidental exposure situation. Furthermore, those 
changes may be transient and not be maintained after repeated dosing.  
Thompson and colleagues used a different approach and focused on early 
molecular events induced by DOX that are maintained after repeated 
administration of low doses in the rats, more closely resembling the clinical 
setting. The authors determined the gene expression changes after 2 weeks of 
chronic DOX administration and identified lists of gene significantly altered 
(Thompson et al., 2009). These were either associated with the cellular response 
to oxidative stress, encoding mitochondrial proteins or calcium homeostasis. 
These observations were consistent with the molecular mechanism of proposed 
DOX-induced cardiac injury due to reactive oxygen species production (Chen et 
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al., 2007). Further cardiotoxicity aspects associated to anthracyclines 
chemotherapy are reviewed in the following chapter. 
1.3.6 Additional Considerations 
In addition to transcriptomics, metabolite profiling and proteomics approaches 
are often used to characterize various aspects toxic liabilities, such as biomarker 
discovery and characterization of off-target effects upon drug pull-down in 
protein extracts. The emerging fields of epigenetics and non-coding RNAs are 
increasingly integrated in mechanistic interpretations of xenobiotics response. 
Relevance of microRNAs in cardiac physiology and toxicity are reviewed in the 
next paragraphs.  
1.4 MicroRNAs biology and function regulation 
1.4.1 MicroRNAs biogenesis and function 
MicroRNAs are ~22 nucleotides long non-coding RNAs, genomically encoded 
and conserved throughout evolution in all superior organisms. They are 
transcribed by DNA Pol II either as independent singular or clustered 
transcriptional units, or originate from hosting gene during intron splicing (Bartel, 
2004; Goymer, 2007; Ruby et al., 2007). Maturation of microRNAs involves 
sequential steps that include the generation of a primary hairpin, trimmed to a 
precursor-microRNA by Drosha, which is then exported to the cytoplasm where 
Dicer cuts the loop, releasing a short double stranded RNA. The duplex is 
separated to single-stranded RNA filaments, incorporated into an Ago2-RNA 
Induced Silencing Complex (RISC) (Figure 1-5). Regulation of microRNA 
expression can take place at all stages of biogenesis, and their function is 
influenced by several factors such as RISC-complex regulators, RNA binding 
proteins (RBP) and target mRNA conformation, among others (Krol et al., 2010). 
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Figure 1-5: MicroRNAs biogenesis. Adapted from (Krol et al., 2010).  
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Increasing evidences implicate non-coding RNAs as central players of cellular 
homeostasis by tuning the expression level of hundreds of mRNAs (Lim et al., 
2005; Stark et al., 2005; Wang et al., 2011a; Wu and Belasco, 2008). Although 
microRNAs were initially described as fine regulators of gene expression, it is 
now believed that single microRNAs can have dramatic effect on genome 
homeostasis, especially in disease state.  
1.4.2 MicroRNAs role in transcriptome homeostasis 
MicroRNAs are gene expression inhibitors, acting at the post-transcriptional 
level by directing the RISC complex to target mRNAs via imperfect pairing with 
its 3’ untranslated regions (UTR) (Bartel, 2004; Guo et al., 2010). MicroRNAs 
embedded in the Ago2-miRISC serves as a guiding strand for RISC towards 
target mRNAs, and exert their inhibitory function inducing translational 
inhibition, mRNA de-adenylation and decay (Figure 1-5). RISC-mediated 
microRNAs inhibition requires an almost perfect complementarity between the 
first 7-8 nucleotides at the 5’ end of the microRNA and the mRNA target, in a 
region called seed (Grimson et al., 2007). MicroRNA target sequences lie mostly 
within the 3’ UTR of mRNAs, and multiple sites can often be found. Globally, 
sites in the coding region appeared to be generally less effective at repressing 
mRNAs, and accumulating evidences suggest that these may escape evolutionary 
pressure (Fang and Rajewsky, 2011). The RISC-mediated direct cleavage of the 
endogenous mRNA is a common mechanism of plant microRNAs, thanks to the 
almost perfect complementarity with their target. In animals, however, the 
complementarity is mostly limited to the seed and additional 3’ sites, and mRNAs 
target decay is induced by a different mechanism. MicroRNAs-loaded RISC 
recruits factors promoting de-adenylation like CCR4–NOT via GW182-dependent 
(Chekulaeva et al., 2011). Loss of the poly-A tail causes the mRNA to be 
degraded (Couttet et al., 1997), consistently with the observation that knock out/in 
of specific microRNAs revealed a detectable variation in mRNAs dependent on 
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the presence of target sequences (Baek et al., 2008; Guo et al., 2010; Lim et al., 
2005).  
MicroRNAs inhibit cap-dependent translation at the initiation step via 
interference with the cap recognition process. Notably microRNAs failed to 
inhibit IRES-dependent translation, which does not rely on the m7Gppp cap to 
recruit the translational machinery (Fabian et al., 2010; Filipowicz et al., 2008). 
Whether microRNAs can inhibit translation at the elongation, as proposed by 
Maroney and colleagues, and at the termination step is controversial (Maroney et 
al., 2006).  
1.4.3 Finding the targets of specific microRNAs 
1.4.3.1 In silico predictions and gene expression analysis 
A few rules apply to the interaction between microRNAs and their targets. 
Pairing at the seed region must be perfect, and comprising at least nucleotides 2 to 
8. The presence of bulges and imperfect match in the central portion of the duplex 
precludes the cleavage of the target mediated by Ago, however additional 
complementarity at the 3’ end increases the repressive efficiency of the 
microRNAs, when the seed interaction is below 8 nucleotides (Grimson et al., 
2007).  
The reduced length and the presence of variable degree of complementarity 
hinder the possibility of exact target prediction via in silico sequence analysis. 
A variety of algorithms exist for identification of microRNAs target genes 
(Table 1-2). These take into account the degree of complementarity to the miRNA 
seed sequence, conservation of the microRNA seed element within the target gene 
across different species, free energy of the miRNA-mRNA duplex binding, and 
accessibility of the target site. Predictions based on evolutionary conserved seed-
matching identified hundreds of potential targets for each microRNA (Lewis et 
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al., 2005). The extent of false-rate prediction is difficult to assess, and oscillates 
between 30% and 50% (Alexiou et al., 2009; Thomas et al., 2010).  
It has to be kept in mind that the function of individual microRNAs depends on 
the molecular context: each cell type expresses a limited repertoire of genes that 
can be under the control of single microRNAs. 
Additional in silico strategies include the mining of extensive gene expression 
databases in order to identify mRNAs profiles compatible with microRNAs 
targeting (Alexiou et al., 2010; Antonov et al., 2009; Le Brigand et al., 2010; van 
Dongen et al., 2008). 
 
Table 1-2: List of in silico microRNAs target prediction tools. (Yokoi and Nakajima, 2011)  
DIANA microT http://diana.cslab.ece.ntua.gr/microT/ 
EMBL-Target Gene Prediction http://www.russelllab.org/miRNAs/ 
MicroCosm http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/ 
MicroRNAdb http://bioinfo.au.tsinghua.edu.cn/micrornadb/ 
miRanda http://www.microrna.org/microrna/home.do 
miRBase http://microrna.sanger.ac.uk/ 
miRGator http://genome.ewha.ac.kr/miRGator/ 
mirnaviewer http://cbio.mskcc.org/mirnaviewer/ 
miRWalk 
http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/ 
PicTar http://pictar.org/ 
PITA http://genie.weizmann.ac.il/pubs/mir07/index.html 
RNA22 http://cbcsrv.watson.ibm.com/rna22.html 
RNAhybrid http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/ 
TargetRank http://hollywood.mit.edu/targetrank/ 
TargetScan http://www.targetscan.org/ 
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1.4.3.2 Experimental identification of microRNAs targets 
A variety of experimental approaches have been set up in order to identify the 
real and biologically relevant targets of microRNAs, as reviewed by Thomson and 
colleagues (Thomson et al., 2011). 
Over expression or knock down of specific microRNAs coupled with 
microarray analysis allowed to observe the changes induced by that microRNA in 
model cell lines (Lim et al., 2005). However these strategies have several caveats, 
in fact not all biologically relevant targets may be expressed in the cell line of 
choice. The analysis of seed matching sequences in down regulated genes helped 
to discriminate potential direct from indirect targets, however in most cases it was 
not assessed whether the observed effects were mediated directly by the 
microRNA, or were rather a result of unspecific regulation.  
Conversely, biochemical approaches involving the co-immunoprecipitation of 
mRNAs with RISC components combined with over expression of a specific 
microRNA (cell re-programming) could in principle  identify direct microRNAs 
targets (Hendrickson et al., 2008; Karginov et al., 2007; Matkovich et al., 2011; 
Tan et al., 2009). However these procedures are difficult to set up and rely on 
sufficiently stable interactions between the mRNAs and the RISC components.  
Cross-linking aided protocols have been developed to overcome this potential 
drawback, such as the high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation HITS-CLIP (Chi et al., 2009) and the 
photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation 
(PAR-CLIP) (Hafner et al., 2010). However it is not clear which percentage of the 
pulled down targets are specific for a single microRNA.  
In order to address this problem Orom and Lund have successfully identified 
the direct targets of miR-10a by using a  biotinilated synthetic microRNA as bait 
for their pull down experiment in (Orom and Lund, 2007) in Drosophila and 
40 
 
human cells. However whether the biotin group had an effect on the microRNA 
functionality was not elucidated. 
1.4.4 Alternative mechanisms of microRNA function 
Noteworthy, microRNAs not only inhibit gene expression, but also mediate 
translational activation of a few target genes in specific cell state, such as 
quiescent cells in G0, germline differentiation, ribosomal protein, HCV RNA etc. 
(Vasudevan, 2011). These effects can be sequence-dependent (i.e. microRNA-
mediated recruitment of activator RNPs), or sequence-independent, (i.e. no direct 
interaction between the microRNA and the transcriptionally activated/stabilized 
mRNA). A number of microRNAs were shown to have direct stimulatory activity 
on the translation of their target mRNAs: miR-122 and miR-10a possess 
translation activation properties on specific transcripts by pairing at the 5’UTR of 
respectively HCV and ribosomal genes (Henke et al., 2008; Orom et al., 2008). 
Others, such as miR-125b and miR-466l mask the binding site for the ARE-decay 
factor tristetraprolin (TTP) on their respective targets κB-RAS2 and IL10 (Figure 
1-6C) (Ma et al., 2010; Murphy et al., 2010). Generic features of direct 
transcriptional activation mediated by microRNA/mRNA direct interaction 
include the modification of RNPs recruited by microRNAs/Ago2 complex, such 
as lack of GW182/PABP complex, recruitment of activator proteins FXR1-iso-a 
(Figure 1-6A) or interference with regulatory AU-rich elements, shortened or 
absent polyA (Figure 1-6B) and binding to a 5’UTR site in closer proximity to the 
cap (Figure 1-6B).  MicroRNAs can also act as decoy for repressive proteins and 
relieve the repression on their targets in a sequence independent manner, such as 
the case of pre-miR-328 interacting with the RNA inhibitory hnRNP. This rescues 
the repression of Cebpa mediated by hnRNP in chronic myelogenous leukemia 
via the miR-328 C-rich cluster, similar to the one present in the 5’ UTR of the 
Cebpa mRNA, shown in Figure 1-6D (Eiring et al., 2010).  
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Figure 1-6: Mechanisms for microRNAs-mediated post-transcriptional activation 
(Vasudevan, 2011). 
 
Some non-functional pseudo-genes have been shown to possess a buffer 
activity on their functional homolog, and accumulating evidences suggest that 
these conserved microRNA targets sequence would be under evolutionary 
pressure in order to release the microRNA-mediated inhibition on their homolog 
gene (Cesana et al., 2011; Poliseno et al., 2010; Sumazin et al., 2011). 
MicroRNAs were also found in the nucleus of cells, but their function is at 
present not fully understood.  
The splicing regulator MBNL1 is implicated in myotonic dystrophy (MD), and 
it has been recently shown to bind to pre-miR-1 in the nucleus and promote its 
maturation in normal conditions. In diseased conditions, MBNL1 is sequestered 
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and as a consequence the levels of mature miR-1 are decreased, suggesting that 
miR-1 could be an effector of the cardiac defects observed in MD patients via its 
targets (Rau et al., 2011). This also suggests that microRNAs could bind to 
transcriptional regulators in the nucleus, and have downstream effects on 
transcriptional gene regulation. Another possibility is that nucleus 
compartmentalization of either the mature or precursor microRNAs could be a 
further layer of post-transcriptional regulation of microRNAs activity. 
Evidences exist that Ago2 recruitment at the promoter of specific genes, driven 
by complementarity with guide microRNA, is a functional mechanism in 
mammals (Li et al., 2006; Younger and Corey, 2011), and was suggested that 
microRNAs can direct transcriptional activation or inactivation of genes with 
complementary sequences in their promoters or regulatory regions (Kim et al., 
2008; Place et al., 2008). Whether microRNAs-mediated gene regulation at the 
transcriptional level is a physiological and common layer of gene regulation in 
animals, similar to the RNAi-induced transcription silencing (RITS) characterized 
in yeast, is a hypothesis that opens complete new avenues of investigations for the 
role of non-coding RNAs (Li et al., 2006; Woolcock et al., 2011; Younger and 
Corey, 2011).  
 
1.4.5 Additional Considerations 
In order to minimize the risks and perform predictive experiments, researchers 
must be confident about the human relevance of the experiments performed in test 
animals. Unfortunately the test species useful for drug development (rat, canine 
and non-human primates) are not thoroughly characterized: extensive genomic 
annotation, detailed proteomics data, gene expression, epigenetic marks and 
transcription factors profiles are lacking. Given the proven impact of microRNAs 
in multiple layers of gene regulation, it makes sense to accumulate knowledge on 
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their role in species of interest for biomedical research and, in our case, in 
cardiovascular safety. 
1.5 MicroRNAs detection and quantification 
In the last ten years all high-throughput techniques available for 
transcriptomics have been adapted for microRNAs detection. These include 
quantitative PCR (qPCR), hybridization-based techniques and next-generation 
sequencing (NGS) (Table 1-3). 
Table 1-3: MicroRNAs detection platforms. AQ: absolute quantification; RQ: relative 
quantification 
  
Single 
assay 
Whole 
genome 
AQ RQ A priori 
knowledge 
Input 
material 
Analysis 
costs 
qPCR 
Single assays x   x x yes Low Low 
Pre-spotted plates   x ? x yes Medium Low 
Hybridization 
MicroArrays   x ? x yes Medium Medium 
Panomics x   x x yes High Low 
Nanostring x   x x yes Low Low 
Northern blot x     x yes Low - 
ISH  x       yes - - 
NGS DGE   x ? x no Medium Intense 
 
1.5.1 Quantitative PCR (qPCR) 
Advantages of qPCR-based microRNA profiling include relative ease of use, 
low demands for amount of starting material, high sensitivity, straightforward 
protocol for sample preparation and data analysis. Since microRNAs are too short 
to design a regular couple of primers, different strategies illustrated in Figure 
1-7A-C can be used to increase the length of the amplicon via ligation, or reverse-
transcription. Then, a microRNA specific primer is mixed with a universal primer 
that recognizes the extended 3’ tail during the PCR reaction. Differentially 
regulated candidates obtained by high-throughput qPCR can be further confirmed 
by other means, or justified by biological consistency (i.e. co-regulation with host 
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genes in the case of intronic microRNAs). However, the specific stem-loop 
primer used to extend microRNAs length during reverse transcription can fail to 
recognize length variants (Figure 1-8), decreasing the qPCR sensitivity. When 
length variants could be present in the sample, the use of a mixture of degenerated 
RT primers can help to reverse transcribe all microRNAs irrespectively of their 3’ 
end. 
 
Figure 1-7: MicroRNAs detection. Schemes of three kinds of RT-PCR methods: Primer 
extension (A), stem-loop primer (B), and 3’ adapter ligation (C). Solid-phase amplification 
of Illumina small RNA libraries (D). Adapted from (Huang et al., 2011). 
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Figure 1-8: Sensitivity of Taqman single assay RT and qPCR on miR-322 length variants. 
Shorter microRNAs variant may not be efficiently reverse transcribed by a single 
microRNAs specific RT primer. 
 
1.5.2 Hybridization based techniques 
Hybridization-based methods have been used since many years, and microarray 
technology adapted to microRNAs is offered by a variety of providers 
(Affymetrix, Agilent, Illumina, Exiqon, Toray). These technologies suffer from 
unspecificity issues intrinsic of all hybridization-based technologies (non-uniform 
Tm, normalization strategies, controversial specificity at the single nucleotide 
level, GC content), exacerbated by the fact that microRNAs are not amenable to 
multiple probe sets design, differently from mRNAs. Furthermore, the restricted 
number of microRNAs analyzed in each chip and the lower signal intensity due to 
inferior labeling efficiency require special attentions during  quality control, 
between-chips normalization and analysis algorithms (Sarkar et al., 2009). 
Pradervand et al. and Sato et al. tested the performances of different microRNAs 
microarray providers (Affymetrix, Agilent, Ambion, Exiqon, Invitrogen and 
Toray) and concluded that Agilent had a superior performance, reproducibility 
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and comparability within same platform and with other platforms (qPCR and 
NGS) (Pradervand et al., 2010; Sato et al., 2009).  
Sample preparation can be a cause of biases, due to enzyme-based tagging or 
pre-amplification, and Nanostring and Panomics technologies are promising in 
that the isolated small RNAs are directly assessed without any further sample 
preparation step and at high sensitivity. However, these technologies may suffer 
from specificity issues common to virtually all hybridization-based platforms. 
 Northern blot is the ultimate and traditional technique for single microRNAs 
quantification, but it is a targeted approach and requires previous knowledge of 
the microRNA of interest. It is often used in confirmatory follow-up experiments. 
 In situ hybridization with either fluorescence or chromogenic detection is used 
for specific localization of relevant microRNAs within a fixed or frozen tissue 
section (Nuovo, 2008, 2010; Nuovo et al., 2009; Obernosterer et al., 2007). This 
technique is still time consuming, requires extensive troubleshooting via 
optimization of conditions, and cannot be used as absolute quantification method. 
Furthermore sample prep conditions (fixation), age of animal, reagents used etc 
can introduce a potentially high variability of results depending on. 
1.5.3 Next-generation sequencing 
The current method of choice to investigate small RNA expression is the NGS 
approach, also called digital expression profiling (DGE). In contrast to other 
methods, NGS profiling is hybridization-independent, can discriminate 
microRNA family members with single nucleotide differences, and capture 5′/3′ 
end variability (for example, isoMirs). Furthermore, sequencing does not require 
a priori information, and can be used to simultaneously detect known and 
discover new microRNAs (Linsen et al., 2009). Small RNA NGS is based on 
high-throughput DNA sequencing of libraries captured and ligated with adaptors 
necessary for building clusters inside the flow-cells (Illumina), for recognition of 
the sequencing beads (in the case of SOLiD) and for priming the synthesis (Figure 
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1-7D). Mammalian cells express a few hundreds of microRNAs at any given time. 
This is a relatively small number compared to a standard gene expression profile, 
and multiplexing of microRNAs samples guarantees a sufficient coverage. This is 
achieved by indexing (or barcoding) the adapters used for each sample with 
additional nucleotide sequences that can unequivocally assign the reads, allowing 
simultaneous analysis of a pool of samples in the same flowcell. However, 
normalization and data analysis is computationally expensive and requires 
specific bioinformatics knowledge. Sample preparation is time consuming and 
requires manual steps, like band excision from gel, which can easily be source of 
batch-to-batch differences.  
1.5.4 Additional Considerations 
As reviewed in (Linsen et al., 2009) it is controversial whether qPCR, arrays or 
NGS are suited for absolute quantification. The extensive sample preparation that 
includes enzyme based reactions (ligation, reverse transcription, starting material 
amplification, gel purification) can bias the population of microRNAs measured, 
as exemplified in the Supplementary Results of Chapter 2. However there is 
general good concordance of relative expression across the different platforms, 
and especially between qPCR and NGS, also reported in Chapter 3  (Pradervand 
et al., 2010).  
 
1.6 MicroRNAs in cardiac physiology and diseases 
1.6.1 Implications of cardiac microRNAs in organ development and diseases 
MicroRNAs are required for correct cardiovascular development and function, 
and Dicer conditional deletion causes heavy developmental defects and 
spontaneous dilated cardiomyopathy mice (Chen et al., 2008b; da Costa Martins 
et al., 2008; Rao et al., 2009). Among the most abundant microRNAs in the heart, 
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miR-1 and miR-133 are encoded from the same precursor (miR-1-2/miR-133a-1). 
 
Figure 1-9: Functional role of microRNAs in normal and diseased heart. MicroRNAs are 
depicted as bulged red ribbons. Arrows indicated activation, while blunted lines indicate 
inhibition of the downstream elements. Cardiomyocytes and fibroblasts are represented. 
Adapted from (Small and Olson, 2011). 
 
They are however under the control of transcription enhancers responsive to 
muscle differentiation factors that include Srf, MyoD and Mef2 (Liu et al., 2008; 
Liu et al., 2007; Zhao et al., 2007; Zhao et al., 2005).  
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MiR-1 and miR-133 have opposing effects in the cardiac lineage fate: miR-1 
induces differentiation, while miR-133a stimulates proliferation (Ivey et al., 
2008). Although their knock-down caused heavy developmental defects, none of 
the two microRNAs were absolutely required, as 50% of heart-specific knock 
down mice are viable (Liu et al., 2008; Zhao et al., 2007). 
 
Figure 1-10: MicroRNAs and genes implicated in cardiac diseases. Different cell types 
involved in cardiac remodeling are indicated: cardiomyocytes (squared red), fibroblasts 
(speared beige), and endothelial cells (small pink). Adapted from (Latronico and 
Condorelli, 2009). 
 
Moreover, microRNAs are implicated in cardiac diseases of different etiologies 
(Catalucci et al., 2009; Kinet et al., 2012; Latronico and Condorelli, 2009). 
Several microRNAs have the ability to influence cardiac remodeling through 
specific effects on signaling pathways (mir-133, mir-1, miR-9, miR-98, mir-199b, 
miR-23a), sarcomere organization (miR-208a/b, miR-499) and inter-cellular 
communication (miR-29 and mir-21) (Small and Olson, 2011) (Figure 1-9). 
Genes that are actively targeted by cardiac microRNAs include regulators of 
metabolism, electrical conduct, proliferation/hypertrophy and angiogenesis 
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(Figure 1-10). MiR-1 was described as a potential arrhythmogenic since it can 
target connexin 43 (GJA1) (Figure 1-10) and the K+ channel subunit Kir2.1 
(KCNJ2), and its deletion ameliorates recovery in post-infarction rodent models 
(Yang et al., 2007). 
Induction of miR-208a was sufficient to induce arrhythmias, and this 
microRNAs was implicated in cardiac performance and maintenance of 
conduction via targeting of two regulators of muscle growth and hypertrophy, 
namely thyroid hormone-associated protein 1 (Thrap1) and myostatin (Mstn) 
(Figure 1-10). Mir-21 and miR-29 were shown to be induced by fibrotic stimuli 
(i.e. after myocardial infarction) and mediated extra-cellular matrix (ECM) 
deposition (Thum et al., 2008; van Rooij et al., 2008). 
In addition, genetic polymorphism in pre-mir-499 and pre-miR-196a-2 are 
associated to human dilated cardiomyopathy (Lu et al., 2008). 
1.6.2 Cardiac microRNAs and pathological heart remodeling 
Pathological (irreversible) cardiac hypertrophy is caused by a variety of stimuli 
(i.e. hypertension, valvular heart disease, infarction, obesity, exaggerated 
pharmacology) and may cause heart failure. The disease progression is complex 
and involves several stages of molecular and histological remodeling (distinct 
from physiological hypertrophy due to exercise and pregnancy). At first, 
hypertrophic growth of cardiomyocytes and thickening of ventricular walls 
compensate for the increased demands (with or without chambers’ restriction), 
however sustained pathological stimuli can lead to a functional decompensation 
due to progressive thinning of the ventricular walls (Hill and Olson, 2008; 
Hoshijima and Chien, 2002; van Rooij and Olson, 2007). The transition from 
physiological to pathological is accompanied by re-expression of fetal genes and a 
switch in myosin isoforms (in rats Myh6 is down-regulated and Myh7 is up-
regulated). Interestingly, three microRNAs called myomiRs (miR-208a, miR-
208b and mir-499) are co-transcribed within the introns of myosin genes. In 
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particular,  a variety of stressors, including pressure overload and thyroid 
hormone cause activation of the fetal Myh7 (and miR-208b) transcription in adult 
rodents in a miR-208a dependent manner (van Rooij et al., 2009). Another 
cardiac microRNA, miR-133a was linked to cardiac hypetrophy: inhibition of 
miR-133 via infusion of an antisense construct in vivo caused sustained cardiac 
hypertrophy in rats. The authors identified the GDP-GTP exchange factor RhoA, 
the kinase Cdc42 and a cardiopoietic nuclear factor Whsc2 as direct targets of 
miR-133a (Carè et al., 2007) (Figure 1-10).  
A calcineurin-dependent transcriptional pathway has been shown to decrease 
apoptosis in a mice model being therefore beneficial for heart failure recovery (De 
Windt et al., 2000). However, the calcineurin-dependent nuclear factor NFATc3 
can induce the over-expression of the pro-hypertrophic miR-23a upon β-
adrenergic hypertrophic stimulation. The knock down of miR-23a was sufficient 
to relieve the isoproterenol induced enlargement (Lin et al., 2009).  
1.6.3 Additional Considerations 
Accumulating evidences strongly implicate microRNAs as key mechanistic 
players in cardiac pathways and regulatory circuits in both development and 
pathogenesis, and suggest microRNAs could be considered as provocative 
therapeutic targets (van Rooij and Olson, 2007). Interference with regulatory 
pathways can have multiple faceted effects, and microRNAs can be involved in 
the tight regulation required for proper homeostasis (i.e. miR-23 and calcineurin 
pathway mentioned above). 
An important caveat in microRNAs research in cardiac diseases is the 
assumption that disease-related microRNAs would be found either over- or down-
regulated in a diseased state. Jentzsch et al. performed a functional screening of 
pro-hypertrophic microRNAs in rat neonatal cardiomyocytes, by transfecting a 
library of human microRNAs and measuring the cell size by high content 
microscopy. They found that most of microRNAs that induced cardiomyocytes 
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hypertrophy (miR-212, miR-365, miR-22, miR-30c, miR-30d) were never found 
dysregulated in previous works (Jentzsch et al., 2011). This intriguing observation 
will have to be further confirmed with mechanistic studies, since potentially not 
all transfected microRNAs could have been be functional in the cells tested and 
that an isolated cell model often does not recapitulate in vivo findings.  
1.7 MicroRNAs in toxicology 
MicroRNAs are considered important genome regulators, and their modulation 
may be prodromal to gene expression changes. This is of particular interest in 
early detection of toxic liabilities and ultimately to explain the mechanisms of 
undersired effects in the affected tissues. 
Systematic toxicological studies involving microRNAs were performed mainly 
with hepato- and neuro- toxicants and carcinogens, while cardiac toxicity was not 
thoroughly investigated. A collection of toxicological studies has been illustrated 
by Lema and Cunningham (Lema and Cunningham, 2010) (Table 1-4). 
 
Table 1-4: microRNAs and toxicology. (↑) up-regulation; (↓) down-regulation. (Lema and 
Cunningham 2010) 
Organism Toxicant miRNA Target Biologic effect Reference 
Mouse Wy-14,643, 
peroxisome 
proliferator-activated 
receptor alpha 
(PPARα) agonist 
↑let-7C Transcription 
factor, c-myc 
Hepatocyte 
proliferation 
Shah et al. 
(2007) 
Mouse Ethanol ↓miR-21, -335, 
-153 
Notch-receptor 
ligand, Jagged-1, 
brain-specific 
regulator of RNA 
stability, ELAVL2 
(embryonic-lethal 
abnormal vision, 
Drosophila-like 2) 
Induction of cell 
cycle and stem cells 
maturation 
Sathyan et al. 
(2007) 
Mouse Hexahydro-1,3,5-
trinitro-1,3,5-triazine 
(RDX), 
environmental 
contaminant 
↑let-7, miR-15, 
-16, -26, -181; 
↓miR-10b 
Cell cycle 
regulators 
Regulation of tumor 
pathogenesis 
Zhang and Pan 
(2009) 
Mouse Hexahydro-1,3,5- ↑miR-206, -30, Brain-derived Neurotoxicity Zhang and Pan 
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Organism Toxicant miRNA Target Biologic effect Reference 
trinitro-1,3,5-triazine 
(RDX), 
environmental 
contaminant 
-195 neurotrophic factors 
(BDNFs) 
(2009) 
Rat Tamoxifen ↑miR17-92 
cluster, -106a, 
-34 
Cell cycle 
regulators, 
chromatin 
modifiers and 
expression 
regulators 
Hepatocarcinogenesis Pogribny et al. 
(2007) 
Rat Cigarette smoke ↑miR-294 Transcriptional 
repressor genes 
Altered gene 
expression 
Izzotti et al. 
(2009) 
Rat Cigarette smoke ↓let-7c, miR-
34c, -222 
Genes involved in 
stress response and 
cell proliferation 
Carcinogenesis Izzotti et al. 
(2009) 
Rat Acetaminophen; 
Carbon tetrachloride 
↓miR-298, -
370 
Thioredoxin 
reductase 3 
Hepatotoxicity Fukushima et 
al. (2007) 
Rat 4-
(methylnitrosamino)-
1-(3-pyridyl)-1-
butanone (NNK), 
tobacco carcinogen 
↓miR-126 Cytochrome P450 
(CYP) 2A3 
Tumorigenesis Kalscheuer et 
al. (2008) 
Human 1alpha,25-
dihydroxyvitamin 
D(3) 
(1,25(OH)(2)D(3)), 
major vitamin D 
metabolite 
↑miR-125b Endogenous 
vitamin D receptor 
(VDR) 
Augmentation of the 
antitumor effects of 
1,25(OH)(2)D(3) 
Mohri et al. 
(2009) 
Human Sodium arsenite ↓miR-210 Cellular methyl-
donor pool 
Alterations of 
genomic methylation 
Marsit et al. 
(2006) 
Human Cigarette smoking ↑miR-218 Transcription 
factor, MAFG (v-
maf 
musculoaponeurotic 
fibrosarcoma 
oncogene homolog 
G) 
Expression of MAFG 
targets 
Schembri et al. 
(2009) 
Human Iron- and aluminum-
sulfate 
↑miR-9, -125b, 
-128 
Regulatory and 
pathogenic genes 
Neurotoxicity Lukiw and 
Pogue (2007) 
Human 5-fluorouracil (5-
FU), antineoplasic 
drug 
↑miR-200b Protein tyrosine 
phosphatase 
(PTPN12) 
Inactivation of 
oncogenes products 
(c-Abl, Src or Ras) 
Rossi et al. 
(2007) 
 
1.7.1 MicroRNAs role in cytochrome toxicity 
Cytochromes and nuclear receptors are pivotal genes in pharmacodynamics and 
toxicology. Recent works suggest a number of these genes may be regulated by 
microRNAs (Figure 1-11) (Yokoi and Nakajima, 2011). MiR-27b, miR-298, miR-
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24, miR-34a and miR-148a were implicated in either direct or Hnf4/Pxr-mediated 
regulation of Cyp3a4 (Pan et al., 2009; Takagi et al., 2010; Takagi et al., 2008). 
Interestingly, Cy1b1 and RXRα were also found to be modulated by miR-27b (Ji 
et al., 2009a; Tsuchiya et al., 2006). Cyp2e1, the most abundant cytochrome in 
human liver, is over expressed in diabetes and obesity and down-regulated by 
insulin treatment. The capability of miR-378 to decrease Cyp2e1 was first 
described by Mohri and colleagues, and is likely to have toxicological relevance 
(Mohri et al., 2010). Cyp2a3 is responsible for the metabolic activation of the 
nicotine-derived pro-carcinogen nitrosamine ketone (NNK) α-hydroxylation. 
Kalscheuer and colleagues found that one of the microRNAs down regulated by 
NNK chronic administration in rat lungs, miR-126*, was also directly targeting 
Cyp2a3 (Kalscheuer et al., 2008), suggesting the implication of miR-126* in 
NNK carcinogenic potential. Cy24a1 and vitamin D receptor are involved in 
calcium homeostasis of solid tumors and are directly inhibited by miR-125b, 
which is itself modulated in a variety of tumors (Komagata et al., 2009; Mohri et 
al., 2009). 
 
Figure 1-11: MicroRNA-related networks of cytochrome P450 and nuclear receptors 
(Yokoi and Nakajima 2011). 
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1.7.2 Xenobiotics-induced carcinogenesis 
MicroRNAs expression was found altered upon xenobiotics administration, 
including cigarette smoke, tamoxifen, acetaminophen, ethanol, hexahydro-1,3,5-
trinitro-1,3,5-triazine (RDX), dioxin, arsenite and carbon tetrachloride (Fukushima 
et al., 2007b; Izzotti et al., 2010; Marsit et al., 2006b; Pogribny et al., 2007; 
Sathyan et al., 2007; Schembri et al., 2009; Yoshioka et al., 2011; Zhang and Pan, 
2009), however the impact of such changes on toxicity was often not investigated.  
Carcinogenesis is a common toxic outcome of xenobiotics exposure (Pogribny 
et al., 2007). Pparα signaling has been implicated in hepatocytes proliferation and 
tumor development. Shah and colleagues reported that let-7c was down regulated 
by administration of a PPARα agonist. Let-7c modulated c-myc cascade by 
directly inhibiting the c-myc oncogene via 3’UTR targeting. Thus let-7c appeared 
to be critical in PPARα -induced liver proliferation (Shah et al., 2007). 
Arsenic is known to induce bronchial epithelium carcinoma, via not completely 
understood mechanism. Wang et al. found that miR-200b was heavily down-
regulated in epithelial cells undergoing arsenic-induced epithelial-to-mesenchimal 
transition (EMT). Re-expression of miR-200b relieved the carcinogenic 
phenotype in vitro and tumorigenicity of arsenic exposed cells in a xenograft  
model (Wang et al., 2011c).  
Another cause of malignant bronchial epithelial cells transformation is 
exposure to benzopyrene. Silencing of miR-106a suppressed benzopyrene-
induced cell proliferation, promoted apoptosis and cell cycle arrest. 
Retinoblastoma1 (Rb1) was confirmed as miR-106a target by luciferase assay. 
These results suggest miR-106a may work as an oncogene in chemical carcinogen 
transformation (Jiang et al., 2011). 
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1.7.3 Additional Considerations 
As for transcriptomics, confirming causal implication of microRNAs in tissue 
injury requires careful in vivo study design. Drug-induced expression changes of 
microRNAs should be monitored at early stages, before overt histopathological 
readouts are present. Also, dosing scheme and duration should mimic foreseen 
applications in patients. Including several time points and a washout phase can 
help observing microRNAs being affected earlier than others, or that persist 
altered even after discontinuation from the treatment.  
Noteworthy, lack of extensive characterization of microRNAs expression in 
different cell types and their multiplicity of downstream effects, hinder the 
possibility to build up cell type or functional lists of microRNAs, as it is instead 
possible with regular genes (expression atlas and gene ontology). Systematic 
target discovery/validation and detailed expression profiling of tissues cell types 
will enable a direct interpretation of changes in a network of microRNAs and 
mRNAs.  
In conclusion, the implication of microRNAs in cardiotoxicity is still to be 
investigated. 
1.8 Circulating microRNAs: from intercellular signaling and organ injury 
biomarkers 
1.8.1 The discovery and function of microRNAs in body fluids 
In recent years, microRNAs were detected and characterized in several cell-free 
fractions of mammalian blood, including vesicles (exosome, microparticles and 
apoptotic bodies), but also in protein associated fractions, and globally called 
circulating microRNAs (Figure 1-12). 
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1.8.1.1 Exosomes, microparticles and apoptotic bodies 
The presence of microRNAs in extracellular exosomes (50-90 nm) was first 
described by Valadi and collaborators in 2007 (Valadi et al., 2007). The same 
study revealed the extreme stability and resistance of cell-free microRNAs to 
enzymatic degradation. Further studies identified microRNAs in microparticles (> 
100 nm) and apoptotic bodies. In fact, studies conducted on mammalian cell lines 
suggest that extracellular and intracellular microRNAs pools are clearly distinct, 
since preponderant cytoplasmatic microRNAs are not the most abundant in the 
respective supernatant (Collino et al., 2010; Ohshima et al., 2010; Pigati et al., 
2010). Furthermore respiratory chain inhibitors (i.e. rotenone) alter the 
microRNAs release kinetic pointing to a potential energy-dependent microRNAs 
secretion pathway (Wang et al. 2010b). 
Microvesicles are important mediators of cell-to-cell communications, as they 
contain protein and chemokines (Ratajczak et al., 2006). In general, release of 
microRNAs form both exosomes and microparticles appear to be an actively 
regulated process, raising the possibility that vesicle-enclosed microRNAs may 
work as long-distance inter-cellular communication and regulation (Kosaka et al., 
2010). Several studies documented how monocyte-secreted microvesicles contain 
high levels of miR-150, and can deliver it to different cells and inhibit miR-150 
target c-Myb (Xiao et al., 2007; Zhang et al., 2010). Pegtel et al. found that an 
Epstein-Barr virus specific microRNA could accumulate in non-infected MoDC 
cells when co-cultured with EBV-infected B cells, and that this process is 
mediated by exosome transfer (Pegtel et al. 2010). Recently, Hergenreider et al. 
showed how vesicles encapsulated miR-143/145 cluster produced by HUVEC can 
control targets in co-cultured human smooth muscle cells, opening new avenues 
for atherosclerosis treatment (Hergenreider et al., 2012). 
In addition to secreted vesicles, pools of microRNAs reflecting their cellular 
origin are also found in apoptotic bodies. Notably, miR-126 contained in 
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endothelial cells apoptotic bodies could mediate CXCL12 production in recipient 
vascular cells, thus mitigating atherosclerosis via incorporation of stem cell 
antigen-1 positive progenitor cells in atherosclerotic plaques (Figure 1-12) 
(Zernecke et al., 2009). 
1.8.1.2 Membrane-free microRNAs complexes 
More recent works proposed that microRNAs are present in membrane-free 
fraction, mainly in association with protein complexes or high-density 
lipoproteins (HDL). Ago2/miRNA complexes were identified in cell culture 
media (Turchinovich et al., 2011) and plasma (Arroyo et al., 2011). Protein-
associated microRNAs originate mainly from cell death by-products and are 
stable in the bloodstream. This is partially attributed to further association of 
particle-free microRNAs to nucleophosmin (NPM1). Intrestingly, specific 
microRNAs, such as miR-16 and miR-92a, preferentially associated with vesicle 
fractions, while others, like let-7a, rather co-purified with protein complexes 
(Wang et al., 2010c). Human HDL was shown to contain microRNAs. Native 
HDL could incorporate microRNAs and deliver genetic material to recipient cells. 
RhoB and Efna1 mRNAs were decreased upon HDL-mediated miR-223 delivery 
in human cultured hepatocytes. HDL-microRNAs transfer was dependent on the 
known HDL receptor scavenger receptor class B type I (SR-BI). Furthermore, 
HDL obtained from familial hypercholesterolemia (FH) patients, contained a 
pattern of microRNAs that differed from control subjects, raising the possibility 
of using HDL-associated microRNAs as diagnostic markers (Vickers et al., 
2011). 
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Figure 1-12: Circulating microRNAs. Mechanisms protecting microRNAs from 
degradation. EC indicates endothelial cells; HDL, high-density lipoprotein; NPM-1, 
nucleophosmin-1; SRB1, scavenger receptor class B member 1; BHK, baby hamster 
kidney (Fichtlscherer et al., 2011). 
 
1.8.2 Circulating microRNAs as tissue injury biomarkers 
Circulating microRNAs have been proposed to be non-invasive, sensitive and 
specific tissue injury biomarkers, thanks to their relative stability in the blood 
stream and the easiness of quantification via qPCR. Upon injury of different 
etiologies (infectious, pharmacological, etc.) microRNAs are released in the 
circulation in apoptotic bodies, or in protein complexes, where are usually stable 
(Laterza et al., 2009). A number of microRNAs are expressed in a tissue specific 
manner and can be relatively stable if released in body fluids. Profiling of 
circulating microRNAs as indicators of drug-induced tissue injury may help to 
reinforce histopathology and clinical chemistry endpoints. However not very 
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many microRNAs are known to be strictly tissue specific. MiR-122 is mostly 
expressed in the liver, miR-124 in the brain and miR-133a in heart and skeletal 
muscle (Laterza et al., 2009). Furthermore tissues are constituted by a 
heterogeneous population of cells assembled in distinct histological structures, 
characterized by different molecular expression.  
1.8.2.1 Biomarkers of cardiovascular diseases  
A growing field for application of circulating microRNAs as tissue injury 
biomarkers concerns the cardiovascular system, summarized in Table 1-5 
(Fichtlscherer et al., 2011). Myonecrosis associated with acute myocardial 
infarction, acute coronary syndrome and viral myocarditis caused increase of 
miR-1, miR-133, miR-499 and/or miR-208 in the plasma of patients, as 
documented by several publications (Adachi et al., 2010; Ai et al., 2010; Cheng et 
al., 2010; Corsten et al., 2010; D'Alessandra et al., 2010b; De Rosa et al., 2011; 
Kuwabara et al., 2011; Wang et al., 2010b; Widera et al., 2011). Notably, miR-
208 is the most cardiac specific microRNA, since its expression is restricted to the 
myocardial tissues, whereas miR-1, miR-133 and miR-499 are also expressed in 
skeletal muscles (Ji et al., 2009b). Furthermore, miR-208 was released in blood of 
rats after coronary artery ligation, while miR-1, miR-133a and miR-499 were 
increased in the circulation of sham operated animals, in respect to non operated 
animals (Wang et al., 2010b). None of the usual cardiac microRNAs was released 
in the circulation of patients suffering from congestive heart failure (CHF) 
(Adachi et al., 2010). However, in one case researchers observed an increase of 
circulating miR-423-5p in a 30 CHF patients cohort (Tijsen et al., 2010). 
Conversely, acute heart failure was associated with detectable increase of miR-
499, reflecting a myocardial damage (Corsten et al., 2010). 
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Table 1-5: Circulating microRNAs in patients with cardiac disease, adapted from 
(Fichtlscherer et al. 2011). AMI: acute myocardial infarction; ACS: acute coronary 
disease; CHF: congestive heart failure; HF: heart failure; CAD: coronary artery disease 
Clinical 
Study 
Cohort 
Groups and 
Numbers of 
Patients 
Studied 
Major 
Findings 
Association/
Correlation 
RNA 
Isolation 
miRNA 
Detection 
Reference 
AMI  
33 pts with 
AMI 
miR-208a, 
miR-1, miR-
133a, miR-
499↑ 
ROC curve: 
miR-208a 
shows highest 
sensitivity 
and 
specificity, 
comparable 
to TnI 
Plasma, TRI 
Reagent BD, 
Spiking with 
cel-miR-39 
qPCR 
TaqMan 
(ABI) 
(Wang et al. 
2010a) 
33 pts with 
stable 
CAD/other 
cardiovascular 
disease 
30 healthy 
controls 
AMI  
33 pts with 
STEMI 
miR-1, miR-
133a, miR-
133b, miR-
499-5p↑ 
Time course 
of 
upregulated 
miR 
associated 
with TnI 
mirVana 
PARIS 
isolation kit 
(Ambion, 
Austin, TX) 
qPCR 
TaqMan 
(ABI) 
(normalized to 
miR-17) 
(D'Alessandr
a et al. 2010) 
17 healthy 
controls 
AMI 
unstable 
angina 
9 pts with 
STEMI 
miR-499↑ in 
STEMI 
(within 48 h) 
Correlation 
with CKMB 
Vana PARIS 
Kit (Ambion) 
Spiking with 
small RNA 
qPCR 
TaqMan 
(ABI) 
(Adachi et 
al. 2010) 
5 pts with 
unstable 
angina 
10 healthy 
controls 
AMI  
93 pts with 
AMI 
miR-1↑ 
Association 
with QRS 
duration 
mirVana 
PARIS 
(Ambion) 
protocol 
qPCR 
(Ai et al. 
2010) 66 healthy 
controls 
AMI  
31 pts with 
AMI 
miR-1↑ 
Association 
with CKMB 
levels 
miR Isolation 
Kit (RNA 
Bioscience) 
qPCR, primer 
ABI, Roche 
Light cycler 
(Cheng et al. 
2010) 20 healthy 
controls 
AMI  
29 pts with 
ACS miR-1, miR-
133↑ 
Correlation 
with TnT 
TRIzol LD 
(Invitrogen) 
qPCR, 
TaqMan 
(ABI) 
(Kuwabara 
et al. 2011) 42 pts without 
ACS 
AMI  
32 pts with 
AMI 
36 pts with 
chest pain but 
normal 
angiogram 
miR-208b, 
miR-133a, 
miR-499↑ 
miR-223↓ 
miR-208b 
and miR-499 
correlate with 
TnT 
mirVana 
PARIS kit 
(Ambion) 
qPCR, 
MiScript 
primers 
(Qiagen), BR 
SYBR Green 
(Quanta 
Biosciences) 
(Corsten et 
al. 2010) 
ACS  
444 pts with 
ACS 
In pts with 
ACS: miR-1, 
miR-133a/b, 
miR-208b↑ 
miR-133a 
and miR-
208b 
associated 
with risk of 
death 
miRNeasy 
RNA isolation 
kit (Qiagen, 
Inc.) 
qPCR, 
TaqMan 
(ABI) 
(Widera et 
al. 2011) 
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Clinical 
Study 
Cohort 
Groups and 
Numbers of 
Patients 
Studied 
Major 
Findings 
Association/
Correlation 
RNA 
Isolation 
miRNA 
Detection 
Reference 
ACS  
7 pts non-
CAD In pts with 
ACS: miR-
133, miR-499, 
miR-208↑ 
Transcoronar
y gradients 
document 
cardiac 
release of 
miR-133 and 
miR-499 
miRNeasy 
RNA isolation 
kit (Qiagen, 
Inc.) 
qPCR, 
TaqMan 
(ABI) 
(De Rosa et 
al. 2011) 
31 pts stable 
CAD 
19 pts ACS 
CHF 
30 pts with 
heart failure 
miR-423-5p↑ 
ROC 
showing that 
miR-423-5p 
is a predictor 
of heart 
failure 
mirVana 
PARIS kit 
(Ambion) 
qPCR High 
Resolution 
Melting 
Master 
(Roche) 
(Tijsen et al. 
2010) 
20 pts with 
dyspnea (non-
HF) 
39 healthy 
controls 
CHF 
15 pts CHF (II 
and III) 
miR-499 
below 
detection limit 
of the PCR in 
CHF pts and 
healthy 
controls 
  
mirVana 
PARIS kit 
(Ambion) 
qPCR 
TaqMan 
(ABI) 
(Adachi et 
al. 2010) 
10 healthy 
controls 
CHF 
33 pts with 
ischemic HF 
17 controls 
miR-126↓ 
miR-126 
negatively 
correlated 
with age, 
BNP and 
NYHA class 
mirVana 
PARIS kit 
(Ambion) 
qPCR 
TaqMan 
(ABI) 
(Fukushima 
et al. 2007) 
Acute 
HF 
33 pts with 
acute HF 
34 controls 
Acute Heart 
failure: miR-
499↑ 
  
mirVana 
PARIS kit 
(Ambion) 
qPCR, 
MiScript 
primers 
(Qiagen), BR 
SYBR Green 
(Quanta 
Biosciences) 
(Corsten et 
al. 2010) 
 
Viral 
myocardi
tis 
14 pts with 
acute viral 
myocarditis 
Acute viral 
myocarditis: 
miR-208, 
miR-499↑ 
Course of 
viral 
myocarditis 
mirVana 
PARIS kit 
(Ambion) 
qPCR, 
MiScript 
primers 
(Qiagen) BR 
SYBR Green 
(Quanta 
Biosciences) 
(Corsten et 
al. 2010) 
20 pts post-
viral 
myocarditis 
20 aged-
matched 
controls 
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1.8.1 Technical aspects of microRNAs quantification in body fluids  
Technically speaking, microRNAs quantification in plasma/serum is affected 
by high variability. Many factors, including withdrawal protocol, preparation of 
samples, age of the subject, diet and plasma components can alter the outcome of 
microRNAs profiling from human samples (Kim et al., 2012). Obtaining plasma 
from whole blood requires addition to the test tubes of anti-coagulant agents, such 
as heparin, EDTA, Na-citrate or NaF/KOx.  These can have inhibitory effect on 
either the RNA isolation or reverse transcription and qPCR (Kim et al., 2012). 
Insufficient blood centrifugation, inaccurate supernatant withdrawal and 
hemolysis can lead to confounding cellular microRNAs to be co-purified and 
quantified. Therefore, standardized methods and accurate removal of 
contaminants (proteins, lipids and enzyme inhibitors) from body fluids is essential 
for quantification of microRNAs by qPCR. 
1.9 Contribution to the field 
In this thesis I will illustrate our strategies to generate data that can support 
elucidation of the molecular mechanisms of cardiac function and drug-induced 
cardiomyopathy. First, we identified a microRNAs signature altered by an anti-
tumoral agent known for its cardiotoxicity (doxorubicin), and proposed a link 
with concomitant transcriptome variation, and we could identify a novel direct 
microRNAs-mRNAs interaction (miR-34/Sipa1). Second, we have uncovered the 
spatial distribution of microRNAs and mRNAs in 8 cardiac structures of rat, dog 
and Cynomolgus monkey, with a level of detail never achieved before in these 
model species. A subset of microRNAs with a patterned expression across cardiac 
structures was further characterized and 3 novel targets relevant for cardiac 
biology were validated (Timp3, Rbm24, Csnk2a2). 
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Ideally, our findings will contribute to develop more predictive safety models 
for drug development, especially for cardiac toxicity, as much needed in the field 
(Stummann et al., 2009). 
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Chapter 2:  Perturbation of microRNAs in rat heart during 
chronic doxorubicin treatment 
2.1 Abstract 
Anti-cancer therapy based on anthracyclines (DNA intercalating 
Topoisomerase II inhibitors) is limited by adverse effects of these compounds on 
the cardiovascular system, ultimately causing heart failure. Despite extensive 
investigations into the effects of doxorubicin on the cardiovascular system, the 
molecular mechanisms of toxicity remain largely unknown. MicroRNAs are 
endogenously transcribed non-coding 22 nucleotide long RNAs that regulate gene 
expression by decreasing mRNA stability and translation and play key roles in 
cardiac physiology and pathologies. Increasing doses of doxorubicin, but not EPS 
(a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically 
induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-
367 in rat hearts. Furthermore, the lowest dosing regime (1 mg/kg/week for 2 
weeks) led to a detectable increase of miR-216b in the absence of 
histopathological findings or alteration of classical cardiac stress biomarkers. In 
silico microRNA target predictions suggested that a number of doxorubicin-
responsive microRNAs may regulate mRNAs involved in cardiac tissue 
remodeling. In particular miR-34c was able to mediate the DOX-induced changes 
of Sipa1 mRNA (a mitogen-induced Rap/Ran GTPase activating protein) at the 
post-transcriptional level and in a seed sequence dependent manner. Our results 
show that integrated heart tissue microRNA and mRNA profiling can provide 
valuable early genomic biomarkers of drug-induced cardiac injury as well as 
novel mechanistic insight into the underlying molecular pathways. 
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2.2 Introduction 
Doxorubicin (DOX), a potent drug used in cancer chemotherapy, intercalates 
with DNA and stabilizes a ternary complex with Topoisomerase II (Top2) thus 
preventing replication of DNA and subsequent cell proliferation(Momparler et al., 
1976).  
Despite its beneficial therapeutic effects, acute administration of high DOX 
doses causes severe kidney damage, whilst toxic cardiomyopathy is observed 
when DOX is chronically administered for several weeks at doses devoid of 
severe nephrotoxicity (Bardi et al., 2007; Chen et al., 2007; Jones et al., 2006; 
Storm et al., 1989). The exact mechanism of its cardiac toxicity remains largely 
unknown. In a clinical setting, the occurrence of DOX-induced cardiomyopathy is 
mitigated by prophylactic treatment with dexrazoxane (DZR), a Top2 inhibitor 
and iron-chelating agent which limits the amount of metal ions interacting with 
DOX and thus reduces oxidative stress (Jones et al., 2006) . The cardioprotective 
mechanism of DZR is at present not fully understood (Hasinoff and Herman, 
2007). 
Administration of DOX ranging from 1 to 3 mg/kg/week to rats during several 
weeks recapitulates the cardiac symptoms observed in humans (Gianni et al., 
2008; Herman and Ferrans, 1998). Similarly, combined treatment with DZR 
lessens the cardiac symptoms in rats treated with DOX (Thompson et al., 2009).  
 MicroRNAs are a class of genomically encoded non-translated short RNAs, 
about 22 nucleotides long, discovered in plants in 1993 (Lee et al., 1993). They 
are evolutionarily conserved throughout higher eukaryotes, from C.elegans to 
human, and their function is exerted via the mammalian RNA interference 
machinery (He and Hannon, 2004). They play a role in the post-transcriptional 
regulation of target genes, via imperfect base complementarities, and control gene 
expression mainly via translation inhibition and mRNA degradation (Filipowicz 
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et al., 2008; Guo et al., 2010; Wu and Belasco, 2008). MicroRNAs are involved in 
a diverse range of physiological and pathological processes including organism 
development (Marson et al., 2008), cancer (Croce, 2009)  and immunity (Cullen, 
2006; Rodriguez et al., 2007; Umbach and Cullen, 2009). In particular, 
microRNAs are key players in the development, physiology and pathology of the 
heart (Latronico and Condorelli, 2009; Thum et al., 2007; van Rooij et al., 2006). 
MicroRNAs have been shown to be differentially expressed in response to various 
signals resulting in post-transcriptional regulation of their predicted target genes. 
This extra level of regulation is critical during heart development and important in 
the cardiac response to stress (Callis et al., 2009; van Rooij et al., 2007).  
Recent studies investigating DOX-induced changes in gene expression at the 
mRNA level in rat cardiac tissue have successfully identified genomic biomarkers 
whose molecular functions are consistent with proposed toxicity mechanisms 
(Thompson et al., 2009). However the emerging importance of microRNAs for 
the regulation of cardiac physiology and pathologies (Latronico and Condorelli, 
2009; Thum et al., 2007; van Rooij et al., 2006), together with their potential to 
provide novel insight into mechanisms of xenobiotics-induced toxicity (Taylor 
and Gant, 2008), suggest that the integration of mRNA and microRNA profiling 
may provide new opportunities for elucidating mechanisms of DOX-induced 
cardiotoxicity. 
In the present study, we report that the chronic myocardial toxicity induced by 
DOX in rats was associated with the modulation of microRNAs, and some of 
these can be phenotypically anchored to histopathology findings.  Alteration of 
miR-216b could be detected earlier than overt myocardial damage. Furthermore, 
by integrating DOX-inducible microRNAs with mRNA profiles generated from 
the same cardiac tissue samples, the putative target genes of the DOX-induced 
microRNA signature were highlighted, including a number of genes that have not 
previously been described in DOX-induced cardiomyopathy. Finally, evidence for 
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the direct targeting of Sipa1 mRNAs by miR-34c was provided for the first time, 
and this microRNA-mRNA interaction could potentially play a role in the 
molecular response to DOX in the rodent heart.  
2.3 Materials and methods  
2.3.1 Rat in vivo study and histopathology evaluation 
This in vivo study was conducted in compliance with the Animal Welfare Act, 
and the Office of Laboratory Animal Welfare, after review and approval by the 
Covance site (Vienna, Virginia) Institutional Animal Care and Use Committee.  
Doxorubicin (Adriamycin, Lot No. 86G23FY, CAS# 23214-92-8), a generous gift 
from Adria Laboratories Inc. (Columbus, OH, USA), etoposide (ETOPOPHOS® 
Lot No. 5E04155, CAS# 117091-64-2) was purchased from Bristol-Myers Squibb 
(Princeton, NJ, USA) and dexrazoxane (Zinecard® Lot No. ADR074B, CAS# 
24584-09-6) purchased from Pharmacia/Pfizer (Kalamazoo, MI, USA) were 
administered once weekly as follows: 11 week old male Crl:CD(SD) rats received 
DOX or EPS via intravenous injection once a week for 2, 4, or 6 weeks according 
to Supplementary table 2-1 at a dose volume of 2 mL/kg.  Animals in the DZR 
groups were given a 10 mL/kg intraperitoneal injection of DZR followed (302 
minutes later) by a 2 mL/kg IV injection of 0.9% sodium chloride or DOX. The 
intravenous (iv) route of administration for DOX and EPS and the intraperitoneal 
(ip) route for DZR respectively, were selected to match the clinical route of 
administration in humans. More details are provided in the Supplementary 
Material and Methods and in a forthcoming publication from Gerrish et al. The 
experimental strategy is summarized in Figure 2-1. 
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2.3.2 Heart tissue RNA extraction 
Total RNA was obtained from 50-100 mg frozen cardiac tissue homogenized in 
Trizol, according to manufacturer instructions (Invitrogen, Life Technologies, 
Carlsbad, CA). Long and short RNA fractions were separated via affinity resin 
column during clean up, according to the manufacturer instructions (miRNeasy 
Mini Kit, Qiagen, MD). Short RNA was quantified by absorbance at 260 nm 
using a Nanodrop (Thermo Scientific, Wilmington, DE), and the quality and 
integrity were determined using Small RNA chips (Agilent Technologies, Santa 
Clara, Ca) and stored at -80°C until analysis.  
2.3.3 Gene expression profiling and analysis 
GeneChip experiment was conducted in the BMD Genechip laboratories 
(Novartis, BS) on Rat Genome Rat230 2.0 Array (Affymetrix, Inc.). Target 
preparation was performed with a starting amount of approximately 1 µg of total 
RNA unless otherwise specified using the Affymetrix GeneChip HT One-Cycle 
Target Labelling and control reagent according to manufacturer’s instruction 
(Affymetrix, Inc.). cRNA size distribution (before and after fragmentation) was 
confirmed by agarose-gel electrophoresis. An amount of biotinylated cRNA of 
approximately 10 µg for each sample was hybridized for approximately 16 hours 
at 45°C on an array. The array was washed and stained on Affymetrix Fluidics 
Workstation 450 and scanned on Affymetrix Scanner 3000 according to 
manufacturer’s technical manual. The scanned image was converted into 
numerical values of the signal intensity (Signal) and into categorical expression 
level measurement (Absolute Call) using the Affymetrix MAS 5.0 software. The 
software scaled the average intensity of each chip to a target intensity of 150. The 
Genechip data will be uploaded in ArrayExpress. 
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2.3.4  Amplification of microRNAs via quantitative PCR 
Using the Taqman Low Density Array (TLDA) technology (Applied 
Biosystems, Life Technologies, Carlsbad, CA), about 500 rodent microRNAs 
were profiled without any pre-amplification step, using 700 ng of small RNA 
according to the manufacturer instructions (Applied Biosystems, Life 
Technologies, Carlsbad, CA). Sufficient RNA amount for the TLDA cards was 
obtained for 3 out of 6 animals receiving DOX 3 mg/kg/week for 4 weeks, and for 
6 out of 6 receiving DOX 3 mg/kg/week for 2 weeks. An arbitrary cut-off at 35 Ct 
was set in order to exclude microRNAs out of the linear range of detection. 
Mammalian snRNA U6 was used as housekeeping gene for its expression was not 
affected by DOX treatment. In order to confirm the results of the TLDA, a subset 
of microRNAs were quantified using single Taqman assays in the 3 remaining 
animals treated with DOX 3 mg/kg/week for 4 weeks. All procedures were 
carried out according to manufacturer instructions (Applied Biosystems, Life 
Technologies, Carlsbad, CA) using a 7900HT Fast Real-Time PCR System.  
2.3.5 Data Analysis 
 MicroRNA data obtained from the TLDAs were quality checked and analyzed 
using Statminer plugin (Integromics, Madrid, Spain) for TIBCO Spotfire (TIBCO 
Software, Palo Alto, CA). Average fold changes and standard deviations were 
calculated and plotted using GraphPad Prism 5.00 (GraphPad Software, San 
Diego California USA). Lists of putative targets for each DOX regulated 
microRNA were obtained from Microcosm (Griffiths-Jones et al., 2008). Raw 
intensity values for each probe set were generated using RMA algorithm, using 
Genespring GX 7.3 (Agilent Technologies, Santa Clara, CA). Gene lists were 
filtered for raw expression (>80 raw signal in at least 50% of arrays) and anti-
correlation with the microRNA (absolute fold change >1.3 or 1.5 in animals 
receiving DOX 3 mg/kg for 4 weeks versus control treated). Candidates passing 
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this cut-off were used to build networks of up- or down-regulated genes with their 
putative cognate microRNAs. P values were generated via unpaired, two-tailed 
Student t-test and were considered significant below 0.05. Phenotypic anchoring 
and Spearman correlation analysis were realized by using TIBCO Spotfire 
(TIBCO).  
2.3.6 Cell culture and DOX treatment 
HEK 293 (CRL-1573, ATCC) and rat myoblastic cells H9c2 (CRL-1446, 
ATCC) were cultured in MEM and DMEM respectively, supplemented with 
10%v/v heat-inactivated fetal bovine serum (Invitrogen). DOX was purchased 
from Sigma, diluted in DMSO to a stock concentration of 10 mM and stored at -
20°C. DOX treatment of H9c2 cells (n= 3) was independently repeated 3 times 
(total of 9 replicates). DOX was added cells transfected with microRNA reagents 
after 4 hours, buy replacing transfection medium with fresh growth medium 
supplemented with DOX at the indicated concentrations. 
2.3.7  MicroRNA target luciferase reporter assay 
Two-hundred nucleotides surrounding the microRNA predicted seed site in the 
3’-UTRs of either murine Tnni3k or Sipa1 were synthesized (GeneArt, 
Invitrogen, Carlsbad, CA) and cloned into a pmiR-GLO vector (Promega, 
Madison, WI) downstream of the luciferase gene via a XbaI-SacI restriction site 
to generate the pmiR-GLO-Sipa1 wt expression vector. The pmiR-GLO 
expression vector contains both the luciferase and the Renilla genes under the 
control of different promoters. Complete insert sequences are listed in 
Supplementary Material and Methods section. Stratagene “Quick change” kit was 
used to introduce a 6 nt mutation in the miR-34c predicted seed site to generate 
the pmiR-GLO-Sipa1 mutant and the pmiR-GLO-Tnni3k mutant expression 
vectors.  
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Sipa1 mutagenesis Primer1: 5’- CTG CGC TGA GGC GCG TCT TAG GGA 
ATT CCC CTC TTC CCA GCC CAT TTG -3’. Sipa1 mutagenesis Primer 2: 5’- 
CAA ATG GGC TGG GAA GAG GGG AAT TCC CTA AGA CGC GCC TCA 
GCG CAG -3’. 
2.3.8 Transfection of HEK 293 
HEK 293 cells were plated in 24 wells plates 24 hours prior to co-transfection 
in antibiotic-free medium. Cells (2x 10
5 
per well) were co-transfected with the 
reporter constructs (20ng/well) and synthetic mmu-miR-34a, b or c (40 or 80 nM) 
mimics (Dharmacon, Lafayette, CO) in serum-free medium, using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). A C. elegans microRNA mimic with no affinity 
for mammalian targets was used as negative control. Dual-GLO Luciferase Assay 
System (Promega, Madison, WI) was used to assess luciferase relative 
luminescence, according to manufacturer instructions. 
2.4 Results 
2.4.1 Doxorubicin induced cytoplasm vacuolation and dysregulation of tissue 
genomic cardiomyopathy indicators 
Male rats were treated with DOX according to the scheme reported in 
Figure 2-1A. Macro-and micro-vesicular vacuolation of individual cardiac 
myocytes was observed in atria and ventricles of DOX-treated animals.  
Representative histopathological image is shown in Figure 2-1B and C. Atrial and 
ventricular vacuolation occurred with increasing frequency and severity over 
time, with or without continued weekly exposure to drug (Supplementary table 
2-2). The vacuoles could be caused by autophagic vesicles accumulation 
(Kobayashi et al., 2010); however, a hierarchical clustering using the expression 
of 31 autophagy-related genes could not discriminate between vehicle and DOX 
treated cardiac samples (data not shown). Given the small proportion of 
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cardiomyocytes undergoing vacuolation within the whole tissue it is possible that 
the expression changes of a large list of genes would be diluted by background 
signals. The treatment of DOXO at 1, 2 or 3 mg/kg/week for 2, 4 and 6 weeks 
showed a statistically significant increase of Ambra1 mRNA, a positive 
autophagy regulator (Fimia et al., 2007)  but did not affect the level of other 
markers (Figure 2-6A).  
 
Figure 2-1: Study design and representative micrograph showing DOX-related 
vacuolation in the myocardium.(A) Six adult male rats were injected with the indicated 
doses of vehicle, doxorubicin (DOX), dexrazoxane (DZR), etoposide (EPS) or a 
combination of DOX and DZR for 2, 4 or 6 weeks. Cardiac tissue was excised and deep 
frozen for gene expression and microRNA profiling experiments. A representative 
micrograph of a toluidine blue stained myocardial section of acontrol (B) and of a DOX 
treated animal (C). Black arrows indicate sarcoplasmic micro- and macro- vacuolation of 
cardiomyocytes. 
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The administration of DOX at 3 mg/kg/week induced time-dependent changes 
in the expression of mRNAs that have previously been associated with molecular 
responses underlying cardiac pathologies (de Bold et al., 1996; Dorn et al., 1994; 
Mikhailov and Torrado, 2008) (Figure 2-2).  
 
Figure 2-2: DOX 3mg/kg/week altered levels of genomic cardiomyopathy indicators 
(Ankrd/Carp, Nppb, Myh7 and Myh6). Expression fold change relative to vehicle were 
represented for DOX 3 mg/kg/week at 2, 4 and 6 weeks time point (n= 6) for (A) 
Ankrd/Carp, (B) Nppb, (C) Myh7 and (D) Myh6. For each time point and each probe set, 
vehicle values were averaged and normalized to 1. The same correction was applied to the 
DOX treated values. Affymetrix probe-set number is indicated in brackets. Error bars 
represent standard deviation. T-test was performed for vehicle- vs. DOX-treated at each 
time point. *P<0.05, **P<0.01, ***P<0.005, NS=Non-Significant. (No t-test for #, as n=2). 
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A significant increase of Ankyrin repeat domain 1 (Ankrd1/Carp), natriuretic 
peptide precursor type B (Nppb) and myosin heavy chain 7 (Myh7/β) mRNA and 
a significant decrease of myosin heavy chain 6 (Myh6/α) mRNA was observed in 
the groups treated with DOX at 3 mg/kg/week. Together, these genomic 
cardiomyopathy indicators were significantly altered between 2 and 4 weeks of 
treatment and remained altered after 6 weeks of treatment. 
Furthermore, they were not affected by EPS and DZR alone (data not shown). 
It is important to note that only two out of six animals survived 6 weeks dosing of 
DOX 3 mg/kg/week. 
 
2.4.2 Perturbation of rat heart microRNAs during chronic DOX treatment 
Expression profiles of 518 rodent microRNAs were generated by using a low 
density array qPCR platform (TLDAs). Approximately 370 microRNAs gave a 
measurable signal below the arbitrary cut-off set at 35 qPCR cycle times (Ct), 
with no major distinction between controls and treated samples. The 
administration of 4 weekly doses of DOX 3 mg/kg/week led to increased levels of 
17 microRNAs and decrease levels of 8 microRNAs (p-value below 0.05) (Table 
2-1). Notably, a subset of those was consistently modulated at the earlier 2 weeks 
time point (fold change > 1.5 are italicized in Table 2-1).  
Table 2-1: Chronic DOX treatment (3 mg/kg/ week) alters levels of 25 microRNAs from 
week 2 onwards. 
 2 weeks 4 weeks 
DOX 3mg/kg/week FC P value FC P value 
mmu-miR-367 # 4.58 1.97E-01 74.69 1.76E-06 
mmu-miR-215 # 1.11 9.41E-01 51.42 7.45E-03 
mmu-miR-216b # 42.58 4.54E-03 24.17 2.92E-03 
mmu-miR-383 # 2.22 5.69E-01 21.50 5.97E-04 
mmu-miR-692 # 1.79 5.16E-01 17.71 9.47E-03 
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mmu-miR-135b 1.74 1.07E-01 12.69 4.04E-02 
mmu-miR-667 1.49 3.08E-01 7.19 1.45E-02 
mmu-miR-298 -1.44 1.83E-01 3.67 1.69E-02 
mmu-miR-145* 1.60 8.87E-02 3.42 1.09E-02 
mmu-miR-208b # 1.09 7.94E-01 3.23 3.05E-03 
mmu-miR-21* 1.16 7.36E-01 3.21 4.26E-02 
mmu-miR-877 1.55 1.79E-01 2.74 2.33E-02 
mmu-miR-709 # 1.04 8.38E-01 2.51 7.28E-03 
mmu-miR-708 # 1.11 7.08E-01 2.34 1.57E-02 
mmu-miR-31 -1.02 9.68E-01 2.32 3.95E-02 
mmu-miR-34c # 1.02 9.55E-01 2.25 3.06E-02 
rno-miR-29b-2* -1.10 6.84E-01 2.01 3.41E-02 
mmu-miR-218-2* # 1.03 9.79E-01 -8.61 3.45E-03 
mmu-miR-434-5p -3.21 3.29E-01 -6.14 4.81E-02 
rno-let-7e* 1.49 6.00E-01 -3.95 1.84E-02 
mmu-miR-337-5p -2.86 2.30E-01 -3.76 4.37E-02 
mmu-miR-335-3p 1.43 1.33E-01 -2.52 3.47E-02 
mmu-miR-384-3p 1.07 7.52E-01 -2.38 4.32E-02 
mmu-miR-221 1.37 1.15E-01 -2.08 1.85E-02 
rno-miR-1* -1.16 8.05E-01 -2.01 3.29E-02 
Variation of cardiac microRNA levels versus vehicle are reported for animals treated with 
DOX 3 mg/kg/week for 2 and 4 weeks. Values were calculated via the relative 
quantification (Ct) method by using the mammalian U6 snRNA as a normalizer. 
MicroRNAs showing same trend at 2 and 4 weeks are italicized. # indicates microRNAs 
selected for further analysis. Significant P values (<0.05) are in bold. FC= fold change. 
 
2.4.3 MiR-367, miR-215, miR-216b, miR-208b and miR-34c are specifically 
dysregulated by chronic DOX treatment 
 A subset of ten microRNAs whose expression was altered by chronic DOX 
treatment was selected based on their lowest p-values (Table 2-1) and evaluated 
their expression profile in additional individual animals from the same DOX 
treatment groups (originating from the same in vivo study) using single Taqman 
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assays (Supplementary figure 2-2). Five of these microRNAs (miR-208b, miR-
215, miR-216b, miR-34c and miR-367) displayed a consistent dose-dependent 
response to DOX at 2 and 4 weeks and were thus chosen as candidates for further 
expression profiling across the larger in vivo study treatment groups including co-
treatment of DOX with DZR and treatment with EPS only (Figure 2-3). 
Following two weeks treatment with DOX alone, a slight up-regulation of miR-
208b, mir-216b and miR-367 was observed in the heart of most animals. 
Following 4 weeks of treatment with DOX alone, the level of all five microRNA 
candidates were significantly increased and dose dependency was observed for 
miR-208b, miR-215, miR-216b and miR-367. Following 6 weeks of treatment 
with DOX alone, the levels of miR-208b, miR-215, miR-216b and miR-367 were 
significantly increased. Dose dependency was difficult to assess at the 6 week 
time point since only 2 animals survived in the high dose group. 
Following treatment with DZR alone for 2 and 6 weeks, none of the five 
candidate microRNAs was affected. After treatment with the combination of 
DOX at 2 mg/kg/week and DZR at 50 mg/kg/week, the level of miR-208b, miR-
216b and miR-367 was either slightly increased or not affected. For all five 
candidate microRNAs, the level was lower when compared to the group of 
animals treated for 2 weeks with DOX alone at 2 mg/kg/week. Following 6 weeks 
of treatment with the same DOX/DZR combination, the level of miR-208b, miR-
216b and miR-367 was increased. However, this level was lower for miR-208b 
and miR-216b when compared to the group of animals treated 6 weeks with DOX 
alone at 2 mg/kg/week and higher for miR-367. 
Following 2 and 6 weeks of treatment with EPS, the expression level of the 5 
microRNA candidates was minimally affected and considered as non statistically 
significant since no dose and time dependency was observed (although these 
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changes might still be biologically relevant). Together, these data suggested that 
the variation of these five microRNAs was DOX-specific.  
 
Figure 2-3: Relative quantification of DOX-responder microRNAs in rat heart across all 
groups. Relative quantification of (A) miR-208b, (B) miR-215, (C) miR-216b, (D) miR-367 
and (E) miR-34c in DOX, DOX + DZR, EPS groups, normalized versus vehicle treated 
animals. Expression levels were measured by single assay qPCR (n= 3, except #, n= 2).  
DOX: Doxorubicin, DZR: dexrazoxane, EPS: etoposide; numbers indicate the weekly 
dose of each compound in mg/kg/week. Empty spaces represent non-sampled animals. 
The vehicle treated is the first column of each time-point. The animals used in this 
experiment were distinct from the ones represented in Table 2-1. Error bars represent 
SD. T-test results are indicated by asterisks for significant DOX-treated groups vs. their 
own vehicle-treated, unless otherwise specified by horizontal range bars; *P<0.05, 
**P<0.01, ***P<0.005, NS=Non-Significant). 
In summary, chronic treatment with DOX at 3 mg/kg/week for 2 weeks led to 
increases in miR-208b, miR-216b and miR-367, with fold change intensities 
comparable to those shown by genomic cardiomyopathy indicators (Ankrd/Carp, 
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Nppb, Myh7 and Myh6) (Figure 2-2 and Table 2-1), suggesting that microRNAs 
may enhance the predictivity of established genomic indicators of drug-induced 
cardiomyopathy (e.g. myosin genes, troponins, natriuretic peptides) when 
assessing the potential for drug-induced cardiotoxicity. 
2.4.4 DOX induced up-regulation of miR-216b and miR-367 earlier than tissue 
lesions as observed by histopathology 
We then compared the variation of DOX-specific microRNA perturbations 
with the severity of cardiac tissue lesions induced by drug (cytoplasm 
vacuolation) in order to evaluate their sensitivity. Increasing doses of DOX led to 
higher cumulative vacuolation grading with time (Supplementary table 2-2), as 
well as progressively larger fold changes for microRNAs miR-208b, miR-216b 
and miR-367 versus vehicle. Notably, treatment with DOX 1 mg/kg/week during 
2 weeks did not cause any detectable vacuolation, but showed a statistically 
significant increase of miR-216b (Figure 2-4). Treatment with DOX at 2 and 3 
mg/kg/week for 2 weeks showed a statistically increase of miR-216b and miR-
367 (Figure 2-4). Interestingly, we observed that miR-208b profile across 
treatment groups had the best statistically significant correlation score in 
comparison to the severity of vacuolation (Spearman R squared = 0.76, p= 4.45E-
04) (Supplementary table 3). Therefore miR-208b may be implicated in the 
pathology mechanism of the vacuolation. These data suggest that DOX-induced 
perturbations of cardiac microRNA expression can precede overt tissue 
histopathology and that specific microRNAs may be useful as genomic indicators 
of drug-induced cardiac toxicity. 
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Figure 2-4: DOX-induced upregulation of miR-216 and miR-367 expression precedes the 
detection of overt histopathological lesions in cardiac tissue. Blue bars show cumulative 
vacuolation grade. X axis shows the DOX regimen in mg/kg/week received by the animals 
at 2 weeks. Y axes report cumulative histopathological scores and microRNA fold change 
vs. untreated cardiac tissues (normalized at value 1). Path grading = cumulative 
vacuolation score. FC= fold change. SEM= standard error on the mean. 
 
2.4.5 MiR-34c regulates  Sipa1 mRNA at the post-transcriptional level and is 
involved in autophagy process 
Out of the 7804 mRNA targets for DOX-inducible microRNAs predicted by 
Microcosm, 132 (1.7%) mRNAs showed the expected profile of anti-correlated 
expression relative to its putative targeting microRNA (>1.5 fold change at DOX 
3mg/kg/week for 4 weeks vs. vehicle) (Supplementary table 2-3). Since this low 
prediction rate could have been obtained by statistical chance, the putative 
microRNA-mRNA interaction of miR-34c/Sipa1was selected for further 
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experimental evaluation. Treatment with DOX at 1, 2 and 3 mg/kg/week showed 
a dose-dependent decrease of signal-induced proliferation-associated 1 (Sipa1) 
and a dose-dependent increase of miR-34c (Figure 2-5A). Similarly, the treatment 
of H9C2 rat myoblasts with DOX at 0.1 and 1µM for 24h showed a decrease of 
Sipa1 mRNA and an increase of endogenous miR-34c (Figure 2-5B). The 
transfection of miR-34c mimics in H9c2 showed a statistically significant 
decrease of Sipa1 mRNA, as the transfection of miR-34c hairpin inhibitor (HI) 
showed a statistically significant increase of Sipa1 mRNA (Figure 5C). Notably 
miR-34c over-expression exacerbated Sipa1 down-regulation induced by DOX, 
while the transfection with mir-34c hairpin inhibitor significantly rescued the 
expression (Figure 2-5C), suggesting that miR-34c is mediating the DOX-induced 
regulation of Sipa1. Finally, to confirm whether the regulatory effect of miR-34c 
on the levels of Sipa1 mRNA was direct, 2 luciferase-based reporter expression 
vectors  (pmiR-GLO-Sipa1 WT and mutated) were generated by cloning a 200 
nucleotide region surrounding the predicted microRNA seed from each of their 
3’-UTR regions downstream of a firefly luciferase reporter gene. The co-
transfection of the Sipa1 reporter with miR-34c in HEK 293 cells showed a 
significant decrease in the luciferase signal. This decrease was observed to a 
lower extent with other members of the miR-34 family (Figure 2-5D) suggesting 
that miR-34c interacted directly and specifically with the 3’-UTR of Sipa1.  
We have also used the rat myoblast H9c2 cell line to assess the DOX-induced 
autophagy process through the regulation of Ambra1 mRNA. Transfection of 
miR-34c mimics showed a statistically significant increase of Ambra1 mRNA. 
Transfection of miR-34c hairpin inhibitor showed a statistically significant 
decrease of Ambra1 mRNA. Treatment with DOX at 0.1 µM for 16h in the 
presence of miR-34c mimics showed a statistically significant increase of Ambra1 
mRNA. Treatment with DOX at 0.1 µM for 16h in presence of miR-34c hairpin 
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inhibitor showed a statistically significant decrease of Ambra1 mRNA when 
compared to the presence of miR-34c mimics. 
 
Figure 2-5: miR-34c directly controls DOX-induced Sipa1 mRNA decrease. (A) Sipa1 
mRNA raw expression values decreased in the heart of rats treated with DOX. #, n= 2. (B) 
DOX treatment for 24h caused a decrease of Spa1 mRNA and an increase of miR-34c in 
cardiac myoblast cells (H9c2). (C) H9c2 endogenous Sipa1 mRNA was decreased by 
transfection of miR-34c mimic, and increased using a miR-34c hairpin inhibitor (HI). 
Transfection with miR-34c mimic and inhibitor respectively exacerbated and rescued 
Sipa1 mRNA levels in H9c2 treated with DOX 0.1 and 1µM overnight in comparison to 
negative controls. (D) Alignment of mammalian miR-34 family. Capital letters indicate 
mismatch in the sequence. Sipa1 3’-UTR wt and MUT construct: 12 nt surrounding the 
predicted seed are shown. HEK 293 cells were co-transfected with pmiR-GLO-Sipa1 and 
the indicated miRNA mimic or a C. elegans negative control mimic. Averaged and 
normalized Renilla luciferase signal was obtained from 3 independent experiments, each 
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run in quadruplicate. Y axis represents percentual residual luciferase activity in the 
indicated conditions. Mutant 3’ UTR restores luciferase activity in Sipa1/miR-34c. 
*P<0.05, **P<0.01, ***P<0.005.  
 
The extent of Ambra1 mRNA regulation is slight but comparable between the 
in vivo systems and the H9c2. Treatment with DOX in H9c2 didn’t affect the 
level of miR-208b ruling out a potential implication of miR-208b with autophagy 
in this cellular model. Therefore miR-34c is directly implicated in the DOX-
induced modulation of Sipa1 mRNA regulation. 
  
 
Figure 2-6: Ambra1 expression was induced by DOX treatment in vivo and miR-34c could 
control its endogenous expression levels in H9c2 cardiac myoblasts. (A) Fold change of 
Ambra1 probe set in rat heart tissue treated with DOX. Fold change and statistical 
significance were assessed vs. each vehicle group. n= 4 to 6 (except #, n= 2) (B) 
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Endogenous levels of Ambra1 were measured after miR-34c over-expression (miR-34c 
mimic) or inhibition (miR-34c HI) in absence of presence of DOX 0.1. Fold change value 
were normalized vs. the respective negative transfection controls in the untreated 
condition (n=3). *P<0.05, **P<0.01, ***P<0.005. FC= fold change. 
 
2.5 Discussion 
In the present study 25 microRNAs were found to be dysregulated by 
pharmacological intervention with DOX in the rat heart. A subset of microRNA 
candidates were further investigated and associated to their putative targets. 
The chronic weekly intravenous administration of DOX was designed to trigger 
cardiomyopathy symptoms within a 6 week time-frame allowing us to identify 
mRNAs and microRNAs that are altered in the early stages of the drug-induced 
cardiac remodeling. Cardiac toxicity at a cumulative dose of 12 mg/kg (3 
mg/kg/week for 4 weeks) was confirmed by histopathological lesions and altered 
expression of genomic indicators associated to contraction performance (Myh6, 
Myh7) and heart failure (Ankrd1/CARP, Nppb) (Figure 2) (Caulfield and 
Wolkowicz, 1990; de Bold et al., 1996; Dorn et al., 1994; Mikhailov and Torrado, 
2008; Suzuki et al., 1998). In most of the cases the dysregulation of these genes 
reached a significantly higher level between 2 and 4 weeks of the DOX 3 
mg/kg/week dosing regimen. Additionally, 2 weeks treatment with DOX at 2 
mg/kg/week onward caused cytoplasm vacuolation to occur with increasing 
severity. 
We profiled hundreds of microRNAs via TLDAs in the heart of rats that 
showed clear signs of toxicity (DOX 3mg/kg for 4 weeks), and found that 25 
microRNAs were dysregulated with p-values below 0.05. Seven out of 25 
microRNAs (miR-367, miR-216b, miR-383, miR-692, miR-135b, miR-145*, 
miR-877, miR-434-5p and miR-337-5p), were already modulated after 2 weeks of 
DOX at 3 mg/kg/week (Table 2-1). Comparable changes for many of these 
85 
 
microRNAs were confirmed in additional animals, and a subset of five 
microRNAs (miR-208b, miR-215, miR-216b, miR-367 and miR-34c) and were 
largely unaffected by the direct Top2 inhibitor etoposide (EPS) (Figure 2-3). 
However DOX-induced up regulation of these microRNAs was not lessened by 
co-treatment with DZR, suggesting that these were not involved in the molecular 
pathways triggered by DZR. 
It is noteworthy that miR-21 and miR-146a, previously linked to DOX-induced 
apoptosis in cardiomyocytes in vitro (Horie et al., 2010; Wang and Li, 2010a) or 
by single administration of a  high dose of DOX in vivo (Horie et al., 2010), were 
not among the microRNAs regulated by our chronic DOX dosing regime in 
Sprague Dawley rats. Similarly, miR-1 and miR-133, known to have alternative 
effects on oxidative stress-induced apoptosis in myocytes (Xu et al., 2007), the 
former being pro-apoptotic and the latter anti-apoptotic, were not altered in the 
present study. These discrepancies may derive from several key differences in the 
model systems and study designs used. Importantly, primary cells or cell lines 
treated in vitro are not comparable to the whole cardiac tissue when exposed to 
metabolized systemic DOX and the work of Horie et al. explores the acute effect 
of a single high dose of DOX, which contrasts to the chronic regimen 
administered here. Our present study describes global changes in microRNAs 
during chronic drug-induced cardiac toxicity, in a way that closely resembles the 
safety signals observed in a clinical setting. 
In our study miR-215, part of the miR-192/miR-215 cluster, and miR-34c, 
involved in DNA damage mediated proliferation arrest (Braun et al., 2008; 
Cannell et al., 2010; Georges et al., 2008; He et al., 2007), were up-regulated, 
consistent with the pharmacological effect of DOX. However miR-215 and miR-
34c were not significantly up-regulated by EPS administration, suggesting that 
this compound may not trigger a p53 response under these experimental 
conditions. 
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Interestingly miR-215, up regulated by DOX in this study, was also linked to 
p53 mediated cell cycle arrest [37,38], consistent with the pharmacology of DOX 
and partially replicating expression changes of miR-34c upon treatment, thus 
strengthening the biological relevance of our findings and consistency with 
previously published mechanisms (Cannell et al., 2010). 
MicroRNA-208b, encoded from the intron 28 of rat Myh7, is associated to 
maintenance of myocardial performance together with 2 other myomirs ,i.e. miR-
208a/miR-499, which play a pivotal role in the myosin balance (van Rooij et al., 
2009). Consistent with previous work, the DOX-induced expression of miR-208b 
parallels the modulation of expression of its host gene Myh7 (Supplementary 
figure 2-1B) and occurs in parallel to the appearance of vacuolation 
(Supplementary table 3). The concomitant decrease of miR-208a and Myh6 levels 
upon DOX treatment (Supplementary figure 2-1A) further support the importance 
of the regulatory role of myomiRs-myosin interactions in the myosin switch, 
which is associated with progressive structural changes and pathological cardiac 
remodeling (van Rooij et al., 2009).  
Of particular interest is the predictive potential of microRNAs as early tissue 
indicators of drug-induced cardiac lesions. The lowest dose of DOX tested in our 
study (1 mg/kg/week for 2 weeks) did not cause detectable tissue vacuolation 
(Supplementary table 2-2). However, miR-216b was already up-regulated (>1.5 
fold) under these conditions, and miR-367 concomitantly increased at the earliest 
time point (2 weeks) in the different treatment groups. Treatment with DOX at all 
doses and time points was associated with sustained up-regulation of these 
microRNAs, together with miR-208b and miR-215 at later time points. Further 
studies will be needed to investigate the potential of circulating microRNAs as 
indicators of DOX- induced cardiac injury. 
In order to gain further insight into the cellular processes that may be 
modulated upon DOX-induced cardiac toxicity, high confidence target mRNAs of 
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DOX-dysregulated microRNAs were identified by using the Microcosm 
prediction tool (Supplementary table 2-3 and Supplementary table 2-3). In 
particular, only the genes that had an anti-correlated change of expression at the 
mRNA level vs. the cognate microRNA were retained. The screening for putative 
targets of microRNAs in DOX treated animals, revealed that a number of DOX-
responsive microRNAs may regulate mRNAs involved in cardiac tissue 
remodeling (data not shown), but we also speculated that the Sipa1 mRNA 
transcripts could be targeted by miR-34c directly. Sipa1 gene product is an 
activator of Rap GTPase and can influence proliferation rate and metastatic 
potential in various types of malignancies (Crawford et al., 2006; Minato and 
Hattori, 2009; Shimizu et al., 2011). Moreover cAMP-mediated Rap signaling, 
and its modulators, played a role in significant aspects of cardiovascular 
physiology, including cardiomyocytes contraction and hypertrophy (Jeyaraj et al., 
2011).  Importantly, Sipa1 mRNA showed an anti-correlated pattern with miR-
34c in H9c2 cells treated with DOX 1 µM during 24h (Figure 2-5B). Reporter 
assay experiments further support that Sipa1 mRNA is a target of the miR-34 
family, in particular miR-34c (Figure 2-5D). In addition, our observations in H9c2 
myoblast cell line suggest that miR-34c could be involved in the stimulation of 
the positive autophagy regulator Ambra1, also in presence of DOX. In fact, miR-
34c over expression increased the endogenous levels of Ambra1 mRNA in H9c2 
cells (both with and without DOX). Vice versa transfection of a miR-34c-directed 
hairpin inhibitor showed a statistically significant decrease of Ambra1 mRNA 
level. However, the functional relevance of this finding in autophagy regulation 
and the exact mechanism of this regulation will have to be elucidated. Further 
studies, such as gain- or loss-of-function in vivo investigations, will be required to 
elucidate the functional significance of altered Sipa1 expression for cardiac 
responses to DOX. Immunochemistry staining of autophagy markers like Ambra1 
in heart tissues will also be required to elucidate the functional involvement of 
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miR-215, miR-216b, miR-367, miR-208b and miR-34c in the DOX-induced 
autophagy process since they seem to be specifically associated to vacuoles 
appearance. 
In conclusion, 25 microRNAs implicated in DOX-induced cardiac toxicity in 
vivo were identified. Among them, miR-216b, which was significantly regulated 
before overt toxicity, has the potential of a genomic indicator of cardiac toxicity. 
Our study also provides the basis for understanding the global role of microRNAs 
in DOX-induced cardiac remodeling and toxicity, and provides evidence the 
direct miR-34c/Sipa1 functional interaction for the first time. 
2.6 Supplementary Material and Methods 
Supplementary table 2-1: Doxorubicin study design in rats. 
    
No. of  Doxorubicin Dexrazoxane Etoposide Dose  
    
animals 
   
duration 
Group       Male (mg/kg/week) (mg/kg/week) (mg/kg/week) (weeks) 
1 Control 
  
6 0 0 0 2 
2 DOX Low 
 
6 1 0 0 2 
3 DOX Mid 
 
6 2 0 0 2 
4 DOX High 
 
6 3 0 0 2 
5 EPS Low 
 
6 0 0 1 2 
6 EPS High 
 
6 0 0 3 2 
7 DZR 
 
6 0 50 0 2 
8 DZR + DOX Mid 6 2 50 0 2 
9 Control 
  
6 0 0 0 4 
10 DOX Mid 
 
6 2 0 0 4 
11 DOX High 
 
6 3 0 0 4 
12 Control 
  
6 0 0 0 6 
13 DOX Low 
 
6 1 0 0 6 
14 DOX Mid 
 
6 2 0 0 6 
15 DOX High 
 
6 3 0 0 6 
16 EPS Low 
 
6 0 0 1 6 
17 EPS High 
 
6 0 0 3 6 
18 DZR  
 
6 0 50 0 6 
19 DZR + DOX Mid 6 2 50 0 6 
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2.6.1 Histopathology investigations of the heart 
At necropsy, the heart was oriented with the left ventricle uppermost (i.e. aorta 
stem pointing towards operator) and then cut in half longitudinally. Each heart 
was longitudinally bisected from base to apex along the middle of the ventricular 
free walls to reveal right and left ventricles; right and left atria; both 
atrioventricular valves and the root of the aorta.  One half of the bisected heart 
was placed in 4% formaldehyde/1% glutaraldehyde while the other half was 
flash-frozen for other studies.  The fixed hemi-sections of heart were processed 
for methylmethacrylate plastic embedment, sectioned at 1-2 µm, stained with 
toluidine blue and examined histologically. Figure 2-1 shows representative 
histologic cardiac sections with evidence of cardiomyocellular injury, more 
specifically microvesicular vacuolation typical of doxorubicin cardiomyopathy 
(Bertinchant et al., 2003; Herman et al., 1985) (Figure 2-1B and C). Vacuolar 
changes in ventricular and atrial cardiomyocytes were recorded separately and 
semi-quantitatively graded using a simple cardiomyopathy scoring method  based 
on the frequency and severity of observed changes on a four step arbitrary scale 
from minimal to marked (1=Minimal,  2=Mild, 3=Moderate and 4=Marked).  
2.6.2 Murine Sipa1 3’-UTR region cloned for reporter assay 
Wild type: 
 5’-
cgttccaatctgaatctggacctgcttggaactgcctggcccctcagagcaactgggtcatactagtgcccttcctcag
gacttcttccctgcgctgaggcgcgtcttagcactgccccctcttcccagcccatttggtggctaatgcctgtccctgttt
gtaaatatcctgtaaagaaaaggagacatcagagtttaaaaaaaagaaacaacaagaagaagcaaacaactct -3’ 
MiR-34 seed mutant: 
5’- 
cgttccaatctgaatctggacctgcttggaactgcctggcccctcagagcaactgggtcatactagtgcccttcctcag
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gacttcttccctgcgctgaggcgcgtcttagGGAATTcccctcttcccagcccatttggtggctaatgcctgtccc
tgtttgtaaatatcctgtaaagaaaaggagacatcagagtttaaaaaaaagaaacaacaagaagaagcaaacaactct 
2.6.3 Murine Tnni3k 3’-UTR region cloned for reporter assay 
Wild type:  
5’-
ccaggtctgacatacacctaaggggagttttcccatcagactgacagcagtgattttatccatggcaggctcacttcca
attataatgctctgccctctgaggtctcttcaagtcgtcttgcttattctgcgctcacgtaattcccttctacagggtaggct
ttcaattgctcagagcatgaagtaccaaggagcagatatagaccgtgcatgaggaactgttcttagtttgatatttaaag
tccttaattgcctgggggtggggttcaagtctgtgtagat 
2.7 Supplementary Results 
2.7.1 Body and organ weight 
Treatment with DOX caused dose-dependent decreases in mean body weight 
and weight gain in animals dosed with 2 or 3 mg/kg/week. Treatment with 
combination of DOX and DZR similarly induced a significant decrease in mean 
body weight gain. The changes in mean body weight and body weight gain appear 
to directly correlate with decreases in mean food consumption.  A similar 
decrease was not noted in animals that received DZR or EPS alone, indicating that 
the decrease in mean body weight gain was attributable to DOX. Of the animals 
that survived to scheduled euthanasia and necropsy, the overall, significantly 
decreased heart weight parameters indicated a progressive, irreversible DOX-
related toxic effect at dose levels of 2 or 3 mg/kg/week.  Decrements in heart 
weight parameters were mitigated when DZR was given in conjunction with DOX 
illustrating protective properties of DZR (data not shown). More details will be 
given in a forthcoming publication by Gerrish et al.. 
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2.7.2 Hematology and clinical chemistry 
Dose and time dependent alterations in hematology and serum chemistry were 
caused by DOX once weekly for 2, 4, or 6 weeks. There were minimal alterations 
in the clinical pathology from rats given DZR or EPS only (data not shown). In 
general, many of the alterations in rats given DOX in combination with DZR were 
of much smaller magnitude suggesting that it alleviates many of the side effects of 
DOX. More details will be given in a forthcoming publication by Gerrish et al. 
2.7.3 Histopathology scores of cytoplasmic vacuolation in the heart 
DOX-induced cardiomyopathy is characterized by sarcoplasmic micro- and 
macro-vacuolisation of the heart atrium and ventricle. These are generally 
categorized as minimal, mild, moderate and marked.  In order to visualize the 
histopathological diagnoses we combined the pathology scores from the 
individual animals in each treatment group.  
 
Supplementary table 2-2: Atrial and ventricular vacuolation incidence increases with 
doses of DOX. Microscopic histopathological findings. Severity of lesion is graded by 
numbers. Low= 1mg/kg/week regimen; Mid= 2 mg/kg/week regimen; High= 3 
mg/kg/week regimen. 
  
Treatment/Dose/Duration 
Control  
2 wks     
Dox Low  
2 wks      
Dox Mid  2 
wks  
Dox High  
2 wks 
  Number of animals 6 6 5 6 
Atrial vacuolation minimal         
  mild       2 
  moderate         
  marked         
Ventricular 
vacuolation minimal     2 1 
  mild         
  moderate         
  marked         
  
Treatment/Dose/Duration 
Control  
4 wks       
Dox Mid 4 
wks 
Dox High       
4 wks 
  Number of animals 6   6 6 
Atrial vacuolation minimal       1 
  mild       1 
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  moderate         
  marked         
Ventricular 
vacuolation minimal   
  
  1 
  mild     2 1 
  moderate         
  marked         
  
Treatment/Dose/Duration 
Control  
 6 wks    
Dox Low     
6 wks 
Dox Mid  
6 wks    
Dox High      
6 wks 
  Number of animals 6 6 6 6 
Atrial vacuolation minimal   2 2 1 
  mild   1 1 2 
  moderate   1 2 1 
  marked         
Ventricular 
vacuolation minimal   5 2 4 
  mild   1 3 1 
  moderate     1   
  marked         
 
There is a progressive increase in the cumulative pathology score in the hearts 
from DOX-treated animals (Supplementary table 2-2). 
 
Supplementary figure 2-1: MicroRNA-208a and 208b are regulated similarly as their 
hosting transcripts upon DOX treatment (Myh6 and Myh7 respectively) (n= 3). (A) Myh6 
and miR.208a and (B) Myh7 and miR-208b fold changes vs. control in DOX 3mg/kg/week 
treated animals. 
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Supplementary figure 2-2. Single assay validation of TLDA data. Ten microRNAs among 
the DOX 3 mg/kg/week 4 weeks dysregulated microRNAs  were assayed in the remaining 
3 animal tissues at the same dose and in 3 animals for each indicated dose and timepoint 
(2 and 3 mg/kg for 2 and 4 weeks). All except miR-709 and miR-692 confirmed the trends 
observed with the LDA-qPCR technique. Fold changes for the given doses are indicated 
vs. untreated animals. (A) miR-208b. (B) miR-215. (C) miR-216b. (D) miR-218-2*. (E) 
miR-34c. (F) miR-367. (G)  miR-383. (H) miR-692. (I) miR-708. (J) miR-709. 
 
94 
 
 
2.7.4 Putative targets of microRNAs responding to high dose DOX at 4 weeks 
Supplementary table 2-3: Number of Microcosm predicted targets of 16 out of 25 
microRNAs, responding to DOX 3 mg/kg/week after 4 weeks.  
Up-regulated Predicted Raw>80 
cutof
f FC 1.3 
cutof
f FC 1.5 Gene symbols 
mmu-miR-367 762 411 31 12 
Alb, 
Igfbp5, 
Serpinf1, 
Cryl1, 
Itga6, 
Pros1, 
Sdc2, 
Dclk1, 
Man2a1, 
Marcks, 
Itgae 
Igtp 
rno-miR-215 429 226 18 6 
Dpp4, 
Bst2, 
Pdp2, 
Pcbd1, 
Pc, 
Man2a1 
hsa-miR-216b 707 336 21 9 
Gbp2, 
Cryl1, 
Map2k6, 
Afap1l1, 
Hrasls, 
Tmod4, 
Pxmp2, 
Pqlc1, 
Hfe2 
mmu-miR-383 443 226 25 12 
Cdh11, 
Slc25a25, 
Pdia4, 
Cryl1, 
Pllp, 
Fn1, 
Dtx3l, 
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Abhd14b, 
Ccl5, 
Cd302, 
Ros1 
Igtp 
rno-miR-135b 345 172 16 5 
Sord, 
Casp12, 
Angpt1, 
Ugdh, 
Actr3b 
mmu-miR-667 651 337 20 8 
Gimap4, 
Sctr, 
Dgat2, 
Comt, 
Adi1, 
Pik3ap1,  
Igtp, 
Ethe1 
rno-miR-298 410 204 11 8 
Rbp1, 
Gamt, 
Pgcp, 
Gimap4, 
Prelp, 
Gpld1, 
Ggcx, 
Marcks 
mmu-miR-208b 572 399 11 5 
Nr4a1, 
Marcksl1, 
Cd53, 
Ethe1, 
Adhfe1 
mmu-miR-877 325 163 15 4 
Cfh, 
Prelp, 
Rev3l, 
Nr1d1 
mu-miR-708 333 158 18 10 
Cfh, 
Fxyd3, 
Srprb /// Tf, 
Gamt, 
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Slc25a25, 
Cryl1, 
Pfkfb1, 
Cp, 
Wfdc1, 
Ttc7 
rno-miR-31 485 233 27 12 
Col3a1, 
Serpinf1, 
Clcn4-2, 
Pdia4, 
Mt1a, 
Fkbp4, 
Ttr, 
Prelp, 
Faim3, 
Wfdc1, 
Adfp, 
Pc 
rno-miR-34c 532 276 24 9 
Fxyd3, 
Stard10, 
Cryl1, 
Itga6, 
Ppm1j, 
Nr1d1, 
Mecr, 
Marcks, 
Nid2 
  
   
    
Down-reg           
rno-miR-337 395 193 15 5 
Srpk3, 
Eef2k, 
Lrrfip1, 
Ecm1, 
Cdc25b 
rno-miR-335 444 238 20 10 
Lrrc48, 
Max, 
Ppm1b, 
Lrrfip1, 
LOC497978, 
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Sln, 
Ctgf, 
LOC500700, 
Baiap2, 
Fhl1 
hsa-miR-384 584 303 24 13 
Eya2 
Pkp4 
Speg 
Plcl1, 
Nt5c3l, 
Itga5, 
Zyx, 
Nt5e, 
Ttc27, 
Ptgds, 
Mllt11, 
Mdk, 
Myl1 
rno-miR-221 387 191 10 4 
Pdlim7, 
Tmbim1, 
Rbm3, 
Bex1 
Raw gene expression was filtered to be higher than 80 in at least 50% of the conditions at 
the cumulative dose of 12 mg/kg. The absolute fold change anti-correlated to the cognate 
microRNA was used to further reduce the lists at 2 different stringencies. Number of 
genes passing these filters is indicated for each signature-microRNA for which prediction 
was available. 
 
2.7.5 Bias in indexed NGS microRNAs profiling 
In order to obtain information on the whole microRNAs population, we 
prepared cDNA libraries of small RNA samples isolated from the cardiac tissue of 
at least 5 animals per treatment condition. 
As mentioned, the reduced size of the cellular microRNAs repertoire allows 
sequencing of multiple samples in the same run (multiplexing). We initially 
attempted pooling small RNA samples ligated with 5’ adapters carrying the 
indexed sequence (barcode) 3’ end, (grey oligo sequence in Supplementary figure 
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2-3, Supplementary table 2-4). However, the composition of the sequenced 
libraries was biased by the index used, as showed by a principal component 
analysis in Supplementary figure 2-4. Samples prepared from the animals 
belonging to different pharmacological treatment groups clustered by the 
“barcode” sequence and not by the condition, possibly due to sequence 
“preferences” of the ligase or polymerase enzymes used in the sample 
preparation, which resulted in apparently enhanced o depleted read counts of a 
number of microRNAs. We therefore proceeded to profiling microRNAs using 
TLDA cards, as described in the coming paragraphs. 
 
Supplementary figure 2-3: Next generation sequencing library with 5’ adapters indexed at 
their 3’ end. Sequential ligation at the 3’ (green) and the indexed 5’ (pink and grey) 
adapters to small RNAs (blue) is followed by library reverse transcription and PCR 
amplification. Only the products running at 123 nt (red box) are excised from 
polyacrylamide gel in order to avoid primers duplexes and unspecific PCR products. 
 
More recently validated protocols for multiplexing were released by 
sequencing suppliers, thanks to the increased read length and improved chemistry 
that allowed paired-end runs for microRNAs applications. In this case the 
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“barcode” sequence is at the 5’ of the adapter and is read during a second round of 
sequencing in the opposite direction. This strategy did not lead to any anomaly in 
the clustering of samples (data not shown). 
 
Supplementary table 2-4: Barcoded adapters used in preliminary sequencing experiment.  
Name Sequence : (5' to 3') 
  
Barcode 1 5'GUUCAGAGUUCUACAGUCCGACGAUCAAAC 
Barcode 2 5'GUUCAGAGUUCUACAGUCCGACGAUCACCC 
Barcode 3 5'GUUCAGAGUUCUACAGUCCGACGAUCAGGC 
Barcode 4 5'GUUCAGAGUUCUACAGUCCGACGAUCAUUC 
Barcode 5 5'GUUCAGAGUUCUACAGUCCGACGAUCCACC 
Barcode 6 5'GUUCAGAGUUCUACAGUCCGACGAUCCCGC 
Libraries of small RNA samples were prepared using 6 different adapters. The 3 sub-
terminal nucleotides (bold) were read within a multiplexed sequencing experiment and 
used to assign each read to the samples of origin. 
 
 
Supplementary figure 2-4: Sequenced libraries cluster according to the index sequence 
(symbols) and not by condition (colors) when adapter indexing is proximal to ligation site. 
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2.7.6 Effect of DOX 2mg/kg/week and its combination with antidote DZR on 
microRNAs related to cardiac diseases after 6 weeks 
MicroRNAs involved in cardiac diseases include miR-1, miR-15 family, the 
myomiRs (miR-208a/b and miR-499), miR-21 and miR-29. Of particular interest 
miR-21 and miR-29b as fibrotic tissue remodeling is one of the most 
characterized outcomes of cardiac stress induced by anthracyclines (Jones et al., 
2006; Migrino et al., 2008). Members of the miR-15/16 family were implicated in 
cardiac remodeling, including angiogenesis and post-ischemic injuries (Hullinger 
et al., 2012). 
Treatment with DOX 2 mg/kg/week (medium dose) significantly altered the 
levels of miR-208b, miR-21 and miR-1. However only for miR-208b this change 
was conspicuous (>2 folds vs. vehicle) and relieved by co-treatment with the 
antidote DZR. DOX treatment did not lead to significant alteration of miR-499 
and miR-15a/miR-16, while a small increase was observed in the co-treatment 
group, but not in the DZR alone group. Neither treatment significantly altered 
miR-208a. No DOX-related effect was detected in the case of miR-29b, but a 
small decrease was caused by the treatment with DZR alone (Supplementary 
figure 2-5).  
In conclusion, among the microRNAs tested, the variation of miR-208b 
measured in the cardiac tissue was a conspicuous and specific change induced by 
DOX, and also reflected the protective effect of DZR.  
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Supplementary figure 2-5: Variation of levels of microRNAs implicated in cardiac 
diseases in the heart tissue of rats after a 6 weeks treatment with DOX 2 mg/kg/week 
alone, or in combination with DZR. Fold change vs. vehicle is indicated for individual 
animals (n=6). Stars indicate statistical significance vs. vehicle, or otherwise indicated. 
*P<0.05, **P<0.01, ***P<0.005 (n=6). 
 
 
 
102 
 
2.7.7 Early changes in gene expression suggest both structural and 
functional damage are induced by DOX 
Changes in expression level of genes implicated in glycolysis/gluconeogenesis, 
Nrf2-mediated oxidative stress, mitochondrial activity, ion homeostasis, 
carbohydrate metabolism and proliferation were among the early changes induced 
by DOX  in SH rats by Thompson and colleagues in 2009 (Thompson et al., 
2009). In our study, DOX 3mg/kg/week caused decrease of Ryr2, Gpd2 and 
Igfbp5 transcripts, and an increase of Hmox1, Pfkp and Scn1a from week 2 
onwards (Supplementary figure 2-6). Ryanodin receptor 2 (Ryr2) plays a major 
role in calcium homeostasis, and intracellular ion disturbances are linked to heart 
failure and arrhythmias (Lehnart et al., 2009; Yano et al., 2005a; Yano et al., 
2005b). The decrease of mRNA levels of glycerol-3-phosphate dehydrogenase 2 
(Gpd2), part of the glycerol phosphate shuttle in mitochondria, and of insulin-like 
growth factor binding protein 5 (Igfbp5), associated with cell proliferation and 
cancer (Akkiprik et al., 2008), might suggest a loss of myofibrillar functionality 
and regeneration potential. 
Also, higher levels of phosphofructokinase (Pfkp) level contribute to the 
impairment of carbohydrate metabolism efficiency caused by chemically-induced 
oxidative stress (Janero et al., 1994), after 4 doses of DOX 3mg/kg. 
Sodium channel, voltage-gated, type I, alpha (Scn1a) is a neuronal sodium 
channel isoform and its expression level was previously characterized by Xi et al. 
in a model of failing heart in rodents, and found increased upon pressure overload 
(Xi et al., 2009). Scn1a transcript levels are increased by DOX in the present 
study, which implies a disruption of the physiological action potential that 
resembles the failing heart.  
In our study DOX 3 mg/kg/week induced changes in expression level of genes 
implicated in these processes from week 2 onwards (Supplementary figure 2-6).  
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Supplementary figure 2-6: Treatment with DOX alters the expression of genes involved in 
several cellular processes, critical to cardiac function. Fold change is represented by the 
ratio between averaged DOX vs. vehicle-treated signal intensity values for each probe-set, 
obtained by microarray genomic profiles. Error bars represent standard deviation. 
*P<0.05, **P<0.01, ***P<0.005 (n=6). 
The behavior of such a gene-signature suggests that both metabolic and 
structural functions are deeply compromised by the DOX treatment, as described 
by previous works. 
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2.7.8 DOX induces expression of anti-tumoral microRNAs 
Consistently with the pharmacological action of DOX, and according to the 
characterization of some microRNAs based on previous works, there is a general 
signature of block of proliferation as suggested by the 4 anti-tumoral microRNAs 
up-regulated (miR-215, miR-216b, miR-31 and miR-708), the 2 p53 
transcriptional responders also up-regulated (miR-34c and miR-215) and 1 
downregulated onco-miR (miR-221) as shown in Supplementary table 2-5. 
 
Supplementary table 2-5: Literature available on DOX dysregulated microRNAs. When 
information was available only for the other arm of the microRNAs the mature miRNA 
name is in bold 
Early regulated at both 2 and 4 weeks   
Up-regulated Function Selected publications 
mmu-miR-367 Expressed in embryo, inhibits Ryr3 gene 
(Suh et al., 2004; Zhang 
et al., 2011) 
mmu-miR-216b Tumor suppressor, targets κ-Ras (Deng et al., 2011)  
mmu-miR-383 Role in spermatogenesis (Lian et al., 2009)  
mmu-miR-145* 
80 papers on miR-145 and inhibition of 
cells growth, in smooth muscle cells 
(Rangrez et al., 2011)  
mmu-miR-877 - - 
mmu-miR-135b 
Placental µRNA, detectable in plasma, 
involved in prostate cancer, miR-135a 
downreg in DMD, osteogenic 
differentiation 
(Chim et al., 2008; Greco 
et al., 2009; Schaap-
Oziemlak et al., 2010; 
Wang et al., 2008)  
mmu-miR-692 - - 
Down-regulated     
mmu-miR-434-5p - - 
mmu-miR-337-5p - - 
      
Late regulated at 4 weeks only   
Up-regulated     
mmu-miR-208b 
Transcribed from fetal gene Myh7 (upreg 
in GEP). Involved in hypetrophic 
remodeling 
(Callis et al., 2009; van 
Rooij et al., 2009)  
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mmu-miR-21* 
MiR-21 induces apoptosis in DOXO 
treated cardiomyocytes, involved in 
fibrosis 
(Han et al., 2011; Roy et 
al., 2009; Si et al., 2007; 
Wang and Li, 2010b)  
mmu-miR-298 
Possible circulating biomarker for brain 
injury, indirectly regulates CYP3A4 
(Liu et al., 2009a; Pan et 
al., 2009)  
mmu-miR-31 
28 publications on miR-31 function, tumor 
suppressor and antimetastatic function in 
varisous contexts,  p53 regulated,  
dystrophin modulator 
(Valastyan et al., 2009)  
mmu-miR-34c 
65 publications, tumor suppressor, inhibits 
replication after DNA damage  
(Hermeking, 2010)  
mmu-miR-708 Tumor suppressor in renal cancer cells (Saini et al., 2011)  
mmu-miR-709 
Inhibits post-transcriptional maturation of 
pro-apoptotic microRNAs in the nucleus 
(Tang et al., 2011)  
rno-miR-29b-2* 
98 publications on miR-29b targets 
collagen genes, involved in fibrosis and 
cancer 
 (Milewicz, 2012)  
mmu-miR-215 
Together with miR-192, responds to p53 
(genotoxic stress) and induces cell cycle 
arrest 
(Braun et al., 2008; 
Georges et al., 2008)  
mmu-miR-667 - - 
Down-regulated     
mmu-miR-218-2* 
MiR-218-2 is tumor suppressor, enriched 
in the brain 
(Uesugi et al., 2011)  
mmu-miR-221 105 publications, oncomiR, targets p27 
(Galardi et al., 2007; 
Pineau et al., 2010)  
mmu-miR-335-3p 
16 publications Mir-335-5p is a tumor 
suppressor, implicated in various cancer 
types. Also associated with obesity and 
lipid metabolism dysfunctions 
(Nakanishi et al., 2009; 
Ronchetti et al., 2008)  
mmu-miR-384-3p - - 
rno-let-7e* 
Let-7 family is associated with cancer and 
organism development 
(Ambros, 2011; Osada 
and Takahashi, 2011)  
rno-miR-1* 
MiR-1 is the most abundant miR in heart, 
involved in differentiation, regulation of 
proliferation and apoptosis, myocardial 
infarction 
(Bostjancic et al., 2010; 
Sluijter et al., 2010; Tang 
et al., 2009; Xu et al., 
2007)  
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Chapter 3:   Heart structure-specific gene expression 
(transcriptomic) profiling reveals conserved microRNA-mRNA 
interactions relevant to cardiac physiology and function  
3.1 Abstract 
MicroRNAs are short non-coding RNAs that regulate gene expression at the 
post-transcriptional level and play key roles in heart development and 
cardiovascular disease. Here, we have characterized the expression and 
distribution of microRNAs across 8 cardiac structures (left and right ventricles, 
apex, papillary muscle, septum, left and right atrium and valves) in rat, canine and 
Cynomolgus monkey using miRNA-seq. Conserved microRNA signatures 
enriched in specific heart structures across these species were identified for 
cardiac valve (miR-let-7c, miR-125b, miR-127, miR-199a-3p, miR-204, miR-
320, miR-99b, miR-328 and miR-744) and myocardium (miR-1, miR-133b, miR-
133a, miR-208b, miR-30e, miR-499-5p, miR-30e*). The relative abundance of 
myocardium- (miR-1) and valve-enriched (miR-125b-5p and miR-204) 
microRNAs was confirmed using in situ hybridization. Potential microRNA-
mRNA interactions were explored using anti correlation expression analysis in 
matched samples and microRNA target prediction algorithms. These included 
miR-1/Timp3, miR-125b/Rbm24, miR-204/Tgfbr2 and miR-208b/Csnk2a2, for 
which respective post-transcriptional inhibition was confirmed by over-expression 
in human pulmonary smooth muscle cells and in a luciferase reporter assay. In 
conclusion, we have generated a high-resolution heart structure-specific 
mRNA/microRNA expression atlas for three mammalian species relevant to 
biomedical research and uncovered novel microRNA regulatory circuits that 
provide novel insight into cardiac physiopathology. 
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3.2 Introduction 
MicroRNAs are ~22 nucleotides long non-coding RNAs, genomically encoded 
and conserved throughout evolution in all superior organisms. MicroRNAs are 
regulators of gene expression, acting mainly at the post-transcriptional level, by 
directing the RISC complex to target mRNAs via imperfect complementarity 
(Fabian et al., 2010) which mediates inhibition of translation and mRNA decay. 
The expression levels of many genes can be influenced by microRNAs (Lim et 
al., 2005). However, the lack of perfect complementarity between microRNAs 
and their target mRNAs jeopardizes the prediction of the targets, and in silico 
prediction tools need further optimization (Thomas et al., 2010). 
During development, cellular microRNA pools are highly dynamic, tuned by 
temporal and spatial cues (Martinez et al., 2008; Mendell, 2008; Shkumatava et 
al., 2009; Stark et al., 2005) and accumulating evidences implicate microRNAs in 
numerous physiological and pathological processes, as well as responses to 
xenobiotics, including drug-induced cardiotoxicity (Fukushima et al., 2007a; 
Izzotti et al., 2010; Lema and Cunningham, 2010; Marsit et al., 2006a; Pogribny 
et al., 2007; Sathyan et al., 2007; Schembri et al., 2009; Yokoi and Nakajima, 
2011; Zhang and Pan, 2009). In particular, several microRNAs preferentially 
expressed in different types of muscles (miR-1, miR-133, and the myomiRs miR-
208, miR-208b and miR-499, among others) play a pivotal role in maintenance of 
cardiac function (Catalucci et al., 2009; Small and Olson, 2011), and the ablation 
of microRNAs-RISC machinery can have dramatic effects on cardiac 
development (Chen et al., 2008b; da Costa Martins et al., 2008; Hauck et al., 
2008a). 
Notably, drug-induced cardiac toxicity, which is often irreversible, ranks 
among the most frequent reasons for compound attrition due to safety liabilities 
during pharmaceutical development. Histopathological read-outs, the golden 
108 
 
standard in safety assessment, often do not provide mechanistic explanations. 
These can be addressed by detection of drug-induced toxic events at earlier stages 
by genomic profiling, which also helps generating mechanistic hypotheses. In 
principle, given the central role played by microRNAs in post-transcriptional 
regulation, a change in the level of a specific microRNA may be prodromal to 
expression change of a target gene, suggesting that integrated 
mRNAs/microRNAs expression profiling can improve the understanding of drug-
induced events at the molecular levels and translatable to the clinical context. 
Although the sequences conservation of microRNAs across species has been 
thoroughly studied, systematic data on the degree of similarity of microRNAs 
distribution within complex organs and/or tissues across mammalian species are 
still lacking. Availability of an expression atlas can help to address the role of 
microRNAs pool in gene expression homeostasis in specific cell types and tissue 
structures at the steady state, revealing novel relevant regulatory circuits, and also 
be a potential source for circulating lesion markers. 
In this work, we generated ad hoc data sets of matching microRNA and mRNA 
profiles from 8 cardiac structures, including apex, left and right ventricular walls, 
papillary muscle, septum, left and right atrial walls and cardiac valves, from 3 
preclinical mammalian species relevant to human biology (Rattus norvegicus, 
Canis familiaris, and Macaca fascicularis). We identified highly expressed 
microRNAs that can cluster apart the different cardiac structures and found that a 
number of microRNAs showed a specific pattern of expression conserved in the 3 
analyzed species, with particular emphasis on the cardiac valves. By comparing 
mRNAs with microRNAs expression across the cardiac structures, we could 
identify genes that had highly anti-correlated expression pattern with their 
predicted targeting microRNA. Among these, we confirmed that miR-1, miR-
208b, miR-204 and miR-125b could directly modulate genes relevant for 
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cardiac/muscle physiopathology (i.e. Timp3, Csnk2a2, Tgfbr2, Akap2 and 
Rbm24). 
Our data provide a large, comprehensive and homogenous amount of cross-
species information for hypothesis-generation on the role of microRNAs, and can 
be further used to 1) identify microRNAs signatures characteristics of cardiac 
structures, 2) further elucidate microRNAs/mRNAs interactions relevant for 
cardiac physiology and 3) propose novel tissue injury specific indicators.  
3.3 Material and methods 
3.3.1 Experimental strategy 
Different cardiac structures were dissected by hand from at least 3 Wistar rats, 
Beagle dogs and Cynomolgus monkeys (Cyno), as indicated in Figure 3-1. Small 
(<200 nt) and long RNA was isolated from the very same samples. Messenger 
RNAs transcriptome was generated via Affymetrix Gene Chip technology from 
all available samples (Figure 3-1). Based on the mRNAs profiles, we sub-selected 
the 3 samples from each structure that had the lowest cross-contamination with 
neighboring regions, and proceeded with microRNAs next-generation sequencing 
(miRNA seq) (Figure 3-1). Sequencing reads were mapped to miRBase, version 
17, containing 1424 human, 720 murine and 383 canine entries. In parallel, rat 
microRNAs were also profiled using a TLDA qPCR approach. On average, a 
Spearman correlation of 0.835 ± 0.016 was observed when comparing the TLDA 
with the miRNA seq data set, confirming the reliability of the miRNA seq 
approach (Supplementary figure 3-4).  
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Figure 3-1: Cross-species microRNA/mRNA cardiac atlas. Data sets obtained for rat, dog 
and/or Cynomolgus monkey are indicated. Inset: a magnified depiction of a papillary 
muscle. 
 
3.3.2 Heart tissue dissection 
Hearts were obtained from naïve adult male Wistar rats, during necropsy. 
Following brief infusion with saline, a first cut was made parallel to the auricles, 
adjacent to the level of the atria; both portions were again rinsed with saline, in 
order to remove most of the blood. Cardiac valves (mitral and tricuspid) were 
dissected at first, followed by atria, septum, ventricles and apex. All tissues were 
snap frozen in liquid nitrogen and stored at -80°C until RNA isolation. Similar 
procedure was carried out for male adult Beagle dogs and female adult 
Cynomolgus monkeys (Macaca fascicularis). 
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3.3.3 RNA isolation 
Cardiac frozen tissue, sectioned and snap frozen as described in the previous 
section, was homogenized in Qiazol reagent according to manufacturer 
instructions. Organic extraction of RNA was achieved by adding chlorophorm 
and high speed centrifugation at 4°C. RNA-containing upper aqueous phase was 
mixed with 1 volume of 70% EtOH and loaded into RNeasy minispin columns 
and briefly spinned at room temperature according to miRNeasy mini kit 
instructions (Qiagen). The content of this filter-column was then processed to 
obtain total RNA, while the first flow through, enriched in <200 nt RNA (small 
RNA fraction) was then processed through an RNeasy Clean-up column, 
according to manufacturer instructions (Qiagen, MD). Small RNA was eluted in 
15 µl of nuclease free water, quantified via 260nm absorbance and quality 
checked using the Bioanalyzer small RNA chips. 
3.3.4 Gene expression profiling 
Processing of total RNA and Gene Chip experiments were conducted as 
recommended by the manufacturer (Affymetrix, Santa Clara, CA). Messenger 
RNAs isolated from rat, canine and Cynomolgus were hybridized on 3’IVT arrays 
Rat230_2, Canine_2 and HG-U133_Plus_2 respectively. 
HPASMC cells endogenous genes expression was obtained using Taqman 
assays for the corresponding human transcript, according to manufacturer 
instructions. Briefly 300 ng of RNA were reverse transcribed to cDNA using the 
High Capacity Reverse Transcription kit. Two µl of cDNA were used in a 20 µl 
qPCR reaction in 7900HT machines (all Applied Biosystems, Life Technologies, 
Carlsbad, CA), 18S was used as reference housekeeping gene. 
3.3.5 MicroRNA Next Generation Sequencing 
Indexed miRNA sequencing libraries were prepared from 100 ng small RNA 
using TruSeq Small RNA Sample Preparation Kits (Illumina). After PCR 
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amplification multiplexed libraries were generated by equimolary pooling of 
individual libraries. The multiplexed libraries were size selected on 6% TBE-
PAGE gels (Invitrogen). The libraries were loaded on HiSeq Single Read Flow 
Cells v1.5 using TruSeq Single-Read Cluster Generation Kits (v2). The 
sequencing runs were done on HiSeq 2000 instruments.   
3.3.6 TLDA qPCR 
Three-hundreds and eighty rodent microRNAs were profiled using the Taqman 
Low Densitiy Array (TLDA) technology (Applied Biosystems, Life 
Technologies, Carlsbad, CA) according to the manufacturer instructions (Applied 
Biosystems, Life Technologies, Carlsbad, CA). Mammalian snRNA U6 was used 
as housekeeping gene. 
3.3.7 Localization of microRNAs via ISH 
Detection of microRNA by ISH was performed using double-digoxigenin 
labeled miRCURY LNA™ probe provided by Exiqon A/S (Vedbaek, Denmark). 
ISH on rat heart tissue section was done using the fully automated instrument 
Ventana Discovery Ultra® (Roche Diagnostics, Rotkreuz, Switzerland). All 
chemicals were also provided by Roche Diagnostics except the “microRNA ISH 
optimization kit” provided by Exiqon A/S. Briefly, formalin fixed paraffin 
embedded sections were de-paraffinized and rehydrated under solvent-free 
conditions (EZprep solution) and pretreated by enzymatic digestion (Proteinase K 
at 12 µg/ml for 16 minutes at 37°C). Hybridization was performed adding to each 
slide 50 nM of DIG-LNA probe diluted in the Exiqon hybridization buffer and 
incubated for 3 hrs. After hybridization, sections were washed on stringency 
conditions (see Supplementary table 3-1 for details). 
DIG-label LNA probe detection was performed using an Alkaline Phosphatase-
conjugated Sheep anti-digoxigenin antibody (Roche Diagnostics) diluted 1/500 in 
antibody diluent. Antibody incubation was carried out for 30 min at 37°C 
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followed by chromogenic detection using BlueMap™ Kit with a substrate 
incubation time of 6 hrs. 
Counterstaining using ISH nuclear fast red was performed for 2 min. Sections 
were mounted in Glycerol-gelatin mounting medium (Sigma-Aldrich Chemie 
GmbH, Buchs, Switzerland) and post-mounted using Pertex™. 
3.3.8 Data analysis of gene expression profiles and microRNAs sequencing 
The generated “.cel” files were loaded in Genespring 11.5.1 (Agilent 
Technologies, Santa Clara, CA) and further processed according to the standard 
RMA workflow. Expression data were analyzed at the gene level. Preferentially 
enriched gene lists were generated by retaining the top 10
th
 percentile most 
expressed genes in all replicates of at least one structure. Genes that were 5 fold 
more expressed in one cardiac structure vs. the median of all the remaining were 
retained. 
Illumina NGS reads were aligned to the respective miRBase v.17 (Griffiths-
Jones et al., 2008) reference sequences for the different species and to the in-
silico computed sequences of their precursor molecules using the Bowtie short 
readaligner (Langmead et al., 2009). The miRNA abundance was quantified using 
an in-house NGS analysis pipeline, normalized to robust estimates of the 
individual sequencing library sizes. MicroRNAs hierarchical Euclidean centroid-
linkage clustering and distance matrix were plotted using MeV package (Saeed et 
al., 2006). The normalized read counts were averaged per structure and the top 
10th percentile most expressed microRNAs in at least one structure were 
compared across the other data sets of the same species in order to determine 
those preferentially expressed in each structure (average expression fold change 
>2, top 10th percentile expressed). All mRNA expression values were computed 
using the standard Bioconductor RMA normalization and quantification algorithm 
(Gautier et al., 2004). The mouse miRNA target predictions were extracted from 
TargetScan (Version 5.2) (Grimson et al., 2007) and translated to the rat and dog 
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genomes by homology mapping based on the ENSEMBL gene orthology 
predictions. These were systematically plotted against the corresponding 
microRNA across cardiac samples in order to generate a Spearman correlation 
scores from -1 to +1. Genes expressed at a lower level in samples enriched with 
their targeting microRNAs, and vice versa, obtained a more negative score and 
will be referred to as anti-correlated. 
The degree of correlation between qPCR and miRNAseq profiles was obtained 
by computing Pearson and Spearman correlation factors (r and rs respectively) for 
each sample pair and for the microRNAs detected by both technologies. 
Gene set enrichment analysis (GSEA) was performed using Ingenuity 
Pathways Analysis 8.8 (Ingenuity® Systems). 
3.3.9 Cell culture, transfection and reporter assay 
Human pulmonary artery smooth muscle cells (HPASMC, Lonza CC-2581 lot# 
7F33558) were cultured according to supplier instructions. The day of 
transfection, cells were trypsinized, rinsed with HEPES, and resuspended in 500 
µl Nucleofector solution (Lonza, CH) supplemented with 50 nM of microRNA-
mimics (Dharmacon, Lafayette, CO) according to Amaxa transfection protocol A-
033. After 24 h, cells were lysed in Qiazol to retrieve RNA. 
Regions of interest of mRNAs 3’UTR (Supplementary figure 3-7 and 
Supplementary Material and Mehtods) were cloned by synthesis in pmirGLO 
Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI). 
Target seeds were mutated using QuikChange II Site-Directed Mutagenesis Kits 
(Agilent Technologies, Santa Clara, CA). Primers were designed according to 
manufacturer instructions. 
Hek293 cells were cultured according to supplier instructions. Cells (2x 10
5 
per 
well, in 24-wells plates) were co-transfected with 5 ng of pmiR-GLO reporter 
construct of interest and synthetic microRNA mimics (40 nM) (Dharmacon, 
Lafayette, CO) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). A C. 
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elegans mimic with no affinity for mammalian targets was used as negative 
control. Dual-GLO Luciferase Assay System (Promega, Madison, WI) was used 
to obtain the luciferase/Renilla relative luminescence, according to manufacturer 
instructions. Data were averaged for n=4 in 3 independent experiments. 
3.4 Results 
3.4.1 MicroRNA profiles separate the different structures of the heart as 
efficiently as mRNAs 
Between 260 and 340 unique mature microRNAs were found expressed 
(normalized counts >10) in each cardiac structure in the different species. A 
hierarchical Euclidean linkage clustering showed that microRNAs profile can 
group the samples in at least 3 distinct clusters, comprising the two ventricles, 
apex, septum and papillary muscles (myocardium), the 2 atria (atria) and the 
cardiac valves (Figure 3-2A) with a threshold of > 7.5. Similarly, principal 
component analysis of microRNAs and mRNAs data sets showed that individual 
samples from these 3 main structures grouped together (Figure 3-2B and C). In 
fact valvular profiles were clearly separated from atrial and ventricular profiles. 
Conversely, expression profiles from ventricles, septum, papillary muscles and 
apex were virtually indistinguishable from each other and therefore pooled 
together for further analysis under the name of “myocardium”. This was 
consistent with the cell type composing these structures, where cardiomyocytes 
are predominant. Similarly, left and right atria profiles were evaluated together in 
further analysis based on the similarity of their profiles.  
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Figure 3-2: Distribution of microRNAs in rat cardiac structures. (A) Cardiac samples are 
grouped according to the structure using microRNAs signatures (top 10%) in a 
hierarchical Euclidean-linkage clustering. (B-C) cardiac structures are separated by 
microRNAs and mRNA distribution in a principal component analysis. Red circles: 
myocardial tissue (apex, left and right ventricle, septum, papillary muscle). Blue circles: 
left and right atrium. Grey circles: cardiac valves. A, apex. LA, left atrium. LV, left 
ventricle. PM, papillary muscle. RA, right atrium. RV, right ventricle. S, septum. V, 
valves. 
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The clusters obtained were reproducible and consistent across several 
individuals, suggesting that the structure-specific signatures were robust enough 
and were not affected by inter-individual differences (Supplementary figure 3-1). 
3.4.2 Conserved structure-enriched microRNAs and mRNAs across species  
For each species, we identified microRNAs that were preferentially expressed 
in each of the 3 described major cardiac structures (valves, myocardium or atria), 
by a two step procedure. At first we retained only the microRNAs in top 10
th
 
percentile most expressed for each structural cluster. Secondly, we further 
compared the expression of each highly expressed microRNAs across structures, 
retaining those that were preferentially enriched in one structure only (see Data 
Analysis section in Material and Methods for details). In this way, we obtained 
lists of microRNAs likely to play a role in gene expression homeostasis in cardiac 
valves, myocardium or atria. These lists are available as supplementary 
information (Supplementary table 3-2, Supplementary table 3-3, Supplementary 
table 3-4). The 3 cardiac structures could still be discriminated in the 3 species by 
a hierarchical clustering when using these limited microRNAs signatures (data not 
shown). The commonly called heart-specific microRNAs were indeed amongst 
the most expressed microRNAs in the myocardium, but were present to a much 
lower extent in valves and atria. Applying a similar analytical process, structure-
enriched messenger RNAs were also identified (see Data Analysis section in 
Material and Methods for details). 
In an attempt to determine the degree of conservation of cross-species 
structure-specific distribution of microRNAs, we found that 9 unique microRNAs  
were highly enriched in the cardiac valves of rat, canine and Cynomolgus monkey 
(miR-let7c, mIR-125b, miR-127, mir-199a-3p, miR204, miR-320, miR-99b, miR-
328 and miR-744) (Figure 3-3A), 7 in the myocardium (miR-1, mir-133a, miR-
133b, miR-208b, miR-30e, miR-499-5p, miR-30e*)(Figure 3-3A). At the 
messenger mRNA level, 4 (S100a4, Inhba, Mfap4 and Cdh11) and 1 (Myl2) 
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mRNAs were found to be expressed consistently in cardiac valves or myocardium 
respectively of rat, canine and monkey (Figure 3-3B). 
 
Figure 3-3: Number of microRNAs (A) and mRNAs (B) preferentially expressed in 
cardiac valves or myocardium across species. Myocardium includes apex, ventricles, 
septum and papillary muscles. Fold change thresholds were >= 2 for microRNAs in (A), 
and >=5 from mRNAs in (B).   
 
A few microRNAs were selected for further analysis and their expression 
relative to apex is shown in Figure 3-4. Mir-1 is highly expressed in almost all 
structures, but to a much lower extent in the valves, in all species. MiR-208b is 
more specific of the myocardium structures, and is almost absent in the atria of rat 
and canine as well as in the valves of all species. MiR-125b-5p and miR-204 are 
enriched in the valves of all 3 species while less abundant in all other structures. 
Notably, mir-125b-5p expression is not restricted to the valves in dog, as for rat 
and Cynomolgus monkey. 
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Figure 3-4: Distribution of miR-1, miR-125b-5p, miR-204 and miR-208b in the cardiac 
structures. Axes represent fold change vs. apex. A, apex; LA, left atrium; LV, left 
ventricle; PM, papillary muscle; RA, right atrium; RV, right ventricle; S, septum; V, 
valve. 
 
3.4.3 Confirmation of microRNAs distribution by in situ 
hybridization  
Relative expression obtained by ISH for miR-1, miR-125b-5p and miR-204 
were consistent with the distribution patterns observed by miRNAs seq and 
qPCR. 
120 
 
MiR-1, miR-204 and miR-125b were detected in rat cardiac tissue by in situ 
hybridization (ISH). Representative micrographs are shown in Figure 3-5. 
Coherently with our miRNAs seq data signal for miR-1 was more intense in the 
myocardium than in the valves (Figure 3-5G, H and I), and staining for miR-204 
and 125b-5p was more intense in the valves than in the rest of the heart (Figure 
3-5A to F). 
MiR-1 showed an intense and uniform staining in the ventricle, while was 
weakly detectable in cardiac valves (Figure 3-5 G, H and I and Supplementary 
table 3-5). The signal for miR-204 appeared more intense at the level of 
endothelial cells in the valves (Figure 3-5 A and B). However, specificity of miR-
204 for endothelial cells will have to be investigated further via ISH in other 
endothelial cells-rich tissues. Mir-204 was weakly expressed in myocardial tissue, 
and the staining was almost undetectable (Figure 3-5 C). Similarly to miR-204, 
also miR-125b-5p showed a more intense signal in the cardiac valves than in the 
myocardium (Figure 3-5 D, E and F). MiR-125b-5p was strongly expressed in the 
myocardium but was more preponderant in the cardiac valves according to 
expression data (Supplementary table 3-5). While signals for miR-1 and miR-
125b-5p were strong, miR-204 was at the limit of detection, consistently with its 
relative abundance as observed by miRNAseq and qPCR (Supplementary table 
3-5). Several attempts of staining for miR-208b were unsuccessful, possibly due 
to the low expression level of miR-208b (Ct value ~27 in rat myocardium).  
In conclusion, the results of the in situ hybridization correlate well with the 
relative distribution of microRNAs observed using the miRNA seq/TLDA 
approach and suggest that the precise dissection of the rat heart successfully 
allowed the isolation of expression profiles from individual structures. 
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Figure 3-5: Localization of miR-204, miR-125b-5p and miR-1 in rat heart. MiR-204 in 
valves (A-B) and myocardium (C). MiR-125b-5p in valves (D-E) and myocardium (F).  
MiR-1 in valves (G-H) and myocardium (I). Bar = 50 µm. 
 
3.4.4 Integration of gene expression and microRNA profiles at the steady 
state 
MicroRNAs targets were obtained from Targetscan (human database was used 
for Cyno microRNAs). Spearman correlation scores for the distribution of each 
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microRNA and their predicted mRNAs targets were calculated across all samples, 
in order to identify avoidant expression profiles. 
 
Figure 3-6: Rat cardiac disease relevant genes are negatively correlated with putative 
targeting microRNA. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and 
miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized 
intensity for the indicated probe set. Black curve represents log2 scaled and normalized 
microRNA read counts. Three replicates are plotted for each structure. 
 
Expression profiles of four microRNAs interesting for their distribution pattern 
(miR-1, miR-125b, miR-204 and miR-208b) and 4 respective predicted target 
mRNAs that show anti-correlated distribution in rat are shown in Figure 3-6. 
Interestingly Timp3, Rbm24, Tgfbr2 and Csnk2a2 were already reported to be 
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implicated in cardiac physiology and/or muscular differentiation (Bujak and 
Frangogiannis, 2007; Hauck et al., 2008b; Jin et al., 2010; Kandalam et al., 2010; 
Limana et al., 2011; Litchfield, 2003; Miyamoto et al., 2009). The sequence of 
the microRNAs predicted binding site is conserved across species, reinforcing the 
hypothesis that the interactions could be relevant for heart biology 
(Supplementary figure 3-5). Expression profiles of miR-1/Timp3 and miR-125b-
5p/Rbm24 were also anti-correlated with microRNAs expression in the canine 
heart (Supplementary figure 3-2) and Cynomolgus monkey (Supplementary figure 
3-3). Expression profiles of miR-204/Tgfbr2 in canine and Cynomolgus monkey 
as well as miR-208b/Csnk2a2 in Cynomolgus monkey were instead positively 
correlated. Human Timp3 was found down-regulated upon miR-1 over expression 
in HeLa cells by Lim and colleagues (Lim et al., 2005), although it was not 
investigated whether the effect was directly mediated by the microRNAs at the 
post-transcriptional level by a direct reporter assay. Interestingly, Tgfbr2 was 
shown to be directly targeted by miR-204 in human epithelial cells (Wang et al. 
2010a), providing us with a suitable positive control for further confirmatory 
experiments. 
Transfection of miR-1 in HPASMC caused a decrease of about 50% of both the 
endogenous Timp3 mRNAs level (Figure 3-7A) and of the corresponding rodent 
Timp3 3’UTR reporter assay in HEK 293 (Figure 3-7E). Interestingly, we 
demonstrated that only one out of 2 predicted binding sites was active: seed 
mutation of site 1 (pmiR-GLO-Timp3-S1-MUT), but not site 2 (pmiR-GLO-
Timp3-S2-MUT), could rescue expression of reporter gene luciferase, suggesting 
that site 2 is not involved in the regulation of this gene by miR-1. Notably, 
Limana et al. previously reported that the site 2, but not site 1, was targeted by 
miR-206, which has identical 5’ seed to miR-1, whilst site 1 did not respond to 
miR-206 over expression. Additional interactions mediated by the 3’ end of the 
microRNA were crucial for alternate miR-1/206 regulation of Timp3, beyond the 
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canonical 5’ seed, suggesting an alternative effect of highly related microRNAs in 
different cell types or tissues.  
 
Figure 3-7: Anti-correlated microRNA targets are directly inhibited by microRNA over 
expression. (A-D) Endogenous expression of Timp3, Rbm24, Tgfbr2 and Csnk2a2 genes is 
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monitored upon transfection of mimics for miR-1, miR-125b-5p, miR-204, miR-499 and 
miR-208b in HPASMC cells (A-D). Corresponding luciferase reporter vector are assayed 
for susceptibility to putative targeting microRNAs, via co-transfection of reporter vectors 
of interest with the paired microRNA (E-H). 
 
Notably, miR-206 was not detected in any of the cardiac structures of any of 
the 3 species investigated in this study, in accordance to what reported by Rao et 
al. (Rao et al., 2009), while it is expressed in the skeletal muscles (data not 
shown). 
Transfection of miR-125b-5p in HPASMC significantly reduced Rbm24 levels 
by 25% (Figure 3-7B), consistently with the effect observed with the 3’UTR 
reporter assay in HEK 293 (Figure 3-7F). Mutation of the predicted target site 
rescues luciferase gene activity. The function of Rbm24 and Rbm38 stabilize the 
mRNAs of myogenin and p21, respectively, in skeletal muscle (Jin et al., 2010; 
Miyamoto et al., 2009). The levels of their mRNAs increase during myoblastic 
differentiation, while at the same time miR-125b-5p expression drop (Ge et al., 
2011). Interestingly, Rbm38 is also anti-correlated to miR-125b in our cardiac 
samples, and has a predicted miR-125b targeting site in its 3’UTR. However only 
Rbm24 is directly affected by miR-125b co-transfection in the luciferase assay 
(Figure 3-7F), while luc-Rbm38 signal was unaffected (data not shown). 
Transfection of mir-204 significantly decreased the level of Tgfbr2 mRNA by 
20% in both HPASMC (Figure 3-7C) and in co-transfection with the 
corresponding Tgfbr2 3’ UTR luciferase reporter assay (Figure 3-7G).  
MiR-208b over expression lowered Csnk2a2 mRNA level in HPASMC by 
25% (Figure 3-7D), and co-transfection with the reporter assay caused a 50% 
inhibition of luciferase activity in HEK cells (Figure 3-7H). Although the 3 
myomiRs miR-208a/miR-208b/miR-499 are almost identical at the seed 
sequence, miR-499 was much less potent at inhibiting luc-Csnk2a2 than miR-
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208a/miR-208b, suggesting a functional role of 3’ compensatory interaction 
between the microRNA and the target in this case (Figure 3-7D and H).  
 
In summary, we have verified that 4 genes important for the cardiac/muscular 
physiology are post-transcriptionally regulated by miR-1, miR-125b-5p, miR-204 
and miR-208b, and the respective anti-correlated profiles suggest that these 
microRNAs are responsible for the homeostasis of these transcripts across tissues 
and species. 
3.5 Discussion 
The tissue-specific deletion of Dicer in murine myocardial lineage causes 
lethality, demonstrating the pivotal role played by microRNAs in cardiovascular 
development (Chen et al., 2008b). In particular, miR-1 and miR-133, which are 
abundant microRNAs in the heart, are implicated in cardiovascular development 
and myocardial lineage differentiation, as they tightly control expression of 
muscle genes and repress ”unwanted” gene levels, through a network of target 
transcription factors (Ivey et al., 2008; Liu et al., 2008; Schlesinger et al., 2011; 
Zhao et al., 2007). Noteworthy, miR-1, miR-133, mir-30, miR-208a, miR-208b, 
mir-499, miR-23a, miR-9 and miR-199a were shown to be functionally involved 
in cardiovascular diseases such as heart failure and hypertrophy (Latronico and 
Condorelli, 2011; Thum et al., 2007; van Rooij et al., 2009; van Rooij et al., 
2006; van Rooij et al., 2007), and have been proposed as therapeutics or disease 
related drug targets (Montgomery et al., 2011; van Rooij and Olson, 2007). 
However one of the issues of studying the function of specific genes/microRNAs 
in the cardiac organ is the heterogeneity of cell type and morphological 
composition. In order to have a better understanding of the significance of 
different microRNA in the physiology of distinct heart structures we have 
generated a comprehensive heart structure-specific transcriptomic resource for 
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three mammalian species that should facilitate the investigation of 
microRNA/mRNA regulatory interactions in cardiac physiopathology 
mechanisms and may also enhance the identification of cardiac tissue injury 
biomarkers.  
Conserved microRNA signatures were identified in valves (miR-let-7c, miR-
125b, miR-127, miR-199a-3p, miR-204, miR-320, miR-99b, miR-328 and miR-
744) and in ventricular-specific regions of the myocardium (miR-1, miR-133b, 
miR-133a, miR-208b, miR-30e, miR-499-5p, miR-30e*) of Wistar rat, Beagle 
dog and Cynomolgus monkey. The putative targets of conserved valvular and 
myocardial microRNAs found in this study are significantly enriched in genes 
implicated in Gene Expression Regulation, Cellular and Organism Development 
according to gene ontology terms enrichment (Supplementary figure 3-6), 
suggesting that they may play important roles in defining the molecular identity of 
heart-specific structures through direct post-transcriptional regulation of mRNA 
targets and their downstream effects on gene regulatory proteins. Conversely, 
microRNAs that exhibit a dissimilar heart-structure specific distribution across 
species are likely to be of high interest for translational science applications 
including the drug cardiosafety assessment. 
Here we have focused on the characterization of four microRNAs, including 
myocardial specific miR-1 and miR-208b and valve enriched mir-204 and miR-
125b-5p, based on their distinct heart-structure-specific distribution patterns and 
known roles in cardiac physiology, disease and pathological remodeling. 
Numerous putative microRNA targets were found to have an anti-correlated 
distribution with these 4 microRNAs across cardiac tissues supporting the 
biological relevance of predicted microRNA-mRNA interactions. We 
demonstrated that miR-1 could directly control Timp3 expression at the post-
transcriptional level. Timp3 is a regulator of adult myogenesis implicated in the 
fibrotic pathological remodeling of infarcted heart, and atrial fibrillation (Barth et 
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al., 2005; Kandalam et al., 2010; Limana et al., 2011; Liu et al., 2010). 
Interestingly, Timp3 has 2 predicted sites for miR-1/206 family and despite miR-1 
and miR-206 (an already known regulator of Timp3) having identical seed 
sequence, miR-206 targets specifically the second site (Limana et al., 2011), 
while miR-1 specifically targets the first site (Figure 3-7E). These observations 
suggest that duplication of targeting sites may be a strategy for redundant 
regulation in cardiac cell types having different microRNA repertoires. RNA 
binding motif proteins 24 and 38 (Rbm24 and Rbm38) play a role in muscle 
differentiation (Jin et al., 2010; Miyamoto et al., 2009) and carry a miR-125b-5p 
targeting site. Interestingly, the function of miR-125b in controlling 
proliferation/differentiation switches was characterized in a number of cell types, 
such as immune system and muscular cells (Ge et al., 2011; Le et al., 2011; Lee et 
al., 2005; Murphy et al., 2010; Rossi et al., 2011). We found that miR-125b-5p 
over-expression could lower Rbm24, but not Rbm38, levels in HPASM cells, and 
that the down-regulation was directly mediated by the microRNAs as verified via 
luciferase reporter assay. The direct relationship between the RNA regulatory 
protein Rbm24 and miR-125b-5p reinforces the key responsibilities of this 
microRNA in cell fate switches. TGF-β receptor 2 (Tgfbr2) has been functionally 
connected to cardiovascular diseases (Barth et al., 2005; Bujak and 
Frangogiannis, 2007; Kato et al., 2009; Wang et al., 2010a) and miR-204 was 
observed to directly inhibit Tgfbr2 mRNA in a direct manner both in HPASM 
cells and in a luciferase assay, thus extending the potential roles for miR-204 in 
cardiac pathogenesis. Casein kinase 2a2 (Csnk2a2) and miR-208ab have both 
previously been implicated in cardiovascular pathologies (Eom et al., 2011; 
Hauck et al., 2008b; van Rooij et al., 2007) and we have shown here for the first 
time that they are inter-related based on the striking anti-correlation between their 
expression profiles in cardiac tissues. Additional predicted targeting sites for miR-
221/222, implicated in muscular development (Cardinali et al., 2009; Davis et al., 
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2009; Liu et al., 2009b), were also found in Timp3 and Rbm24 3’ UTRs 
(Supplementary figure 3-7), however the corresponding luciferase reporter assays 
were unaffected when miR-221 mimic was co-transfected in Hek 293 cells (data 
not shown) suggesting that miR-221/222 could not directly regulate these genes at 
the post-transcriptional level. 
MicroRNAs can easily be quantified in body fluids using assays that are fully 
translatable across species based on the sequence conservation (Wang et al., 
2009) and numerous publications support the use of tissue-specific microRNAs in 
the peripheral circulation as marker of tissue injury (Starkey Lewis et al., 2011; 
Wang et al., 2010b; Wang et al., 2009; Wang et al., 2011b). Furthermore, heart 
ventricular microRNAs (miR-1, miR-133 and miR-499) were found to be 
increased in the plasma of patients with myocardial infarction, and might 
represent an alternative to the classical cTnI cardiac injury biomarkers (Cheng et 
al., 2010; Corsten et al., 2010; D'Alessandra et al., 2010a; Wang et al., 2010b; 
Wang et al., 2011b). MicroRNAs involved in drug-induced cardiac injury may 
also provide earlier safety endpoints as their expression change could be 
prodromal to the corresponding target gene/protein variations. Here, for the first 
time, we describe conserved valve-enriched microRNAs that may help to monitor 
or predict valvular disease and drug-induced valvular injury, for which no 
translational circulating biomarkers currently exist (Bhattacharyya et al., 2009).  
The identification of microRNAs that are highly specific for a cell type or 
morphological structure is challenging, as most of them are ubiquitous, but this 
may be overcome by measuring a signature of several microRNAs. This strategy 
can help to discriminate between closely related tissues (such as skeletal vs. 
cardiac muscle), or isolate the signal of an under-represented structure in global 
genomics analyses.  
In conclusion, data presented here provided a valuable resource to investigate 
potential roles of specific microRNAs as conserved regulators of cell homeostasis 
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and tissue pathological remodeling. Our data sets can be further analyzed to 
answer different open questions, such as cell type specific genes/microRNAs 
distribution, involvement of microRNAs in genome plasticity, disease and cellular 
homeostasis and co-regulation between intronic microRNAs and their hosting 
transcripts. One important future direction is to obtain suitable clinical samples 
for the extension of this molecular atlas to human heart-specific structures. A 
similar transcriptomic atlas strategy can also be extended to other heterogeneous 
organs in order to characterize potential tissue structure-specific specific 
mechanisms and biomarkers. 
3.6 Supplementary Material and Methods 
3.6.1 In situ hybridization  
Supplementary table 3-1: LNA probe hybridization conditions 
Probe Name 
Reference  
number 
Hybridization  
temperature 
Stringency washes 
hsa-miR-204 18098-15 55°C 0.5x SSC at 37°C (3x 
times) 
hsa-miR-125b 18022-15 57°C 0.5x SSC at 37°C (3x 
times) 
rno-miR-1 41336-15 47°C 2.0x SSC at 37°C (3x 
times) 
 
3.6.2 Cloned regions of Timp3, Rbm24, Rbm38, Akap2, Tgfbr2 and Csnk2a2 
Relative position of cloned stretches is shown in Supplementary figure 3-7. 
Mutations are in indicated in bold. 
Timp3 WT 5’-3’ (Murine NM_011595.2):  
AGTTTAATCTTTTTTTCTTTTGTTGTTTGATGGGAAATTGTGACATTC
CAAGTTGACTTTTTTTTATTATCTGAACAGATTATGGGTATTTATCCTC
TATTAGTATCATATCGTTTTCATTCCACTTTAGAAACACAGTTACCAGT
TGAGTATTTCACCTGTTCACTTACTGTATAATTTAAAATCATTTATGTA
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GCTGAGACACTTTGATACTTCAATTATATCGAGAAAACCCCCTCTAGA
AGGAATGTATTTGTTGCTAAATTTTGTAGCACTGTTTACAGTTTTCCTC
CATGTTA 
Timp3 S1-S2 MUT 5’-3’ (Murine NM_011595.2): 
AGTTTAATCTTTTTTTCTTTTGTTGTTTGATGGGAAATTGTGTGTAAG
GAAGTTGACTTTTTTTTATTATCTGAACAGATTATGGGTATTTATCCTC
TATTAGTATCATATCGTTTTGTAAGGTCTTTAGAAACACAGTTACCAG
TTGAGTATTTCACCTGTTCACTTACTGTATAATTTAAAATCATTTATGT
AGCTGAGACACTTTGATACTTCAATTATATCGAGAAAACCCCCTGAAG
AAGGAATGTATTTGTTGCTAAATTTTGTAGCACTGTTTACAGTTTTCCT
CCATGTTA 
Rbm24 WT 5’-3’ (Rat NM_001191100): 
AGGACACGATGGCAGGGGTACCCATGGGACTTCACTTTTGTATGGG
GATTTTTATTTTTTTTGCTCTTTTTTATAGTATCAGGGAAGCAAACTGC
CTTTTCCAAGTTAGAAAACGCTACGTGAATCTAGCTGAACCAGGGAAT
ACGGAGTCTCTAAAGGAAGGAACTTTAGAAGTGACACTGTAAAATTAT
GTATTCATCTCATGGCATAAGTTATTCAGTAGGTCTAGATGTAGCATAT
TAAATATTAACCTATTCAACTAAAGATGTTGGCTTTGGATTTATTTAAA
TTCTTATGTGC 
Rbm24 MUT 5’-3’ (Rat NM_001191100): 
GAGAGGACACGATGGCAGGGGTACCCATGGGACTTCACTTTTGTAT
GGGGATTTTTATTTTTTTTGCTCTTTTTTATAGTAAGTCCCTAGCAAAC
TGCCTTTTCCAAGTTAGAAAACGCTACGTGAATCTAGCTGAACCAGGG
AATACGGAGTCTCTAAAGGAAGGAACTTTAGAAGTGACACTGTAAAA
TTATGTATTCATCTCATGGCATAAGTTATTCAGTAGGTCTAGATGTAGC
ATATTAAATATTAACCTATTCAACTAAAGATGTTGGCTTTGGATTTATT
TAAATTCTTATGTGC 
Rbm38 WT 5’-3’ (Rat NM_001108965.1): 
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CACCCAGCCCCCCATTGTCACCTGTACCAGTCTGGAGCATGACCTAG
CTGCACAGGGAGAAGGTCCAGCCCACACACGTCTGGGAGGGGAGGAG
TGGGCATCTCTGGCAGCATGGGCTGCCCACAGGCTGGGCAGTGGGTCC
CTCCACACCTACCTCAGGGAGCCAGTGTGTAGGCACTCCACAGCATGC
CTGTTAGTCAAGGCCTGGAGGACAGAGGGAGTAATGTTATAATAATAT
TTTTATTAGAATGTTCTGATTATAAAAAATAAAACTTGTTTTCTTTAAA
G 
Akap2 WT 5’-3’ (Human NM_001004065): 
ATTGTGTGTTTGTAAAATGTGTATGTTCATGAGTAAGGGTGTGTGTG
TGTGTGTATTAAAATTCCAGAGTGACCGTGGCACTTGGGTGTACAGGT
AATTCCTCCAGAGCTGTTTGCTGGCTTCAGGAGTGGAGTGAGAATTTC
TTTTTTATGAAAAGGGATATAAAGGCACCGAGCTGATGCAGTATTTGT
AATATTAAGTTGACCTAACAAGGTATTTGCATGAGTCACAATTACAAA
GTTTTGAGCGGTTTTGTAATTTGACATTTAGGAGAGTCTCCTATTTATT
CTCATACTTTAC 
Akap2 MUT 5’-3’ (Human NM_001004065): 
ATTGTGTGTTTGTAAAATGTGTATGTTCATGAGTAAGGGTGTGTGTG
TGTGTGTATTAAAATTCCAGAGTGACCGTGGCACTTGGGTGTACAGGT
AATTCCTCCAGAGCTGTTTGCTGGCTTCAGGAGTGGAGTGAGAATTTC
TTTTTTATGATTTCCCTTATAAAGGCACCGAGCTGATGCAGTATTTGT
AATATTAAGTTGACCTAACAAGGTATTTGCATGAGTCACAATTACAAA
GTTTTGAGCGGTTTTGTAATTTGACATTTAGGAGAGTCTCCTATTTATT
CTCATACTTTAC 
Tgfbr2 WT 5’-3’ (Human NM_001024847): 
CTCACTTCTGGGTTATCAGCATAAACTGGAATGTAGTGTCAGAGGAT
ACTGTGGCTTGTTTTGTTTATGTTTTTTTTTCTTATTCAAGAAAAAAGA
CCAAGGAATAACATTCTGTAGTTCCTAAAAATACTGACTTTTTTCACTA
CTATACATAAAGGGAAAGTTTTATTCTTTTATGGAACACTTCAGCTGTA
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CTCATGTATTAAAATAGGAATGTGAATGCTATATACTCTTTTTATATCA
AAAGTCTCAAGCACTTATTTTTATTCTATGCATTGTTTGTCTTTTACATA
AATAAAA 
Tgfbr2 MUT 5’-3’ (Human NM_001024847): 
CTCACTTCTGGGTTATCAGCATAAACTGGAATGTAGTGTCAGAGGAT
ACTGTGGCTTGTTTTGTTTATGTTTTTTTTTCTTATTCAAGAAAAAAGA
CCAAGGAATAACATTCTGTAGTTCCTAAAAATACTGACTTTTTTCACTA
CTATACATTTTCCCTAAGTTTTATTCTTTTATGGAACACTTCAGCTGTA
CTCATGTATTAAAATAGGAATGTGAATGCTATATACTCTTTTTATATCA
AAAGTCTCAAGCACTTATTTTTATTCTATGCATTGTTTGTCTTTTACATA
AATAAAA 
Csnk2a2 WT 5’-3’ (Rat NM_001107409): 
CTTCTACCCGGTGGTGAAGGAGCAGTCCCAGCCTTGTGCTGAGAAC
ACCGTGCTTTCCAGTGGTCTCACCGCAGCACGATGAAGCCTGGGGAAT
CGACGGTCTGTTGCGGTTCCTCCCACTTTTCCATAAGCAGAACAAGAA
CCAAATCAAAACGTCTTAACGCGTGTAGCGAGATCACGTCCCGAGAG
CAGACACAAAATGGTGGCAGGCTTGGCGAACAGGAACTAGACCACCC
GAAGGGCAGCCCACCACCGTAAATCAGACCTCACTTCCGAATGTAAA
AGGTTCACATGCCTTTG 
Csnk2a2 MUT 5’-3’ (Rat NM_001107409): 
CTTCTACCCGGTGGTGAAGGAGCAGTCCCAGCCTTGTGCTGAGAAC
ACCGTGCTTTCCAGTGGTCTCACCGCAGCACGATGAAGCCTGGGGAAT
CGACGGTCTGTTGCGGTTCCTCCCACTTTTCCATAAGCAGAACAAGAA
CCAAATCAAAAGCAGAATACGCGTGTAGCGAGATCACGTCCCGAGAG
CAGACACAAAATGGTGGCAGGCTTGGCGAACAGGAACTAGACCACCC
GAAGGGCAGCCCACCACCGTAAATCAGACCTCACTTCCGAATGTAAA
AGGTTCACATGCCTTTG 
134 
 
 
Supplementary figure 3-1: Cardiac structures are similarly clustered by microRNA and 
mRNA profiles of dog (A) and Cynomolgus (B), accordingly to their histological 
characteristics. Red circles: myocardial tissue (apex, left and right ventricle, septum, 
papillary muscle). Blue circles: left and right atrium. Grey circles: cardiac valves. A, apex. 
LA, left atrium. LV, left ventricle. PM, papillary muscle. RA, right atrium. RV, right 
ventricle. S, septum. V, valve.  
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Supplementary table 3-2: Rat cardiac structure enriched microRNAs 
Valves 
miRNA id Sequence 
Fold 
enrichment 
rno-let-7e mirnaUID2686 TGAGGTAGGAGGTTGTATAGTT 17.94 
rno-miR-3554 mirnaUID1040 CTATGCCAGCATCTTGCCT 17.93 
rno-miR-204 mirnaUID0307 TTCCCTTTGTCATCCTATGCCT 17.68 
rno-miR-10b mirnaUID2476 TACCCTGTAGAACCGAATTTGTG 7.31 
rno-miR-497,mmu-miR-497 mirnaUID0236 CAGCAGCACACTGTGGTTTGTA 6.42 
mmu-miR-5109 mirnaUID0403 TGTTGCGGACCAGGGGAATCCGA 6.42 
rno-miR-199a-3p,mmu-miR-199a-
3p,mmu-miR-199b 
mirnaUID2023 ACAGTAGTCTGCACATTGGTTA 5.14 
rno-miR-140*,mmu-miR-140* mirnaUID2487 TACCACAGGGTAGAACCACGG 4.90 
rno-miR-434,mmu-miR-434-3p mirnaUID0606 TTTGAACCATCACTCGACTCCT 4.84 
rno-miR-31 mirnaUID1686 AGGCAAGATGCTGGCATAGCTGT 3.71 
rno-miR-23b mirnaUID0633 ATCACATTGCCAGGGATTACC 3.59 
rno-let-7b mirnaUID1072 TGAGGTAGTAGGTTGTGTGGTT 3.21 
rno-miR-423*,mmu-miR-423-5p mirnaUID2095 TGAGGGGCAGAGAGCGAGACTTTT 3.14 
rno-miR-320 mirnaUID0965 AAAAGCTGGGTTGAGAGGGCGA 3.07 
rno-miR-125a-5p mirnaUID0109 TCCCTGAGACCCTTTAACCTGTGA 3.01 
rno-miR-3596c mirnaUID1636 ACTATACAACCTCCTACCTCA 2.94 
rno-let-7d* mirnaUID1929 CTATACGACCTGCTGCCTTTCT 2.78 
rno-miR-3588 mirnaUID2671 TCACAAGTTAGGGTCTCAGGGA 2.76 
rno-let-7c mirnaUID1210 TGAGGTAGTAGGTTGTATGGTT 2.72 
rno-miR-3543 mirnaUID2716 CAGGAGTCGAGTGATGGTTCAAA 2.51 
rno-miR-99b mirnaUID0532 CACCCGTAGAACCGACCTTGCG 2.51 
rno-miR-125b-5p mirnaUID2699 TCCCTGAGACCCTAACTTGTGA 2.29 
mmu-miR-744 mirnaUID0939 TGCGGGGCTAGGGCTAACAGCA 2.29 
rno-miR-127 mirnaUID0088 TCGGATCCGTCTGAGCTTGGCT 2.29 
rno-miR-3585-5p mirnaUID1381 TTCACAAGAAGGTGTCTTTCAT 2.17 
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rno-miR-328a,mmu-miR-328 mirnaUID1067 CTGGCCCTCTCTGCCCTTCCGT 2.05 
Myocardium 
miRNA id Sequence 
Fold 
enrichment 
rno-miR-30e mirnaUID0677 TGTAAACATCCTTGACTGGAAG 30.37 
rno-miR-30e* mirnaUID1498 CTTTCAGTCGGATGTTTACAGC 14.42 
rno-miR-133a*,mmu-miR-133a* mirnaUID2046 AGCTGGTAAAATGGAACCAAAT 3.76 
rno-miR-499 mirnaUID1007 TTAAGACTTGCAGTGATGTTT 3.73 
rno-miR-133a,mmu-miR-133a mirnaUID0106 TTTGGTCCCCTTCAACCAGCTG 2.78 
rno-miR-3567 mirnaUID1032 TACCAAAAGTAATAATGTGCTG 2.78 
mmu-miR-1a mirnaUID0152 TGGAATGTAAAGAAGTATGTAT 2.70 
rno-miR-133b mirnaUID2652 TTTGGTCCCCTTCAACCAGCTA 2.68 
rno-miR-150 mirnaUID1542 TCTCCCAACCCTTGTACCAGTG 2.44 
rno-miR-208b-3p,mmu-miR-208b mirnaUID0997 ATAAGACGAACAAAAGGTTTGT 2.44 
rno-miR-450a mirnaUID2119 TTTTGCGATGTGTTCCTAATGT 2.40 
rno-miR-3582 mirnaUID1365 CAGCTGGTTGAAGGGGACCAA 2.35 
mmu-miR-149 mirnaUID2194 TCTGGCTCCGTGTCTTCACTCCC 2.07 
rno-miR-143,mmu-miR-143 mirnaUID0897 TGAGATGAAGCACTGTAGCTCA 2.04 
rno-miR-322,mmu-miR-322 mirnaUID0573 CAGCAGCAATTCATGTTTTGGA 2.03 
Atria 
miRNA id Sequence 
Fold 
enrichment 
rno-miR-31 mirnaUID1686 AGGCAAGATGCTGGCATAGCTGT 7.41 
rno-miR-3554 mirnaUID1040 CTATGCCAGCATCTTGCCT 7.41 
rno-miR-127 mirnaUID0088 TCGGATCCGTCTGAGCTTGGCT 3.95 
rno-miR-490,mmu-miR-490-3p mirnaUID0503 CAACCTGGAGGACTCCATGCTG 3.02 
rno-miR-434,mmu-miR-434-3p mirnaUID0606 TTTGAACCATCACTCGACTCCT 2.95 
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Supplementary table 3-3: Monkey cardiac structure enriched microRNAs 
Valves 
miRNA id Sequence 
Fold 
enrichment 
mml-miR-
320,hsa-miR-
320a,hsa-miR-
320d 
mirnaUID0965 AAAAGCTGGGTTGAGAGGGCGA 50.76 
hsa-miR-320b mirnaUID0343 AAAAGCTGGGTTGAGAGGGCAA 40.96 
mml-miR-214 mirnaUID0512 ACAGCAGGCACAGACAGGCAGT 37.44 
hsa-miR-3120-5p mirnaUID0899 CCTGTCTGTGCCTGCTGTACA 31.12 
mml-miR-197 mirnaUID0938 TTCACCACCTTCTCCACCCAGC 22.56 
mml-miR-92b mirnaUID0054 TATTGCACTCGTCCCGGCCTCC 20.74 
mml-let-7b mirnaUID1072 TGAGGTAGTAGGTTGTGTGGTT 11.88 
hsa-miR-574-3p mirnaUID2267 CACGCTCATGCACACACCCACA 9.14 
mml-miR-140-3p mirnaUID2487 TACCACAGGGTAGAACCACGG 9.12 
mml-miR-
134,hsa-miR-134 
mirnaUID1573 TGTGACTGGTTGACCAGAGGGG 8.65 
mml-miR-125b mirnaUID2699 TCCCTGAGACCCTAACTTGTGA 8.44 
hsa-miR-1296 mirnaUID0319 TTAGGGCCCTGGCTCCATCTCC 7.86 
mml-miR-204 mirnaUID0307 TTCCCTTTGTCATCCTATGCCT 7.83 
mml-let-7c mirnaUID1210 TGAGGTAGTAGGTTGTATGGTT 6.06 
hsa-miR-328 mirnaUID1067 CTGGCCCTCTCTGCCCTTCCGT 5.69 
hsa-miR-125b-1* mirnaUID2553 ACGGGTTAGGCTCTTGGGAGCT 5.36 
mml-miR-34a mirnaUID1747 TGGCAGTGTCTTAGCTGGTTGT 5.34 
hsa-miR-744 mirnaUID0939 TGCGGGGCTAGGGCTAACAGCA 4.90 
mml-miR-
127,hsa-miR-127-
3p 
mirnaUID0088 TCGGATCCGTCTGAGCTTGGCT 4.77 
hsa-let-7b* mirnaUID2339 CTATACAACCTACTGCCTTCCC 4.72 
mml-miR-423-5p mirnaUID2095 TGAGGGGCAGAGAGCGAGACTTTT 4.52 
mml-miR-193b mirnaUID1124 AACTGGCCCTCAAAGTCCCGCT 4.41 
mml-miR-100 mirnaUID0973 AACCCGTAGATCCGAACTTGTG 4.07 
mml-miR-140-5p mirnaUID0183 CAGTGGTTTTACCCTATGGTAG 3.99 
hsa-let-7d* mirnaUID1929 CTATACGACCTGCTGCCTTTCT 3.66 
mml-miR-409-3p mirnaUID2437 GAATGTTGCTCGGTGAACCCCT 3.60 
mml-miR-99b mirnaUID0532 CACCCGTAGAACCGACCTTGCG 3.06 
hsa-miR-335* mirnaUID1199 TTTTTCATTATTGCTCCTGACC 2.98 
mml-miR-125a-
5p 
mirnaUID0109 TCCCTGAGACCCTTTAACCTGTGA 2.75 
mml-miR-181d mirnaUID1317 AACATTCATTGTTGTCGGTGGGT 2.66 
hsa-miR-106b* mirnaUID2147 CCGCACTGTGGGTACTTGCTGC 2.60 
mml-miR-152 mirnaUID1339 TCAGTGCATGACAGAACTTGG 2.45 
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mml-miR-199a-
3p,hsa-miR-199b-
3p 
mirnaUID2023 ACAGTAGTCTGCACATTGGTTA 2.43 
mml-miR-423-3p mirnaUID0925 AGCTCGGTCTGAGGCCCCTCAGT 2.40 
hsa-miR-3184 mirnaUID2607 TGAGGGGCCTCAGACCGAGCTTTT 2.40 
mml-miR-23a mirnaUID2468 ATCACATTGCCAGGGATTTCC 2.32 
hsa-miR-125b-2* mirnaUID2235 TCACAAGTCAGGCTCTTGGGAC 2.26 
hsa-miR-3120-3p mirnaUID0801 CACAGCAAGTGTAGACAGGCA 2.24 
hsa-miR-214* mirnaUID1165 TGCCTGTCTACACTTGCTGTGC 2.23 
mml-miR-130a mirnaUID1062 CAGTGCAATGTTAAAAGGGCAT 2.17 
mml-miR-92a mirnaUID0699 TATTGCACTTGTCCCGGCCTGT 2.16 
mml-miR-
145,hsa-miR-145 
mirnaUID1820 GTCCAGTTTTCCCAGGAATCCCTT 2.10 
mml-miR-
199a,mml-miR-
199a-5p 
mirnaUID2233 CCCAGTGTTCAGACTACCTGTTC 2.08 
mml-miR-28,hsa-
miR-28-5p 
mirnaUID2058 AAGGAGCTCACAGTCTATTGAG 2.04 
mml-miR-181b mirnaUID0653 AACATTCATTGCTGTCGGTGGGTT 2.03 
mml-let-7a,hsa-
let-7a 
mirnaUID2005 TGAGGTAGTAGGTTGTATAGTT 2.02 
mml-miR-191 mirnaUID0921 CAACGGAATCCCAAAAGCAGCTG 2.01 
Myocardium 
miRNA id Sequence 
Fold 
enrichment 
hsa-miR-499a-3p mirnaUID0074 AACATCACTGCAAGTCTTAACA 12.05 
mml-miR-499-5p mirnaUID1007 TTAAGACTTGCAGTGATGTTT 11.96 
mml-miR-208b mirnaUID0997 ATAAGACGAACAAAAGGTTTGT 10.88 
mml-miR-363 mirnaUID2513 AATTGCACGGTATCCATCTGTAA 10.08 
hsa-miR-378d mirnaUID0020 ACTGGACTTGGAGTCAGAAA 6.63 
mml-miR-133a mirnaUID0646 TTGTCCCCTTCAACCAGCTGT 6.04 
mml-miR-30e mirnaUID0677 TGTAAACATCCTTGACTGGAAG 5.87 
mml-miR-10b mirnaUID2476 TACCCTGTAGAACCGAATTTGTG 5.37 
mml-miR-
133c,hsa-miR-
133a 
mirnaUID0106 TTTGGTCCCCTTCAACCAGCTG 5.21 
hsa-miR-30d* mirnaUID0175 CTTTCAGTCAGATGTTTGCTGC 4.93 
hsa-miR-30e* mirnaUID1498 CTTTCAGTCGGATGTTTACAGC 4.64 
hsa-miR-145* mirnaUID0432 ATTCCTGGAAATACTGTTCTTG 4.63 
mml-miR-133b mirnaUID2652 TTTGGTCCCCTTCAACCAGCTA 4.55 
mml-miR-143 mirnaUID0897 TGAGATGAAGCACTGTAGCTCA 4.33 
mml-miR-29b mirnaUID0341 TAGCACCATTTGAAATCAGTGTT 4.21 
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mml-miR-29c mirnaUID2148 TAGCACCATTTGAAATCGGTTA 4.11 
mml-miR-22 mirnaUID2497 AAGCTGCCAGTTGAAGAACTGT 4.06 
mml-miR-30a-
5p,hsa-miR-30a 
mirnaUID0712 TGTAAACATCCTCGACTGGAAGC 3.63 
mml-miR-
30b,mml-miR-
30c,hsa-miR-30b 
mirnaUID2059 TGTAAACATCCTACACTCTCAGCT 3.50 
hsa-miR-30c-1* mirnaUID0178 CTGGGAGAGGGTTGTTTACTCC 3.36 
mml-miR-1,hsa-
miR-1 
mirnaUID0152 TGGAATGTAAAGAAGTATGTAT 3.23 
mml-miR-301a mirnaUID2381 CAGTGCAATAGTATTGTCAAAGC 3.21 
hsa-miR-378i mirnaUID1256 ACTGGACTAGGAGTCAGAAGG 3.14 
mml-miR-338-3p mirnaUID1371 TCCAGCATCAGTGATTTTGTTGA 3.08 
hsa-miR-3065-5p mirnaUID1514 TCAACAAAATCACTGATGCTGGA 3.08 
mml-miR-
378,hsa-miR-
378c 
mirnaUID0205 ACTGGACTTGGAGTCAGAAGAGTGG 2.97 
mml-miR-142-5p mirnaUID0690 CATAAAGTAGAAAGCACTACT 2.93 
mml-miR-27b mirnaUID2565 TTCACAGTGGCTAAGTTCTGC 2.91 
mml-miR-340 mirnaUID0680 TTATAAAGCAATGAGACTGATT 2.72 
mml-miR-451 mirnaUID2416 AAACCGTTACCATTACTGAGTT 2.53 
hsa-miR-126* mirnaUID1796 CATTATTACTTTTGGTACGCG 2.45 
mml-miR-107 mirnaUID1208 AGCAGCATTGTACAGGGCTATCA 2.43 
mml-miR-150 mirnaUID1542 TCTCCCAACCCTTGTACCAGTG 2.43 
mml-miR-221 mirnaUID2188 AGCTACATTGTCTGCTGGGTTTC 2.41 
mml-miR-30d mirnaUID0941 TGTAAACATCCCCGACTGGAAGCT 2.32 
mml-miR-101 mirnaUID1884 TACAGTACTGTGATAACTGAAG 2.22 
mml-let-7f mirnaUID1332 TGAGGTAGTAGATTGTATAGTT 2.21 
mml-miR-
126,hsa-miR-126 
mirnaUID0048 TCGTACCGTGAGTAATAATGCG 2.20 
mml-miR-148b mirnaUID1084 TCAGTGCATCACAGAACTTTGT 2.14 
mml-miR-30a-
3p,hsa-miR-30a* 
mirnaUID1016 CTTTCAGTCGGATGTTTGCAGC 2.12 
mml-miR-222 mirnaUID1145 AGCTACATCTGGCTACTGGGT 2.03 
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Supplementary table 3-4: Canine cardiac structure enriched microRNAs 
Valves 
miRNA id Sequence Fold enrichment 
cfa-miR-204,hsa-
miR-204 
mirnaUID0307 TTCCCTTTGTCATCCTATGCCT 8.17 
cfa-miR-127,hsa-
miR-127-3p 
mirnaUID0088 TCGGATCCGTCTGAGCTTGGCT 4.29 
cfa-miR-328,hsa-
miR-328 
mirnaUID1067 CTGGCCCTCTCTGCCCTTCCGT 3.52 
hsa-miR-744 mirnaUID0939 TGCGGGGCTAGGGCTAACAGCA 3.32 
cfa-miR-199,hsa-
miR-199a-3p,hsa-
miR-199b-3p 
mirnaUID2023 ACAGTAGTCTGCACATTGGTTA 3.15 
cfa-miR-320,hsa-
miR-320a,hsa-
miR-320d 
mirnaUID0965 AAAAGCTGGGTTGAGAGGGCGA 3.07 
cfa-let-7c,hsa-let-
7c 
mirnaUID1210 TGAGGTAGTAGGTTGTATGGTT 2.71 
cfa-miR-99b,hsa-
miR-99b 
mirnaUID0532 CACCCGTAGAACCGACCTTGCG 2.40 
cfa-let-7e,hsa-let-
7e 
mirnaUID2686 TGAGGTAGGAGGTTGTATAGTT 2.27 
hsa-miR-151-3p mirnaUID1826 CTAGACTGAAGCTCCTTGAGG 2.25 
cfa-miR-149,hsa-
miR-149 
mirnaUID2194 TCTGGCTCCGTGTCTTCACTCCC 2.21 
cfa-miR-181b,hsa-
miR-181b 
mirnaUID0653 AACATTCATTGCTGTCGGTGGGTT 2.18 
cfa-miR-125b,hsa-
miR-125b 
mirnaUID2699 TCCCTGAGACCCTAACTTGTGA 2.18 
cfa-miR-152,hsa-
miR-152 
mirnaUID1339 TCAGTGCATGACAGAACTTGG 2.07 
Myocardium 
miRNA id Sequence Fold enrichment 
cfa-miR-208b mirnaUID0997 ATAAGACGAACAAAAGGTTTGT 70.0304 
cfa-miR-31,hsa-
miR-31 
mirnaUID1686 AGGCAAGATGCTGGCATAGCTGT 17.620426 
cfa-miR-499,hsa-
miR-499-5p 
mirnaUID1007 TTAAGACTTGCAGTGATGTTT 17.01442 
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hsa-miR-499a-3p mirnaUID0074 AACATCACTGCAAGTCTTAACA 16.83687 
cfa-miR-1,hsa-
miR-1 
mirnaUID0152 TGGAATGTAAAGAAGTATGTAT 9.188781 
hsa-miR-378i mirnaUID1256 ACTGGACTAGGAGTCAGAAGG 5.7802687 
hsa-miR-378d mirnaUID0020 ACTGGACTTGGAGTCAGAAA 4.8989153 
cfa-miR-378,hsa-
miR-378,hsa-miR-
378c 
mirnaUID0205 ACTGGACTTGGAGTCAGAAGAGTGG 4.191974 
hsa-miR-133a mirnaUID0106 TTTGGTCCCCTTCAACCAGCTG 4.075601 
cfa-miR-133a,cfa-
miR-133c 
mirnaUID0013 TTGGTCCCCTTCAACCAGCTGT 4.07559 
cfa-miR-30b,cfa-
miR-30c,hsa-miR-
30b,hsa-miR-30c 
mirnaUID2059 TGTAAACATCCTACACTCTCAGCT 3.9003046 
cfa-miR-126,hsa-
miR-126* 
mirnaUID1796 CATTATTACTTTTGGTACGCG 3.619509 
hsa-miR-126 mirnaUID0048 TCGTACCGTGAGTAATAATGCG 3.5997996 
hsa-miR-486-5p mirnaUID1023 TCCTGTACTGAGCTGCCCCGAG 3.3498151 
cfa-miR-363,hsa-
miR-363 
mirnaUID2513 AATTGCACGGTATCCATCTGTAA 3.2826152 
hsa-miR-486-3p mirnaUID2078 CGGGGCAGCTCAGTACAGGAT 3.1971457 
cfa-miR-133b mirnaUID2652 TTTGGTCCCCTTCAACCAGCTA 3.1729188 
hsa-miR-30d* mirnaUID0175 CTTTCAGTCAGATGTTTGCTGC 3.1622963 
cfa-miR-30d,hsa-
miR-30d 
mirnaUID0941 TGTAAACATCCCCGACTGGAAGCT 2.9301157 
cfa-miR-10b,hsa-
miR-10b 
mirnaUID2476 TACCCTGTAGAACCGAATTTGTG 2.885671 
cfa-miR-30e,hsa-
miR-30e* 
mirnaUID1498 CTTTCAGTCGGATGTTTACAGC 2.8295717 
hsa-miR-30e mirnaUID0677 TGTAAACATCCTTGACTGGAAG 2.8032448 
cfa-miR-30a,hsa-
miR-30a 
mirnaUID0712 TGTAAACATCCTCGACTGGAAGC 2.5368807 
cfa-miR-144,hsa-
miR-144 
mirnaUID1312 TACAGTATAGATGATGTACTAG 2.46647 
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cfa-miR-22,hsa-
miR-22 
mirnaUID2497 AAGCTGCCAGTTGAAGAACTGT 2.426751 
cfa-miR-29c,hsa-
miR-29c 
mirnaUID2148 TAGCACCATTTGAAATCGGTTA 2.0725322 
Atria 
miRNA id Sequence Fold enrichment 
cfa-miR-184,hsa-
miR-184 
mirnaUID1958 TGGACGGAGAACTGATAAGGGT 41.79 
cfa-miR-208a mirnaUID2674 ATAAGACGAGCAAAAAGCTTGT 31.20 
cfa-miR-490,hsa-
miR-490-3p 
mirnaUID0503 CAACCTGGAGGACTCCATGCTG 4.09 
cfa-miR-221,hsa-
miR-221 
mirnaUID2188 AGCTACATTGTCTGCTGGGTTTC 2.47 
cfa-miR-222,hsa-
miR-222 
mirnaUID1145 AGCTACATCTGGCTACTGGGT 2.38 
cfa-miR-204,hsa-
miR-204 
mirnaUID0307 TTCCCTTTGTCATCCTATGCCT 2.32 
 
Supplementary table 3-5: Normalized miRNA seq reads for mir-1, miR-125b-5p, miR-204 
and miR-208b in rat myocardium or valves. 
 
Average normalized 
miRNA seq reads 
Average Ct 
Rat miRNA 
Valve
s 
Myocardium 
Valve
s 
Myocardium 
mmu-miR-
1a 
141 1223 15 11 
miR-125b-
5p 
17256 2506 17 15 
miR-204 4482 244 18 20 
miR-208b 814 11250 30 25 
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Supplementary figure 3-2: Correlation of 4 cardiac disease relevant genes with putative 
targeting microRNA in canine. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), 
Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 
normalized intensity for the indicated probe set. Black curve represents log2 scaled and 
normalized microRNA read counts. Three replicates are plotted for each structure. 
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Supplementary figure 3-3: Correlation 4 cardiac disease relevant genes with putative 
targeting microRNA in Cyno monkey. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p 
(B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 
normalized intensity for the indicated probe set. Black curve represents log2 scaled and 
normalized microRNA read counts. Three replicates are plotted for each structure. 
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Supplementary figure 3-4: Robustness of microRNA seq and validation with qPCR. Data 
obtained with miRNAseq or TLDA cards are compared for each rat cardiac sample. rs = 
Spearman’s rank correlation, r = Pearson’s correlation. 
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Supplementary figure 3-5: Conservation of (A) Timp3 miR-1/206 targeting seed, (B) 
Rbm24 miR-125b-5p targeting seed , (C) Tgfbr2 miR-204 targeting seed, (D) Csnk2a2 
miR-208b targeting seed. Rno: Rattus norvegicus. Hsa: Homo sapiens. Ptr: Pan 
trogloditus. Mml: Macaca mulatta. Mmu: Mus musculus. Cfa: Canis familiaris. 
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Supplementary figure 3-6: Gene ontology analysis of all Targetscan putative targets of 
structure-enriched conserved microRNA targets. Targets of conserved myocardial 
enriched microRNAs (A). Targets of conserved valves enriched microRNAs (B). 
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Supplementary figure 3-7: Cloning of 3’ UTRs of Timp3, Csnk2a2, Rbm24, Rbm38, 
Tgfbr2 and Akap2 in pmiR-GLO. Yellow arrows indicate ORFs. Grey arrows identify the 
region surrounding the microRNA Targetscan targeting site cloned in pmiR-GLO. 
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Chapter 4:  Concluding discussion 
4.1 Brief summary of results 
In the context of toxicogenomics, it would be desirable to be able to interpret 
the results of microRNAs profiling upon xenobiotics administration in terms of 
“functional signatures”, similarly to what is possible today with mRNAs 
expression. However in order to do this, much more information is needed on the 
real microRNAs “targetome”, and on microRNAs relative distribution across the 
tissues of the model species. 
In this thesis we generated data that can support further elucidation of the 
molecular mechanisms of cardiac function and drug-induced cardiomyopathy. 
First, we identified a microRNAs signature altered by an anti-tumoral agent 
known for its cardiotoxicity (doxorubicin), and proposed a link with concomitant 
transcriptome variation, and we could identify a novel direct microRNAs-mRNAs 
interaction (miR-34/Sipa1). Second, we have uncovered the spatial distribution of 
microRNAs and mRNAs in 8 cardiac structures of rat, dog and Cynomolgus 
monkey, with a level of detail never achieved before in these model species. A 
subset of microRNAs with a patterned expression across cardiac structures was 
further characterized and 3 novel targets relevant for cardiac biology were 
validated (Timp3, Rbm24, Csnk2a2). 
Ideally, our findings will contribute to develop more predictive safety models 
for drug development, especially for cardiac toxicity. 
4.2 MicroRNAs toxicity/pharmacodynamics indicators in the tissue 
We identified for the first time the microRNAs dysregulated in vivo by DOX in 
the rat heart. Notably, 2 of them (miR-216b and miR-367) were increased earlier 
than first signs of cardiotoxicity. Importantly the myomiR miR-208b was 
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increased concomitantly with its genomic host gene, Myh7, underpinning the 
occurrence of a dose/time dependent cardiac remodeling. However, since a 
consistent number of DOX-induced microRNAs were not previously 
characterized, it was difficult to suggest their implication in pathological events 
associated to DOX in the heart. In particular, we could not find evidence of a 
correlation between the DOX-induced microRNAs with autophagy or fibrosis 
(data not shown and Supplementary figure 2-5), two mechanisms that can 
contribute to DOX-induced cardiac toxicity (Kobayashi et al., 2010). In first 
place, there were no clear signs of autophagy induction from the gene expression 
in vivo, and we did not observe any concomitant increase of DOX-induced 
microRNAs in neonatal rat ventricular myocytes treated with DOX (data not 
shown). However, it is possible that the signals of the autophagy gene signature 
would be diluted, as only a few myocytes displayed lesions compatible with 
autophagy. Importantly, the use of a non-cardiotoxic Top2 inhibitor (etoposide, 
EPS) suggests that the increase of miR-215, mir-216b, miR-208b, mIR-34c and 
miR-367 is DOX specific. We could not exclude that these microRNAs could be 
implicated in other toxic events implicated with DOX cardiotoxicity, such as 
mitochondrial stress (Thompson et al., 2009). 
Nevertheless, consistently with the anti-proliferative effect of DOX, a subset of 
the dysregulated microRNAs were related to cell proliferation, including the 4 
upregulated onco-suppressors (miR-215, miR-216b, miR-31 and miR-708), the 2 
p53 transcriptional responders (miR-34c and miR-215) and 1 down-regulated 
onco-miR (miR-221) (Supplementary table 2-5). 
Therefore, although we could not elucidate a critical toxic pathway that directly 
involved the microRNAs (with the exception of mir-208b over-expression that 
most likely is a consequence of its host gene up-regulation), those microRNAs 
that were related to arrest of cell proliferation could be potential 
pharmacodynamics endpoints for anti-proliferative drugs for example.  
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4.3 Heterogeneity of heart tissue and cross-species heart atlas 
Tissues and organs are heterogeneous, and it is often debatable how tissues 
should be sampled in order to capture relevant molecular changes. In addition to 
the well studied ischemic diseases, cardiovascular liabilities relevant to drug 
safety include dilated cardiomyopathy, arrhythmias, contractile toxicity, valvular 
and secondary toxicity leading to heart failure (Stummann et al., 2009). Other 
than ventricle walls, also atrial walls, cardiac valves, papillary muscles and 
septum can be involved in cardiac pathologies of different etiology. However 
little is known about the molecular mechanisms implicated in remodeling and 
diseases affecting these areas. This has particular relevance in the case of drug-
induced valvular toxicity, which is often assessed neither during histopathological 
readouts, nor with toxicogenomics.  
We addressed the cardiac heterogeneity issue by combining microRNAs 
sequencing and gene expression microarrays from 8 distinct cardiac structures and 
generated a large amount of data highly relevant to the preclinical cardiac safety 
assessment for rat, dog and Cynomolgus monkey, three species widely used in 
pharmacological research, but not much as basic research models, and therefore 
still poorly annotated. 
It was evident that each cardiac zone can be differentiated by the pattern of 
expression of both mRNAs and microRNAs. Structures mainly composed of 
cardiomyocytes (ventricles, apex, septum and papillary muscles) of course were 
very similar, while atria and valves were markedly distinct. In a word, when 
generating the expression profiles of generic heart samples, the cardiomyocytes 
“fingerprint” is predominant, and we would recommend defining the highly 
expressed mRNAs or microRNAs as “cardiomyocytes” specific, rather then 
“heart” specific.  
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Figure 4-1: Percentual representation of selected gene lists in 8 cardiac structures of the 
heart. LA=left atrium, RA= right atrium. Six gene lists were manually curated and 
contained in total 222 Affymetrix probe sets. 
 
In conclusion, our data sets will allow researchers to obtain more accurate 
cardiac samples and to detect dissection abnormalities by looking at the 
percentual composition of structure enriched genes or microRNAs, as exemplified 
in Figure 4-1.  
Gene/microRNAs structure signatures can help to understand whether an 
increase/decrease of a certain transcript in a complex tissue is reflecting a real 
increase of the average cellular content of the transcripts, or rather an over-/under-
representation of a specific cell type/structure due to the applied stimulus. 
4.4 Cardiac microRNAs-mRNAs regulatory circuits and pathways  
One challenge of microRNAs research is to characterize their function by 
defining the real targets, among all the predicted ones. Systematic identification 
of functional microRNAs targets and their co-distribution across 
tissues/organs/cell types is crucial to elucidate microRNAs-controlled regulatory 
circuitries. At present, it is not yet possible to associate alteration in specific 
microRNAs expression to pathways and biological processes (GO analysis) 
altered upon drug administration, since most the function of the microRNAs is 
defined by their “targetome”. Extensive comparison between microRNAs and 
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mRNAs expression will open new avenues for the identification of microRNAs 
implicated in specific pathways. 
Typically, the effect of microRNAs on their target genes is observed by 
introducing a perturbation in the system (in vitro or in vivo), such as a mutation or 
pharmacological treatment with an active compound, and we also used 
pharmacological treatment in the DOX study (see Chapter 2). However we 
speculated it would be possible to functionalize microRNAs also at the steady 
state by comparing different tissues. This would identify mainly key microRNAs-
mRNAs interactions key to maintain the tissue identity, as discussed in Chapter 3 
and briefly below. 
4.4.1 Effect of DOX on cardiac remodeling in vivo 
We described for the first time that Sipa1 was a direct target of miR-34 family 
and of m iR-34c in particular. This finding is most likely related to the 
pharmacological effect of DOX, since Sipa1 has been described as pro-metastatic 
gene (Park et al., 2005), and miR-34 family as onco-suppressors (Ichimura et al., 
2010).  
A subset of microRNAs involved in fibrosis was monitored by single assay 
qPCR across the study conditions, with and without DZR co-administration. 
However only miR-208b was increased by DOX, and brought down to baseline 
levels by DZR (Supplementary figure 2-5). 
DOX was shown to induce autophagy in cardiomyocytes (Kobayashi et al., 
2010) and we found clues of miR-34c activity on autophagic regulator Ambra1 in 
H9c2 cells treated with DOX (Supplementary figure 2-6B), although the observed 
effect is most probably indirect. 
4.4.2 Anti-correlation of microRNAs with target mRNAs at the steady state 
The second strategy we employed to identify and validate microRNAs targets 
was the comparison of heterogeneous, but still highly similar samples. Matched 
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mRNAs and microRNAs expression from 8 cardiac structures from 3 mammalian 
species suggested a number of microRNAs/mRNAs anti-correlations interesting 
for heart physiology and diseases. Direct inhibition of the transcript mediated by 
the microRNAs was confirmed for 4 candidate genes by reporter assays.  
Unexpectedly, one interesting finding was that each of the 2 targeting sites 
predicted for miR-1/miR-206 family in Timp3 3’UTR were extremely specific for 
either miR-1 (as shown in Chapter 3) or miR-206 (as shown by Limana et al.). 
MiR-206 is normally not expressed in the mammalian heart, but was found up-
regulated in presence of fibrosis (Limana et al., 2011), while miR-1 is normally 
down-regulated. The importance of the microRNAs mediated control of this gene 
was further reinforced by the reportedly high potency of both miR-1 and miR-206 
in the Timp3-3’ UTR reporter assay, and the different sites of action argues 
against the belief that members of the same family should share the same targets. 
Further functional studies will be needed to elucidate the role in cardiac 
physiology of the 3 other miRNA/mRNAs couple described in our work (mir-
125b-5p/Rbm24, miR-204/Tgfbr2, mir-208b/Csnk2a2). 
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Chapter 5:   Final remarks and future directions 
5.1 MicroRNAs as “early” biomarkers of toxicity in the tissue 
In principle, variation of specific microRNAs expression induced by external 
stimuli (including xenobiotics) can potentially precede downstream molecular 
alterations of the transcriptome. Therefore microRNAs could be early 
pharmacodynamics/toxicity biomarkers in the tissue, even earlier than tissue 
biomarkers (Figure 5-1). This can be exemplified by our finding that miR-1 was 
able to strongly down-regulate Timp3, a key gene in extra-cellular matrix 
remodeling and cardiac fibrosis, suggesting that a decrease in miR-1 could be 
prodromal to an increase in Timp3 associated to a fibrotic process. Furthermore, 
an important aspect is that microRNAs involved in a specific process (i.e. cell 
proliferation) may not necessarily be dysregulated by perturbation of that same 
process (either pharmacological or genetic), as suggested by Jentzsch et al. who 
identified, via a cardiomyocytes hypertrophy screening, microRNAs that were 
never found altered in hypertrophy models (Jentzsch et al., 2011). 
5.2 MicroRNAs as source of circulating biomarkers of tissue lesions 
MicroRNAs are increasingly regarded as promising non-invasive damage 
biomarkers and these data sets are a resource for circulating indicators of cardiac 
lesions at the preclinical level. Furthermore, since microRNAs sequences and 
distribution are usually conserved, observations common to the 3 species could be 
highly relevant to the human. Our cardiac atlas constitutes a repository for 
selection of translatable circulating microRNAs for cardiac structure lesions in 
human.  
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5.3 Non-canonical regulatory circuits and transcriptional regulation of 
microRNAs 
Increasing interest is growing around specific cases in which microRNAs 
control of expression extends to RNA-RNA interactions, or in which pseudo-
genes modulate microRNAs activity (Poliseno et al., 2010; Sumazin et al., 2011). 
Open questions remain regarding the regulation of microRNAs expression, and 
our miRNA seq data sets could be a starting ground for elucidating transcriptional 
regulation mechanisms.  
 
Figure 5-1: microRNAs may be earlier predictors of gene expression in toxicogenomics 
evaluation of drug-induced tissue injury. 
 
However, the scarce genomic annotation of the pre-clinical species used for 
pharmaceutical research advocates for better annotation, since many choices 
regarding the patients are done based on the information extracted from these 
models. 
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